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Abstract 
 
Patients on dialysis are subject to hugely elevated rates of cardiovascular 
mortality. This thesis describes research work focusing on the large scale 
haemodynamic changes that occur during dialysis and how they may 
negatively impact on the cardiovascular system. Our results show that the 
haemodynamic disturbances that occur during haemodialysis are of 
sufficient magnitude to cause left ventricular (LV) regional wall motion 
abnormalities, reflecting subclinical myocardial ischaemia (myocardial 
stunning). This is pertinent as in non-dialysis patients repeated episodes 
of myocardial stunning lead to chronic heart failure, and in dialysis 
patients the presence of LV dysfunction dramatically increases the risk of 
death. We also explore how the haemodynamic effects of dialysis and the 
genesis of LV regional wall motion abnormalities can be ameliorated by 
using various interventions comprising of biofeedback dialysis 
(Hemocontrol® and Diacontrol®), cooling the dialysate and acetate free 
paired haemodiafiltration (PHF). We also examine the haemodynamic 
and metabolic effects of peritoneal dialysis (both continuous ambulatory 
and automated peritoneal dialysis) and show that these are much greater 
than previously thought. We also investigate possible mechanisms 
underlying these changes, namely alterations in cardiac filling and 
systemic glucose absorption leading to hyperinsulinaemia, and go on to 
examine the differential effects of the commercially available peritoneal 
dialysis solutions. Finally, we examine whether regional LV function is 
affected by the haemodynamic changes of CAPD. 
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1.1 Prevalence of renal disease 
 
Established renal failure (ERF) is defined in the current UK guidelines for 
the management of chronic kidney disease as an estimated glomerular 
filtration rate of <15ml/min/1.73m2 [1]. ERF or chronic kidney disease 
stage 5 (CKD 5) is the complete or near complete failure of the kidneys to 
perform their normal functions. These functions comprise of excretion of 
waste products, regulation of fluid and electrolyte balance, acid-base 
homeostasis and secretion or metabolism of hormones (in particular 
erythropoietin, renin and cholecalciferol). CKD 5 implies that kidney 
function is impaired to a degree that is unlikely to be able to sustain life in 
the longer term and so renal replacement therapies are often instituted. 
ERF presents an increasingly large health and economic burden to the 
NHS. Currently, 626 patients per million population (37,050 in total) with 
ERF are treated in the UK at a cost of approximately £22,000 per patient 
per year [2, 3]. Furthermore, the ERF population is consistently 
increasing, with predicted growth rates between 4-8% per year for at least 
the next 15 years [2, 4]. In particular, the rate of increase of ERF is most 
rapid in the elderly. Transplantation remains the gold standard for treating 
ERF, but with a shortage of donor kidneys and an increasingly older ERF 
population many of whom are unfit for transplantation, dialysis remains 
the treatment for the majority. 39% of ERF patients in the UK are treated 
with haemodialysis, and 15% with peritoneal dialysis [2]. 
1. Introduction 
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1.2 Dialysis modalities 
 
Dialysis works by the principle of diffusion, with solutes removed from the 
blood down a concentration gradient across a semi-permeable 
membrane (which prevents loss of larger proteins and blood cells).  
 
1.2.1 Haemodialysis 
Haemodialysis involves moving patients’ blood through an extracorporeal 
circuit, with the blood flowing along one side of a semi-permeable 
membrane and dialysis fluid (dialysate) flowing along the other side. A 
typical dialysis machine is shown in figure 1-a. Patients receive 
haemodialysis intermittently, typically three times a week for 3-4 hours at 
a time. 
 
 
 
 
 
 
Figure 1-a. 
Standard haemodialysis  
monitor 
 
Dialyser 
Blood to 
patient 
Blood from 
patient 
Dialysate  
concentrate 
Blood pump 
Heparin 
Bicarbonate 
Water supply 
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1.2.2 Peritoneal dialysis 
Peritoneal dialysis involves the instillation of dialysate into the abdomen 
to allow effective dialysis to occur across the membrane lining the 
abdominal cavity. Peritoneal dialysis is continuous and fluid exchanges 
can either be performed manually, usually four times a day (continuous 
ambulatory peritoneal dialysis, CAPD) or can be done automatically 
overnight (automated peritoneal dialysis, APD) which allows a greater 
number of fluid exchanges to be performed whilst the patient sleeps.  
 
 
 
 
 
 
 
 
 
 
Figure 1-b.     Figure 1-c.  
Peritoneal dialysate.   Tenckhoff catheter. 
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1.3 The history of dialysis 
 
1.3.1 Haemodialysis 
Haemodialysis (HD) was first described in the early 1900s. However, it 
was not until the 1960s that HD became a viable technique for the long-
term treatment of patients with ERF. This was enabled by the 
development of a reliable and safe Teflon arteriovenous shunt that 
allowed adequate rates of blood flow, and also by the availability of 
heparin to prevent clotting in the extracorporeal circuit (as opposed to the 
unpredictable natural hirudins). Although viable, early HD was beset with 
problems. Low efficiency of the dialysers in terms of solute removal led to 
long treatment times. Ultrafiltration (UF) was controlled manually by 
adjustment of the blood and dialysate pumps to create a pressure 
gradient that led to unpredictable UF rates. Blood leaks in the dialyser 
and lines were common and there were concerns about bacterial 
contamination of the dialysate fluid. Also, it was not possible to produce a 
commercially viable dialysate solution that contained bicarbonate as a 
buffer because bicarbonate and calcium precipitate at a pH greater than 
7.4. Therefore, non-physiological acetate was employed as a buffer that 
diffused into the patient and was subsequently converted into bicarbonate 
by the liver. However, acetate transfer into the patient strongly 
predisposes to intradialytic symptoms, in particular hypotension (IDH), 
headaches and hypoxia [5].   
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Significant advances have been made over the subsequent years. The 
advent of hollow fibre dialysers industrialised the process of dialysis and 
greatly increased the ease of setting up a dialysis circuit. As hollow fibre 
dialysers became more efficient treatment times have become shorter, 
although shorter dialysis sessions with greater UF rates may themselves 
contribute to IDH. Dialysis membranes are now synthetic, which improves 
their biocompatibility. Bicarbonate-based dialysis became possible, 
initially using concentrated bicarbonate solutions although these solutions 
were prone to bacterial contamination. Subsequently dry bicarbonate 
concentrates were developed that overcame the problems of 
precipitation, microbial growth and the storage of large amounts of 
bicarbonate solution. In the 1980s the concept of Kt/V, a measure of the 
amount of urea cleared by dialysis in relation to body size, became widely 
accepted. Importantly, it was shown that too little dialysis (as measured 
by a low Kt/V) was associated with increased mortality [6, 7]. Finally, 
various modifications of the dialysis technique have become common 
practice. The most widespread of these is haemodiafiltration (HDF), a 
technique based on additional convective clearance due to high UF 
volumes and subsequent fluid reinfusion. HDF may confer benefit in 
terms of stability on dialysis and greater clearance of some uraemic 
middle molecules.  
However, despite these technological advances HD remains an imperfect 
treatment. Dialysis only partially replicates the removal of fluid and 
uraemic toxins by the kidney, and does not replace any of its hormonal 
functions. The intermittent nature of dialysis dictates repeated, rapid shifts 
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between fluid overload and euvolaemia, and IDH remains a complication 
of up to a third of treatments. In addition, the cardiovascular death rate of 
haemodialysis patients is extraordinarily high [8]. 
 
1.3.2 Peritoneal dialysis 
The earliest report of instillation of fluid into the peritoneal cavity for 
therapeutic purposes was in 1743, when Christopher Warrick instilled 
Bristol water and claret wine to treat ascites. The first description of 
successful dialysis using the peritoneum as a semi-permeable membrane 
was in 1923. The dialysate consisted of an electrolyte solution designed 
to mimic normal plasma, tempered by a series of compromises to allow 
production and stability under storage conditions of the fluids. These 
meant that glucose was used as the main osmotic agent, buffered with 
lactate alone (that produced a low pH). This allowed sterilisation of the 
fluids by heat with avoidance of caramalisation of the glucose. Early 
peritoneal dialysis (PD) techniques were hampered by high rates of 
infection and the requirement for repeated placement of catheters. In 
addition, early PD was an intermittent hospital-based technique, with 
some patients needing up to 60 hours per week of in-patient dialysis. PD 
became a viable technique to treat large numbers of patients with ERF in 
the late 1970s following the development of the Tenckhoff catheter 
(polyethylene catheter with Dacron cuffs designed to be tunnelled 
subcutaneously) and a simple, commercially available closed system for 
drainage and instillation of the fluid which minimised the chances of 
bacterial contamination (see figures 1-b and 1-c). These advances 
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allowed PD to be performed on an out-patient basis. Currently, it is still 
convention to use glucose as the osmotic agent, although different 
glucose concentrations have become available to allow tailoring of UF 
volumes. These conventional fluids employ lactate as the buffer, and this 
renders the fluids acidic. Again bicarbonate has traditionally been avoided 
due to problems with precipitation. Low pH results in increased infusion 
pain [9] and directly effects neoangiogenesis and mesothelial cell 
damage [10]. Furthermore, due to the acidic nature of the fluids and the 
heat sterilisation process, such fluids also contain glucose degradation 
products (GDPs) that also have been shown to have undesirable effects 
both on the peritoneum and systemically after absorption [11]. 
Continuous ambulatory peritoneal dialysis (CAPD) and automated 
peritoneal dialysis (APD) are now well established techniques in the 
treatment of ERF. Recent improvements to the technique have also been 
made, largely based around the development of more biocompatible 
dialysate fluids. There are those that do not contain glucose and therefore 
have very few or no GDPs; these comprise of Icodextrin (Extraneal®, a 
large molecular weight glucose polymer that is not systemically absorbed) 
and 1.1% amino acid solution (Nutrineal®, which may have beneficial 
effects on protein malnutrition). However, both of these solutions use a 
lactate buffer. Newer glucose-based fluids have also been developed with 
bicarbonate as a buffer, present in a separate chamber and mixed 
immediately prior to instillation. These fluids have a neutral pH and 
therefore also have much lower levels of GDPs as compared to 
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conventional solutions. Current commercially available peritoneal dialysis 
fluids are summarised in table 1-a. 
However, peritoneal dialysis remains imperfect. Peritonitis remains a real 
problem, and over time the peritoneal membrane undergoes diabetiform 
change. Eventually, the peritoneum fails as an adequate selectively 
permeable membrane [12]. This is in part due to the bioincompatible 
nature of conventional fluids with an acidic pH and the presence of GDPs. 
However, the presence of glucose is also strongly implicated and 
supraphysiological glucose concentrations still occur with the newer 
dialysate solutions (Icodextrin and Nutrineal are only licensed for once 
daily administration). In addition, glucose and possibly GDPs are 
systemically absorbed, which in the case of glucose leads to weight gain 
and hyperinsulinaemia [13]. Registry data have suggested that 
conventional solutions may even have a negative impact on patient 
survival, although this must be interpreted within the limitations of a 
retrospective observation study [14]. As with HD, PD patients are also 
exposed to greatly increased rates of cardiovascular death. This is 
present at similar level to HD despite the differences between the dialysis  
techniques [15].  
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 Potential 
drawbacks 
Potential  
Benefits 
 
Single bag solutions 
  
Glucose containing, 
lactate buffer 
• Dianeal® 
(Baxter) 
• Low pH 
• High GDP content 
• Poor peritoneal 
membrane 
biocompatibility 
• Infusion pain 
• Local and systemic 
glucose exposure 
• Ease of manufacture 
• Low cost 
Icodextrin containing, 
lactate buffer 
• Extraneal® 
(Baxter) 
 
• Hypersensitivity 
• Low pH 
• Licensed for single daily 
use only 
• Lactate containing 
 
• Sustained ultrafiltration 
• Preservation of residual 
renal function 
• Replacement for hypertonic 
glucose solutions 
• Reduced hyperglycaemia 
• Improved short term 
systemic haemodynamic 
profile 
• Desirable effects on 
metabolic profile and body 
composition 
Amino acid containing, 
lactate buffer 
• Nutrineal®   
       (Baxter) 
• Low pH 
• Licensed for single daily 
use only (to avoid 
exacerbation of uraemic 
symptoms and acidosis) 
 
 
• No GDPs 
• Avoid systemic and 
peritoneal glucose exposure 
• Peritoneal membrane 
protection 
• Enhance nutrition 
 
Multibag solutions 
  
Lactate buffered 
• Balance® 
(Fresenius) 
• Gambrosol 
Trio® 
(Gambro) 
• More physiological pH, 
but not neutral 
• Local and systemic 
glucose exposure 
 
• Lower GDP levels 
• More physiological pH 
• Improved peritoneal 
membrane biocompatibility 
• Preserved membrane 
defence 
Lactate/ bicarbonate 
buffered 
• Physioneal® 
(Baxter) 
• Local and systemic 
glucose exposure  
• Does not eliminate 
peritoneal lactate 
exposure 
• Lower GDP levels 
• More physiological pH 
• Improved peritoneal 
membrane biocompatibility 
• Preserved membrane 
defence 
• Reduced infusion pain 
Bicarbonate buffered 
• bicaVera® 
(Fresenius) 
• Local and systemic 
glucose exposure 
• Lower GDP levels 
• More physiological pH 
• Improved peritoneal 
membrane biocompatibility 
• Preserved membrane 
defence 
• Improved correction of 
acidosis 
 
 
Table 1-a. Summary of the characteristics of currently available PD solutions. 
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1.4 Cardiovascular disease in haemodialysis patients 
 
It is well recognised that dialysis patients display hugely elevated rates of 
cardiac mortality, at least thirty-times greater than age-matched controls 
(figure 1-d, [8]). Although there are undoubtedly several mechanisms that 
contribute to this, the development of cardiac failure (which occurs in as 
many as 25-50% of haemodialysis patients) confers a particularly bleak 
prognosis [16]. Such high levels of cardiovascular disease are in part due 
to the high prevalence of ‘traditional’ risk factors (diabetes, hypertension, 
hyperlipidaemia, smoking, and physical inactivity). However, treating 
these traditional risk factors in dialysis patients has been disappointing; 
for example no benefit was observed with cholesterol lowering in diabetic 
haemodialysis patients [17]. The management of hypertension is 
particularly contentious, with no clear evidence that aggressive blood 
pressure lowering leads to a reduced risk of mortality [18, 19]. 
 
 
Figure 1-d.  
Graph showing the cardiovascular mortality rates by age and ethnicity for dialysis 
patients and healthy controls [8]. The y-axis is a logarithmic scale, emphasising the huge 
excess of cardiovascular death seen with dialysis patients. 
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Therefore this excess of cardiovascular disease in dialysis patients must 
be explained by the presence of unique metabolic and haemodynamic 
derangements, the so-called ‘uraemic’ risk factors. These uraemic risk 
factors are less well defined but are multiple. Vascular calcification with 
increased vessel stiffness is common, is associated with the development 
of left ventricular hypertrophy (LVH) and also independently predicts 
mortality [20]. The presence of LVH itself predicts a worse long term 
outcome, and is associated with an increased propensity to cardiac 
arrhythmias [21]. In addition to vascular calcification, hypertension also 
leads to LVH [22], as does recurrent volume overload with rapid fluid 
shifts (that occur on dialysis). Hyperparathyroidism and anaemia have 
also been implicated in the genesis of LVH (although the issue of 
anaemia remains controversial as interventional studies have not always 
demonstrated that an improvement in haemoglobin concentration 
reduces LVH [23, 24]). Cardiac mortality in dialysis patients has also 
been linked to chronic inflammation, often manifest as hypoalbuminaemia 
and elevated C-reactive protein (CRP) levels. Inflammation is associated 
with accelerated atherosclerosis, vascular calcification and increased 
muscle catabolism [25]. Certainly, the elevation of several cytokines (in 
particular CRP and interleukin-6) have also been shown to be associated 
with an increase in mortality [26, 27]. In addition, it is possible that risk 
factors exist that are directly related to the dialysis procedure. 
 
It has long been suspected that myocardial ischaemia may be 
precipitated by haemodialysis, with the first report of silent ST segment 
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depression during dialysis dating back to 1989 [28]. However, this 
concept of dialysis induced subclinical ischaemia (occurring without acute 
atherosclerotic plaque rupture) has received remarkably little attention, 
despite its theoretical plausibility. Short intermittent haemodialysis 
treatments by necessity lead to high UF rates, and as such exert 
significant haemodynamic effects; 20-30% of dialysis treatments are 
complicated by IDH [29-31]. In conjunction with this, haemodialysis 
patients are particularly susceptible to myocardial ischaemia. In addition 
to the high prevalence of coronary artery atheroma [32, 33], diabetic 
dialysis patients have been shown to have a reduced coronary flow 
reserve (CFR) even in the absence of coronary vessel stenoses [34]. 
There is preliminary evidence that the same phenomenon is also seen in 
non-diabetic dialysis patients [35]. In part this may be due to LVH, 
present in 74% of patients on dialysis [36]. LVH leads to both structural 
and functional reductions in the myocardial microcirculation; a capillary-
myocyte mismatch has been described, and the presence of LVH per se 
reduces CFR even in the absence of large vessel disease [37]. In 
addition, the presence of concentric LVH renders the ventricle more 
sensitive to acute changes in filling pressure, exactly as occurs during 
haemodialysis [38]. Increased peripheral artery stiffness is also 
recognised to have an adverse effect on myocardial perfusion and 
reduces the ischaemic threshold [39]; therefore, LVH in tandem with 
increased vascular stiffness leads to a propensity to reduced 
subendocardial blood flow [40]. In addition, dysregulation of blood 
pressure control due to abnormal baroreflex sensitivity [41] and 
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vasoregulatory failure leading to the increased reliance of blood pressure 
on cardiac output [42] also increase the risk of myocardial hypoperfusion. 
 
Since the initial report by Zuber et al [28], there have been a further nine 
studies that have demonstrated silent ST segment depression occurring 
during dialysis [43-51]. These studies report the occurrence of dialysis 
induced ST depression at rates that vary between 15 and 40%. However, 
there has been ongoing debate as to whether these electrocardiographic 
abnormalities reflect silent ischaemia or changes in electrolyte 
concentrations. Other than this, there has been only one subsequent 
study that has demonstrated ischaemia using an alternate technique. 
Singh et al assessed dialysis induced ischaemia using sestamibi single 
photon emission computed tomography (SPECT) [52]. In an unselected 
group of ten dialysis patients who were not known to have coronary artery 
disease, seven developed perfusion defects during dialysis. Importantly, 
concurrent ST depression occurred with the perfusion defects in only 
three patients, suggesting that electrocardiographic assessment alone 
may underestimate the incidence of dialysis induced ischaemia. 
However, none of these studies included an intervention to attempt to 
reduce the frequency of dialysis induced ischaemia, nor did any search 
for potential long term sequelae on LV function.  
 
In non-renal patients, transient myocardial ischaemia may lead to LV 
dysfunction that can persist after the return of normal perfusion. This 
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prolonged dysfunction is known as myocardial stunning [53]. Myocardial 
stunning has been demonstrated in patients with coronary artery disease 
after exercise and dobutamine stress, and recent studies have provided 
evidence that repetitive episodes of ischaemia can be cumulative and 
lead to prolonged left ventricular dysfunction (myocardial hibernation) [53-
59]. Myocardial stunning is therefore increasingly thought to be a 
causative mechanism for heart failure, with stunning and hibernation 
existing as part of a single spectrum (figure 1-e). Therefore, if myocardial 
ischaemia is induced by haemodialysis then the process of haemodialysis 
itself, repeated thrice weekly, may potentially contribute to chronic cardiac 
damage in this patient group. However, all of the available human data 
concerning myocardial stunning has been derived from patients with large 
vessel coronary artery disease and normal renal function.   
 
 
 
 
 
 
 
 
 
 
 
Figure 1-e. 
Repeated episodes of transient myocardial ischaemia lead to maladaptive intracellular changes 
resulting in reduced myocardial function, hibernation and eventually cell death [60]. 
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1.5 Dialysis induced changes in biomarkers of cardiac damage  
 
It is well recognised that cardiac troponins are often elevated in dialysis 
patients, and that elevated levels independently predict mortality [61, 62]. 
Although this trend is seen for both troponin T (cTnT) and troponin I 
(cTnI), the data are more compelling for cTnT due to the larger number of 
studies, the uniformity of assays and greater homogeneity of cut off 
points employed. In addition, cTnT is elevated more frequently than cTnI, 
suggesting this molecule may be a more sensitive marker [61, 63]. These 
findings have previously been summarised in an excellent meta-analysis 
[62]. Although there was initial debate about the origin of elevated 
troponins in renal disease, it is now clear that the troponins are cardiac in 
origin, and it is the intact molecule (as opposed to smaller fragments) that 
are detected by the current assays [64]. 
 
However, there is continuing debate as to whether troponin rises acutely 
following dialysis.  Several authors have reported significant rises in cTnT 
post dialysis consistent with acute myocardial cell injury [63, 65, 66]. 
Others have found no difference in pre and post dialysis cTnT or cTnI 
levels, or found that any difference disappears after correction for 
haemoconcentration [67-69]. Although it is convenient to collect the post 
dialysis blood sample at the end of the dialysis session, plasma troponin 
levels may only become elevated after 6 to 12 hours following an episode 
of ischaemia. Therefore, these discrepant results may arise from the 
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timing of the second blood sample, which in all of these studies was 
immediately post dialysis.  
 
There is a much smaller literature concerning acute effects of dialysis on 
creatinine kinase (CK) and creatinine kinase MB (CKMB). CK and CKMB 
are chronically elevated less often in dialysis patients as compared to 
troponins [70-75]. Elevations in CK have not been shown to have long-
term prognostic implications [76, 77], although there have been some 
data to show that chronically elevated CKMB levels do predict cardiac 
events and mortality, albeit to a lesser extent than troponins [70]. CK 
does not appear to rise with dialysis and although one author has 
reported a fall in CK post dialysis, this is not consistent with its large 
molecular weight [68]. There have been suggestions that CKMB may rise 
acutely following dialysis [66, 78], although this has not been a universal 
finding [71]. It has been previously demonstrated that CKMB rises acutely 
following dialysis complicated by IDH, but remains unchanged when 
patients are stable [78]. Although this is also consistent with subclinical 
myocardial injury, the consistency of this finding (with blood sampling 
immediately post dialysis) requires confirmation by other studies as 
CKMB may also take up to six hours to rise following an ischaemic insult. 
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1.6 Intradialytic hypotension 
 
IDH remains a significant cause of morbidity in the haemodialysis 
population, occurring in 20-30% of treatments [31]. In addition, a fall in 
blood pressure during dialysis predicts mortality [79]. Furthermore, IDH 
could potentially contribute to myocardial hypoperfusion during dialysis.  
The initiating factor in the aetiology of IDH is the rate of UF exceeding the 
plasma refill rate, leading to a reduction in circulating volume. 
Hypotension occurs when this reduction in blood volume surpasses the 
compensatory mechanisms of the cardiovascular system. As such, there 
are several factors of importance that can influence the genesis of IDH 
(summarised in figure 1-f). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-f. 
Summary of the many inter-related factors that lead to intradialytic hypotension.  
TPR = total peripheral resistance, SV = stroke volume, CAD = coronary artery disease.  
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1.6.1 Haemodynamic response to dialysis 
Dialysis with ultrafiltration provokes several cardiovascular responses 
[30]. Stroke volume (SV) and cardiac output (CO) fall, traditionally thought 
to be in response to reduced ventricular refill rates that reflect falling 
blood volume. In response to this, total peripheral resistance (TPR) rises 
in an attempt to maintain blood pressure (BP). This rise in TPR appears 
to be mediated by changes in small artery compliance [80], which are in 
turn due to activation of the sympathetic nervous system [81]. Often there 
is little change in heart rate (HR). At the end of dialysis BP is largely 
dependent on CO, suggesting that the adaptive vasoconstriction 
response is often maximal [42]. The rising TPR (which leads to a fall in 
pressure in the venous capacitance vessels, thereby increasing venous 
recoil) and the rise in sympathetic outflow combine to cause 
venoconstriction with centralisation of blood volume. However, in many 
dialysis patients these compensatory responses are impaired. Many 
patients have cardiac failure and LVH, both of which influence SV, CO 
and therefore BP; a stiff, hypertrophied ventricle is much more sensitive 
to acute changes in preload (as occurs during dialysis) as compared to 
those without LVH. This is manifest in some patients that are prone to 
IDH, in whom SV appears to decline to a greater degree as compared to 
stable patients [29]. Autonomic neuropathy is associated with an 
increased propensity to IDH and is present in many patients on dialysis 
[82, 83]. In addition, considerable variability in venous compliance exists. 
Therefore, as long as haemodialysis is a short intermittent treatment 
there will be a requisite for high UF rates and IDH will remain a prevalent 
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complication. As such, there have been many different attempts to try and 
modify the dialysis technique to improve cardiovascular response and 
reduce IDH.  
 
1.6.2 Relative blood volume and ultrafiltration rate 
UF rate is important in determining blood volume [84]. Studies have 
shown that IDH occurs once the reduction in blood volume exceeds a 
critical threshold that is specific for each patient, although there remains a 
small but significant proportion of patients for whom this relationship 
between blood volume and IDH does not exist [85]. It is possible to 
reduce the rate of UF by extending the length of dialysis sessions and 
although this approach may be efficacious, it is often unacceptable to 
patients. Other than reducing the interdialytic weight gain, which to a 
large extent is patient-dependent, a form of biofeedback dialysis has 
been designed to preserve blood volume to an extent that avoids 
hypotension (Hemocontrol, Gambro-Hospal, Mirandola, Italy) [86]. 
Relative blood volume (RBV) is monitored by an optical absorption 
biosensor, and significant falls (defined on an individual basis) are 
countered by temporarily reducing the UF rate and increasing the 
dialysate sodium conductivity. This is done within defined limits to ensure 
that total ultrafiltration and sodium depuration are unaffected. Several 
studies have shown biofeedback dialysis to be effective in reducing IDH 
frequency in both IDH prone and resistant patients [87-89]. 
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1.6.3 Dialysate temperature 
Standard dialysis (with a dialysate temperature of 370C) leads to an 
increase in patient body temperature [90]. The reasons for this are not 
entirely clear, but may include heat transfer to the patient from warm 
dialysate (especially as many dialysis patients have low baseline core 
temperatures), reduced heat loss from the skin due to vasoconstriction or 
possibly increased thermogenesis from an inflammatory response to a 
blood-membrane reaction. Cooling the temperature of the dialysate has 
been shown to reduce the incidence of IDH [90]. However, cooling the 
dialysate remains a relatively under utilised technique. In part this may be 
due to fears of causing unacceptable symptoms of cold and shivering, as 
empirical reduction of dialysate temperature may in some patients lead to 
excessive cooling. In addition, there has also been concern that cooling 
the dialysate will lead to a reduction in dialysis adequacy due to 
peripheral solute sequestration as a result of greater vasoconstriction. 
More recently, a biofeedback device has been developed (BTM, 
Fresenius, Bad Homburg, Germany). This device measures the 
temperature of blood in the arterial and venous bloodlines leaving the 
fistula and makes a correction for recirculation. It is able to calculate 
energy transfer and can make constant adjustments to the dialysate 
temperature during dialysis in response to the calculated body 
temperature. BTM can therefore be programmed in a variety of ways; it 
can deliver a predetermined energy balance (either negative balance or 
thermoneutral dialysis where energy balance is neutral), or it can deliver 
a prescribed change in body temperature (programmed cooling or 
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isothermic dialysis where patient’s body temperature is maintained). 
Isothermic dialysis requires a negative energy balance to maintain body 
temperature. By reacting to an individual patient’s core temperature, BTM 
and in particular isothermic dialysis should theoretically avoid severe 
thermal symptoms. 
Dialysis techniques that use proportionally greater degrees of convection 
to remove uraemic toxins (haemofiltration, HF or haemodiafiltration, HDF) 
have also been linked to improvements in stability during dialysis (in 
addition to their other potential advantages on solute clearance) [91]. 
However, there is accumulating evidence that most, if not all of this 
benefit on stability is due to thermal effects. When dialysis and HDF are 
matched for thermal energy transfer, low flux dialysis is equivalent in 
terms of IDH frequency and changes in systemic haemodynamics to both 
pre and post dilution HDF [92-94]. 
 
1.6.4 Dialysate sodium concentration 
Dialysate sodium levels also influence IDH. Complete removal of the 
inter-dialytic accumulation of sodium is a key requirement of 
haemodialysis. Failure to do so leads to greater thirst, increased 
interdialytic weight gains (IDWG) and hypertension, which in turn impact 
on cardiovascular outcomes [95]. Furthermore, large IDWG also 
predispose to IDH. Current practice of a fixed dialysate sodium for all 
patients may not only result in repeated failure to adequately remove the 
interdialytic sodium load, but could lead to intradialytic diffusion of sodium 
into those patients with lower pre-dialysis plasma sodium levels [96].  
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Empirical reduction of dialysate sodium to below plasma water sodium 
enhances sodium removal by diffusion, and may lead to a reduction in 
total body sodium. However, in the early period of dialysis this may result 
in an excessive reduction in plasma tonicity with resultant symptoms and 
hypotension. Although most studies show that this approach results in 
improvements in blood pressure (BP), reductions in IDWG and fewer 
symptoms of thirst, others do not report such differences or find the 
reverse [97-103]. Furthermore, the greatest benefits seen at the lowest 
dialysate sodium conductivities (13.0mS/cm) were only achievable in a 
limited number of patients due to intradialytic symptoms [102]. 
A fixed dialysate sodium does not always lead to the same amount of 
sodium depuration as pre dialysis plasma sodium levels vary both 
between and within individuals [104]. Individualising dialysate sodium 
concentration based on pre dialysis sodium levels does avoid sodium 
loading during dialysis [96, 97]. However, this method is time consuming 
and requires ongoing monitoring of pre-dialysis sodium levels. A more 
sophisticated approach is a biofeedback system (Diacontrol, Gambro-
Hospal, Mirandola, Italy) that returns plasma conductivity (as a surrogate 
marker of plasma sodium concentration) to a prescribed level. Diacontrol 
(DC) aims to achieve total removal of the interdialytic sodium load by 
returning the patient to a predefined post-dialysis sodium level, and 
therefore a fixed total body sodium by the end of each dialysis (assuming 
dry weight is also attained). This is achieved by online monitoring of 
plasma conductivity, which reflects plasma sodium [105]. Automatic 
adjustment of the dialysate conductivity is then performed via a negative 
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feedback loop to deliver the prescribed end-dialysis plasma conductivity. 
Therefore, the interdialytic sodium is completely removed even when pre 
dialysis sodium levels vary. Diacontrol (DC) has been shown to 
repeatedly achieve prescribed end dialysis plasma conductivities within 
very tight limits at settings above 14.0mS/cm [105]. However, although 
early studies suggested improved haemodynamic stability with this 
technique [106-108], clinical evaluation of DC remains relatively limited. 
The improved stability was thought to be due to the biofeedback system 
maintaining dialysate sodium levels at a higher level early in the dialysis 
session, thereby avoiding rapid reductions in plasma tonicity. This is 
shown in figure 1-g.  
 
 
 
Figure 1-g.  
Diacontrol. The upper figure shows plasma (Γpeff) and dialysate (ΓD) conductivity. Note 
the higher time averaged dialysate conductivity in the early part of the dialysis session, 
and that blood volume rises at 90min corresponding to the increase in dialysate 
conductivity. 
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1.6.5 Buffer composition 
Historically, acetate was used as the sole buffer in haemodialysis. 
However, it was recognised that acetate was an aetiological factor in IDH, 
and switching from acetate to bicarbonate as the principle buffer 
improved cardiovascular stability and reduced intradialytic symptoms [5].  
However, the aetiology of acetate-induced IDH remains contentious. 
Acetate has been shown to cause vasodilatation that is mediated by nitric 
oxide release, but has also been shown to reduce myocardial contractility 
[109-112]. Many of these studies were carried out in animal models, and 
debate remains about validity of the results from some of the studies in 
humans. Despite this, standard bicarbonate based dialysis is not acetate 
free. Small amounts of acetate (3-4mmol/l) are required to prevent 
precipitation of calcium carbonate, and although the concentration of 
bicarbonate in dialysate is relatively large compared to that of acetate, the 
difference in dialysate/plasma concentration gradients is much less 
because plasma acetate levels are usually very low (<100µmol/l) [113]. 
Therefore, standard bicarbonate based dialysis can still result in 
significant transfer of acetate to the patient, making up as much as 25-
49% of the buffer load [113, 114]. The original solution to this problem 
was the development of acetate-free biofiltration (AFB). AFB is a 
haemodiafiltration technique in which a post-dilution bicarbonate infusion 
is used in combination with base-free dialysate. This technique is 
significantly more complex than standard dialysis, and also incurs 
problems due to storage and handling of the bicarbonate re-infusion fluid. 
Nonetheless, AFB has been shown to be associated with less IDH and an 
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improvement in pre-dialysis BP [115, 116]. However, an alternate acetate 
free dialysis method has now been developed. Paired haemodiafiltration 
(PHF, Bellco, Mirandola, Italy) is a novel online technique that employs a 
double chamber dialyser (consisting of a high flux dialyser and ultrafilter, 
see figure 1-h) that allows re-infusion to take place inside the dialyser. 
PHF is designed to be used with dialysate that is completely acetate free. 
In place of acetate, the dialysate concentrate contains hydrochloric acid 
to prevent calcium precipitation (this is converted to water and sodium 
chloride during online dialysate preparation) and there is no requirement 
for a sterile bicarbonate infusion. PHF is therefore much easier to perform 
as compared to AFB. One previous study has shown that PHF is a 
feasible technique [117], but there are no studies examining the clinical 
and haemodynamic response to acetate-free PHF.  
 
 
 
 
Figure 1-h.  
Double chamber dialyser used for PHF. The smaller chamber is the ultrafilter for the 
reinfusate, the larger chamber is the high flux haemodiafilter. 
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1.7 Cardiovascular effects of peritoneal dialysis 
 
CAPD and APD are widely used treatments for ERF. Overall and 
cardiovascular death rates are similar in haemodialysis and peritoneal 
dialysis populations [15]. Some uraemic risk factors, such as LVH and 
vascular calcification exist in both HD and PD patients; however, there 
are many differences between haemo- and peritoneal dialysis. In contrast 
to haemodialysis, UF and solute removal take place continuously and at a 
much slower rate. CAPD is generally regarded as being better tolerated 
from a cardiovascular point of view, but as compared to haemodialysis 
there is a relative of paucity of research in this area. One recent study 
suggested that haemodynamic changes in response to CAPD are greater 
than previously thought when examined during a 30min dwell of a 
standard peritoneal permeability analysis [118]. Other work on this 
subject dates back more than 20 years, used intermittent monitoring 
techniques and produced conflicting data [119-121]. It is also conceivable 
that there may be variation in the haemodynamic response to the wide 
selection of commercially available peritoneal dialysis solutions. These 
fluids differ in the strength and type of osmotic agent (glucose, Icodextrin, 
amino acids), their buffer type and biocompatibility. The different tonicities 
of the glucose based solutions produce different amounts and rates of 
ultrafiltration. However, there are no data available on the haemodynamic 
effects directly attributable to glucose-containing or alternative dialysate 
fluids, or whether buffer type and biocompatibility of the fluid exert an 
effect. 
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In contrast to haemodialysis, peritoneal dialysis may be associated with 
greater metabolic perturbation. Glucose is systemically absorbed leading 
to impaired insulin sensitivity and weight gain [13]. In non-diabetic 
cohorts, insulin resistance and excursions of plasma glucose to outside of 
the normal range in response to an oral glucose load are recognised as 
predicting cardiovascular death [122, 123]. Furthermore, there is also 
some evidence that GDPs disappear from the peritoneal cavity and are 
systemically absorbed [124, 125]. This is of importance as some GDPs 
have been shown to directly cytotoxic and to increase the production of 
advanced glycation end-products, another factor implicated in 
atherogenesis [11, 126-128].  
In addition, there is a theoretical link between haemodynamic and 
metabolic changes induced by peritoneal dialysis using glucose 
containing dialysate. BP has been shown to rise in response to 
hyperglycaemia in several studies in both non diabetic and diabetic 
patients, while glucose and insulin exert independent effects on systemic 
haemodynamics [129, 130]. Marfella et al demonstrated a rise in BP 
during hyperglycaemia, during both normal and elevated insulin levels 
[130]. BP was returned to baseline with a glutathione infusion, suggesting 
the direct effect of hyperglycaemia on haemodynamics may be mediated 
by free radical production leading to reductions in nitric oxide.  Equally, 
hyperinsulinaemia during euglycaemic clamp experiments has been 
shown to cause elevations in HR, SV and CO whilst also causing a fall in 
TPR [131]. It is not currently known whether GDPs are active in this way.  
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As seen in haemodialysis patients, elevated cTnT levels in CAPD 
patients independently predict mortality [132, 133]. Elevated cTnT levels 
also correlate with increasing LV mass index (LVMI). However, the 
predictive power of an elevated cTnT on mortality is independent of its 
association with increased LVMI or elevated CRP. The reasons behind 
elevated cTnT levels in peritoneal dialysis patients have not been 
elucidated. Some authors postulate that they may reflect subclinical 
myocardial damage due to undetected coronary artery disease, a 
combination of LVH and microvascular coronary disease or direct injury 
to myocardial cells (uraemic toxins, stretching due to fluid overload, or 
hypoxia) [132]. However, if the process of peritoneal dialysis is 
associated with significant haemodynamic disturbance then this may also 
impact on cTnT release. 
 
APD is an increasingly utilised modality in the treatment of ERF, used in 
preference to continuous ambulatory peritoneal dialysis to improve 
dialysis adequacy or for lifestyle reasons. Residual renal function (RRF) 
is extremely important in maintaining adequacy in peritoneal dialysis 
patients, and also in helping maintain fluid and electrolyte balance. In 
addition, maintenance of RRF has been shown to affect survival [134, 
135]. However, several studies have implicated APD in increasing the 
rate of decline of RRF as compared to CAPD, although the reasons for 
this remain unexplained [136-138]. Some authors have postulated that 
APD causes greater shifts in osmotic load and exerts more intensive 
ultrafiltration as compared to CAPD, and this in turn may potentially 
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cause adverse haemodynamic effects [136, 139]. However, there are no 
published data reporting the haemodynamic response to APD, despite 
the recent work showing CAPD to be associated with significant 
haemodynamic disturbance [118]. 
 
To summarise, relatively little is known about the effects of peritoneal 
dialysis on short term haemodynamic and myocardial function, although 
recent data suggest that such effects may have previously been under-
estimated. In the face of an excess of cardiovascular death it is important 
to search for novel cardiac risk factors, including those potentially related 
to the dialysis procedure itself. This is increasingly important as there are 
now several different opportunities to modify the technique of PD, in 
particular by altering the glucose content and biocompatibility of dialysate 
fluids. 
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2. Aims of thesis 
 
This thesis has been planned to test the following hypothesis: 
 
The haemodynamic stress of dialysis therapies leads to subclinical 
myocardial ischaemia and stunning, which may be novel risk factors for 
the development of uraemic cardiomyopathy. 
  
To do this, the following interrelated research questions will be 
addressed: 
 
 Is it possible to confirm that dialysis induced myocardial ischaemia 
and stunning occurs? 
 If so, can we intervene to reduce dialysis induced myocardial stunning 
by improving haemodynamic stability? 
 Which novel haemodialysis technologies are effective in improving 
haemodynamic stability and reducing IDH? 
 How extensive are the haemodynamic effects of peritoneal dialysis, 
and are these affected by the type of dialysate fluid used? 
 Does myocardial stunning occur in response to the haemodynamic 
changes of CAPD? 
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3. Generic Methods 
 
The following techniques are used in more than one chapter, and are 
therefore described fully only once. 
 
 
3.1 Non-invasive continuous haemodynamic monitoring 
 
The Finometer (Finapres Medical Systems, Arnhem, The Netherlands) is 
a tool for blood pressure and haemodynamic monitoring (figure 3-a). It is 
particularly useful due to its non-invasive nature and ability to provide 
continuous readings over a period of several hours. The Finometer works 
by continuous pulse-wave analysis at the digital artery and utilises the 
finger-clamp method, in which changes in digital arterial diameter are 
detected by means of an infrared photoplethysmograph [140] and 
opposed by an ultra-fast pressure servo controller that changes pressure 
in an inflatable air bladder, both mounted in a finger cuff. This generates 
an arterial waveform that is measured on a beat-to-beat basis and is used 
to reconstruct a central aortic waveform [141].  This allows calculation of 
a full range of haemodynamic variables on a continuous basis; these 
include pulse rate (HR), blood pressure (BP), stroke volume (SV), cardiac 
output (CO) and peripheral resistance (TPR). All data are subsequently 
downloaded to a PC based analysis program, allowing averaging of 
results over defined time periods. This technology provides 
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unprecedented resolution of changes in the critical cardiovascular 
variables. Previous work has validated the Finometer against invasive 
haemodynamic measurements in normals, unstable intensive care 
patients and in cardiac surgery patients, a proportion of whom had 
vascular calcification [142-144]. This has shown the Finometer to be 
accurate in tracking relative change. Data are therefore presented as 
percentage change from baseline except for BP, which is calibrated 
against brachial readings using a return to flow method and absolute 
values can therefore be used [145]. Validation of the Finometer in dialysis 
patients is presented in chapter 4.                                        
 
  
 
 
 
 
 
 
     
 
 
Figure 3-a. 
Non-invasive continuous haemodynamic monitoring with the Finometer. 
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3.2 Echocardiography 
 
We used two-dimensional echocardiography to assess regional LV 
function as a marker of ischaemia.  The development of new LV regional 
wall motion abnormalities (RWMAs) during physiological or 
pharmacological stress occurs in response to ischaemia and its onset 
precedes that of symptoms and electrocardiographic changes. This 
principle underlies dobutamine stress echocardiography [146].  
LV regional wall motion was assessed by recording standard apical views 
before, during and after dialysis procedures and then performing 
specialised semi-automated analysis on the images. Images were 
acquired using commercially available equipment (1.5-3.6 MHz 3S probe, 
Vivid 3®, GE medical systems, Sonigen, Germany). A single experienced 
technician (who was blinded to dialysis modality) carried out all 
examinations with the patients in the left lateral position. Timing of the 
echocardiography varied between studies but is stated in each relevant 
chapter. Standard apical 2-chamber and 4-chamber views (to visualise 
the LV endocardial border in two planes at 900 to each other) were 
recorded onto super-VHS videotape for off-line analysis. 
Videotaped images were subsequently analysed using a personal 
computer based digitising programme (Echo-CMS, MEDIS, Leiden, The 
Netherlands) as previously described [147]. Three consecutive 
heartbeats were analysed for each time point (extrasystolic beats were 
excluded). Endocardial borders (excluding papillary muscles) were traced 
semi-automatically for each videoframe of the 3-beat sequence, and any 
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anomalies corrected manually (see figure 3-b). Maximal displacement of 
the endocardial border from a centrepoint was then measured over each 
of 100 chords around the LV wall, corrected for end-diastolic LV 
circumference and expressed as percentage shortening fraction (SF), as 
shown in figure 3-c. Each apical view was divided into five segments and 
SF for the chords in each segment was averaged so ten regions of the 
left ventricle were assessed at each time point. New RWMAs were 
defined as those segments that demonstrated a decline in SF of >20% 
from baseline. This technique uses endocardial borders as the sole 
marker of abnormal contraction, and therefore could be criticised as it 
does not take account of wall thickening or transmyocardial 
heterogeneity. However, this method does have the advantage that it is 
repeatable and quantitative. 
We also used echocardiography to measure cardiac dimensions and 
global LV function. Ejection fraction (EF) was calculated using LV 
volumes at end systole and end diastole, measured by the biplane disk 
method. Left atrial volume, which has been used as a marker of diastolic 
function in haemodialysis patients [148], was calculated using single-
plane Simpson’s method from the apical 4-chamber view and indexed for 
body surface area. M-mode echocardiography was used to measure LV 
dimensions and LVMI was calculated from each patient’s original 
baseline images using the Devereux formula corrected for height2.7.  
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Figure 3-b.     Figure 3-c. 
Echo CMS. Figure 3-b shows semi-automatic tracing of the endocardial border. The 
movement of the endocardial border is then measured over 100 chords around the left 
ventricle – this is shown in figure 3-c with each red line representing a measurement. 
 
 
3.3 Dialysis methodology 
 
3.3.1 Blood volume measurement 
Blood volume measurement was performed by dialysis monitors in 
several of our experiments. Measurement of the change in the 
concentration of blood components (blood cells, proteins, haemoglobin) 
during dialysis reflects the balance between fluid removal from the 
circulation (ultrafiltration) and the plasma refill rate. There are two 
commonly available methods to measure blood volume - optical and 
ultrasonic. The optical method measures either haemoglobin 
concentration or the haematocrit by measuring the light absorbance of 
blood at two different frequencies. Measurement at two frequencies 
 36
allows correction for the degree of oxygenation, which can alter the light 
absorbance characteristics of blood.  
The ultrasonic method calculates the total protein concentration in blood 
(plasma proteins and haemoglobin) by measuring the velocity of sound in 
blood (which is determined by protein concentration) and compares this 
to the velocity of sound in isotonic saline. For this method, the 
temperature of the blood and saline must be accurately fixed, and the 
haematocrit is deduced from the total protein concentration using simple 
formulae.  
In our experiments, we used the optical method that has been 
commercially developed and incorporated into dialysis monitors [149].  
 
3.3.2 Conductivity measurement and ionic dialysance 
The conductivity of a substance is defined as the ability to carry electrical 
current. In dialysate fluid, the conductivity is determined by the 
concentration of ions capable of carrying electrical current, providing the 
temperature remains constant. This is almost entirely dependent on 
sodium concentration, although the other ions (such as potassium and 
calcium) that are present in much smaller quantities do exert a small 
effect. Therefore, by measuring conductivity of the dialysate it is possible 
to derive a value for dialysate sodium concentration [150]. This technique 
has a variety of applications. A conductivity monitor can be placed at the 
dialysate inlet and outlet ports of the dialyser and by changing the inlet 
conductivity by a set amount and measuring the resultant change in 
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dialysate outlet conductivity, it is possible to calculate ionic dialysance 
(value representing the amount of electrolytes that have passed from 
plasma to dialysate). From the degree of ionic dialysance that occurs at a 
set dialysate conductivity, it is possible to calculate plasma conductivity 
and this can be used a surrogate for plasma sodium concentration. As 
the transfer characteristics of sodium and urea are similar, the ionic 
dialysance also reflects the clearance of urea. Therefore, using this 
technology it is possible to estimate from each dialysis session the ionic 
mass balance (amount of sodium removed), the dialysis adequacy for 
small solute removal (Kt/V, providing the patient’s volume of distribution is 
known) and the plasma conductivity at the end of the treatment [150].  
 
3.3.3 Dialysis technique 
All dialysis described in this thesis was performed using Hospal Integra 
monitors (Gambro-Hospal, Mirandola, Italy) except for chapter 6, in which 
Bellco Formula 2000® monitors were used. In all cases, we used low-flux 
polysulphone dialysers either 1.8m2 or 2.0m2 as per individual patients’ 
usual prescription (LOPS 18/20, Braun Medical Ltd, Sheffield, UK) 
unless otherwise stated. Dialysate contained sodium 138mmol/l, 
potassium 1mmol/l, calcium 1.5mmol/l, magnesium 0.5mmol/l, 
bicarbonate 32mmol/l, glucose 1g/l and acetate 3mmol/l. All treatments 
were of 4 hours duration and anti-coagulation was achieved with 
unfractionated heparin. Dialysate flow was 500ml/min, dialysate 
temperature was set at 370C and blood flow was 250-460ml/min. For 
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paired sessions, care was taken to ensure blood flows were similar for 
each patient. Net fluid removal was set on an individual basis according 
to ideal dry weight. No patients underwent sodium or ultrafiltration 
profiling. 
 
 
3.4 ELISAs 
 
Enzyme linked immunosorbent assays (ELISAs) were used to 
quantitatively detect cytokines, proteins and hormones. Briefly, a 
monoclonal antibody against the molecule to be detected is adsorbed 
onto the surface of microwells. Samples or standards are then added to 
the wells and the molecule binds to these solid phase antibodies. A 
labelled antibody against the molecule is then also added and this also 
binds to the molecule to form a sandwich (solid phase antibody - test 
molecule - labelled antibody). After incubation, the wells are washed to 
remove unbound labelled antibody and a chromogenic reagent is added 
that reacts with the labelled antibody to produce a colour change. A stop 
solution is added to prevent excess colour development and the 
absorbance of each well is measured spectophotometrically. The 
absorbance is proportional to the concentration of test molecule present. 
A standard curve is drawn and values for the concentration of samples in 
each well can then be calculated. We used standard ELISA kits that 
provided precoated 96 well plates for detection of the following 
molecules. 
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3.4.1 Insulin (Biosource, Nivelles, Belgium) 
Blood was collected from patients in EDTA tubes and immediately 
centrifuged at 3500rpm for 10min. The plasma was then removed and 
frozen at -800C until time of assay. Samples were centrifuged again upon 
thawing at 17,000rpm for 3min to remove particulates. The INS-EASIA kit 
uses two monoclonal antibodies directed against distinct epitopes of 
insulin. 50µl of each calibrator solution, standards and samples were 
pipetted in duplicate into the precoated wells. 50µl of anti-insulin antibody 
conjugated with horseradish peroxidase (HRP) was then added to each 
well. The plate was then incubated at room temperature for 30min on a 
horizontal plate shaker (set at 700rpm). Each well was then aspirated and 
washed three times using 400µl of wash solution. 200µl of chromagen 
tetramethylbenzydine (TMB) solution was then added to each well and 
the plate incubated for 15min at room temperature on a horizontal shaker. 
50µl of stop solution (H2SO4) was then added to each well and 
absorbances read at 450nm (reference filter 650nm).  
 
3.4.2 C-reactive protein high sensitivity (DRG diagnostics, Marburg, 
Germany) 
Serum was isolated from blood collected in plain tubes and prepared as 
for the insulin ELISA. Before assaying, the serum was diluted 100-fold. 
The C-reactive protein (CRP) high sensitivity ELISA uses monoclonal 
mouse antibody for the solid phase and a goat anti-CRP antibody labelled 
with HRP. The methods were similar to the insulin ELISA but with the 
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following differences: 10µl of calibrators and samples and 100µl of HRP-
antibody were used, samples and antibody were incubated for 45min, 
wells were washed five times with distilled water, 100µl of TMB and stop 
solution were used. 
 
3.4.3 Interleukin-6 (Diaclone, Besancon, France) 
Interleukin-6 (IL6) was measured in plasma that was isolated as above. 
100µl of samples and calibrators were pipetted in duplicate into each well. 
50µl of anti-IL6 antibody conjugated to biotin was then added to each 
well, and the plate incubated at room temperature for one hour. The wells 
were then washed three times using 300µl of wash solution. 100µl of 
streptavidin-HRP was then added to each well and the plate incubated for 
30min. The wells were then washed in the same way and 100µl of TMB 
substrate added. The plate was then incubated for a further 15min. 100µl 
of stop solution was added and the plates read at 450nm (reference 
650nm). 
 
3.4.4 Tumour necrosis factor alpha (Bender MedSystems, Vienna, 
Austria) 
Tumour necrosis factor alpha (TNFα) was measured on plasma isolated 
as for insulin ELISA. The TNFα kit employed a monoclonal solid phase 
antibody and a biotin conjugated polyclonal antibody, and also required a 
tyramide signal amplification step. 50µl of diluent, 50µl of samples or 
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calibtrators and 50µl of biotin-conjugate were added to each well. The 
plate was then incubated at room temperature for two hours on a 
horizontal shaker at 100rpm. Wells were then aspirated and washed six 
times with wash solution. 100µl of streptavidin-HRP was then added to 
each well and the plate incubated at room temperature for one hour on 
the horizontal shaker. Wells were aspirated and washed as previously. 
100µl of the first amplification solution was added to each well and the 
plate incubated for 15min at room temperature. Wells were again washed 
and 100µl of the second amplification solution added. The plate was 
incubated for 30min before a further washing step and addition of 100µl 
of TMB solution to each well. The plate was incubated at room 
temperature for 10min before 100µl of stop solution was added to each  
well and absorbance measured as previously. 
The amplification step consisted of the addition of biotinyl-tyramide. This 
was converted by HRP to free radicals that bind any protein in the well, 
with the amount of bound biotinyl-tyramide proportional to the amount of 
HRP initially present. The second amplification solution contains further 
streptavidin-HRP that binds biotin sites created during the biotinyl-
tyramide reaction, thus multiplying the total number of available HRP 
molecules for the subsequent reaction with TMB. 
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4. Results: occurrence of regional left ventricular 
dysfunction in patients undergoing standard and 
biofeedback dialysis 
 
4.1 Introduction 
 
This chapter describes a study to determine whether standard 
haemodialysis with ultrafiltration is capable of inducing new LV regional 
wall motion abnormalities (RWMAs), reflecting subclinical myocardial 
ischaemia. To test the hypothesis that maintaining intradialytic blood 
pressure and improving the haemodynamic tolerability of dialysis reduces 
the development of LV RWMAs we compared standard dialysis (HD) to a 
form of biofeedback dialysis (BFD, Hemocontrol®). Hemocontrol 
(Gambro-Hospal, Mirandola, Italy) is a system that has been designed to 
preserve blood volume to an extent that avoids hypotension. Significant 
falls in relative blood volume (defined on an individual basis) are 
countered by temporarily reducing the UF rate and increasing the 
dialysate sodium conductivity. This is done within defined limits to ensure 
that total ultrafiltration and sodium depuration are unaffected. Several 
studies have shown BFD to be effective in reducing IDH frequency in 
both IDH prone and resistant patients [87-89]. 
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4.2 Methods 
 
4.2.1 Patients 
Eight chronic haemodialysis patients prone to IDH were recruited. All 
were male and had been on dialysis for more than 12 months.  All had LV 
hypertrophy (defined as LV mass index of >51g/m2.7) on analysis of 
baseline echocardiograms, and there was a high prevalence of 
atherosclerotic vascular disease. Six patients were treated with aspirin, 
one with clopidogrel and five were taking statins. Individual patient 
characteristics are shown in table 4-a.  
 
4.2.2 Study protocol 
Upon entry to the study, patients had their dry weight confirmed with 
reference to clinical examination. Following this, dry weight and anti-
hypertensive medications remained unchanged for the duration of the 
study. Patients were then randomised to group A or B. Group A patients 
were commenced on standard thrice weekly HD, whereas group B 
patients started thrice weekly BFD treatment. Both groups underwent one 
week of the dialysis therapy before undergoing a monitored session 
during one of the midweek dialysis sessions of the second week, 
consisting of serial echocardiography and non-invasive haemodynamic 
monitoring (using the Finometer). At the end of the second week, patients 
then crossed over to the other dialysis modality thereby acting as their 
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own controls. After a further week on the alternate modality, patients 
underwent a second monitored session. 
All patients gave informed consent prior to commencement, and ethical 
approval for the project was granted by Derbyshire Research Ethics 
Committee. 
 
 
Patient Age  Months 
on 
dialysis  
Cause of 
ESRF 
Vascular 
disease 
IHD LVMI 
(g/m2.7) 
Angiogram Anti-BP 
drugs 
1 68 45 APKD Y Y 
(angina) 
63.8 N† Diltiazem 
180mg od 
2 58 40 Obstructive 
uropathy 
N N 94.2 N  
3 53 15 Crescentic 
GN 
Y Y 
(angina) 
86.9 N Nifedipine 
60mg od 
4 72 47 Unknown Y Y (MI) 79.7 Y* ISMN 30mg 
od 
5 69 59 Diabetes Y Y (MI x 
3) 
86.5 N Lisinopril 
40mg od 
6 73 36 ARVD Y N 94.6 N Atenolol 
50mg od 
Lisinopril 
20mg od 
7 71 13 ARVD Y N 96.4 N  
8 80 22 Diabetes Y Y 
(angina) 
80.8 N  
Mean ± 
SD, or 
total 
number 
(%) 
8 ± 
8.6 
34 ± 16  7 (88%) 5 (63%) 85.4 ± 
10.7 
1 (13%)  
 
Table 4-a.  
Patient demographics. APKD= adult polycystic kidney disease, GN= glomerulonephritis, 
ARVD= atherosclerotic renovascular disease. IHD = ischemic heart disease, LVMI = LV 
mass index.  
* Angiogram result for patient 4: Circumflex occluded with some retrograde filling, right 
coronary artery occluded with good retrograde filling, left anterior descending artery 
some atheroma but no occlusive disease. 
†
 Patient 1 had recently had a dipyridamole stress test, showing a fixed apical perfusion 
defect with reversible inferior wall hypoperfusion. 
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4.2.3 Haemodialysis details 
Dialysis was performed as described in chapter 3. For standard HD, 
dialysate sodium conductivity was set at 13.6mS/cm. For BFD, 
conductivity limits were set at 13.0mS/cm and 14.0mS/cm. Automatic 
adjustment of dialysate conductivity by the dialysis monitor during 
Hemocontrol has been shown to achieve equivalent overall dialysate 
conductivity and therefore equal change in plasma water sodium 
concentration [86]. Limits for relative blood volume were set on an 
individual basis depending on measurements taken during the week prior 
to echocardiographic assessment. 
 
4.2.4 Echocardiography 
Echocardiography and subsequent analysis were performed as described 
in chapter 3. Images were recorded prior to commencing dialysis 
(baseline), at 120min and 240min during dialysis and 30min after dialysis 
was finished (recovery). 10 regions of the left ventricle were assessed for 
the development of new RWMAs at each time point. We calculated mean 
SF for all ten segments (SF(mean)) and for those segments that developed 
new RWMAs (SF(WMA)). Peak stress was defined for each patient as the 
point during the first monitored dialysis session when most RWMAs were 
present (either 120min or 240min). When comparing dialysis modalities, 
the same time point was used in the second dialysis session.  
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4.2.5 Finometer 
The Finometer was used as described in chapter 3. In addition, baroreflex 
sensitivity was also calculated from the regression slope between 
continuous interbeat interval and beat-to-beat BP changes. Three 
consecutive changes in the R–R interval in the same direction were 
required before a phase shift calculation (incorporated into Finometer 
software) was performed. Baroreflex sensitivity measured in this way is a 
composite marker of the overall activity of the autonomic nervous system 
[151]. 
Although the Finometer is becoming increasingly used to assess chronic 
dialysis patients [29, 30, 118] it has not been validated in patients with 
ERF. This may be important as dialysis patients are subject to a variety of 
unique pathophysiological processes affecting the vascular tree that may 
impact upon the reliability of results from the Finometer. We therefore 
carried out work to verify the accuracy of the Finometer in dialysis 
patients. 
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4.3 Validation of the Finometer in dialysis patients  
 
We performed simultaneous Finometer and echocardiographic 
measurements of stroke volume (SV) in chronic dialysis patients. We 
selected echocardiography as a standard as it is a widely accepted 
technique and is non-invasive. Invasive haemodynamic measurement 
techniques carry a small but significant risk of serious complications and 
in view of the available evidence supporting the accuracy of the 
Finometer it was considered unethical to use these as a comparator. 
 
We studied 13 unselected dialysis patients, four on haemodialysis and 
nine on CAPD, all of whom had been on dialysis for more than four 
months. The HD patients were examined before and at the end of a 
standard four-hour dialysis session (with ultrafiltration). The CAPD 
patients were examined before and after an exchange, where waste 
dialysate fluid was drained out of and 2.5L of fresh fluid drained into the 
abdominal cavity. 2-dimensional echocardiography was performed as 
described in chapter 3. A single experienced technician carried out all 
measurements with the patients in the left lateral position. Images were 
subsequently analysed and SV derived using the biplane disk method. 
Finometer values are a time average mean for a 5min period during 
which echocardiograms were acquired. As the Finometer is accurate in 
tracking change, data are expressed as percentage change from baseline 
(baseline data derived a 10min period before dialysis was commenced). 
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4.4 Statistical analysis 
 
Results are expressed as mean ± SD unless otherwise stated. 
Echocardiographic, BP and haemodynamic data were analysed using 
one-way analysis of variance (ANOVA) with a design for repeated 
measures and Bonferroni’s test to correct for multiple comparisons. The 
frequencies of IDH and of new RWMAs occurring during each dialysis 
modality were compared using Poisson regression. For other data, the 
paired t-test was used after significant deviations from a normal 
distribution were excluded with the Kolmogorov-Smirnov test. An alpha 
error at P<0.05 was judged to be significant. 
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4.5 Results 
 
4.5.1 Validation of the Finometer in dialysis patients 
We found a good correlation between percentage change in SV as 
derived by the Finometer and by echocardiography (r2 = 0.64, p<0.0001). 
Bland-Altman analysis demonstrated a mean difference of 1.7% change 
from baseline between SV measured by the two techniques, with limits of 
agreement of ± 9.3%. These data are shown in figure 4-a. 
This is the first validation of the Finometer in dialysis patients. These 
results support the premise that the Finometer is a useful and accurate 
monitoring tool in this patient group. 
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Figure 4-a.  
Bland-Altman plot of stroke volume (SV) measured as percentage change from baseline 
by the Finometer and by echocardiography in chronic dialysis patients. 
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4.5.2 Blood pressure data 
During standard HD, systolic BP (SBP) was 135 ± 30.8 mmHg, diastolic 
BP (DBP) was 73.2 ± 13.9 mmHg and mean arterial pressure (MAP) was 
93.9 ± 19.8 mmHg. During BFD all three BP parameters were higher - 
mean SBP was 143.1 ± 21.1 mmHg (p<0.001), mean DBP was 76.4 ± 
12.3 mmHg (p=ns) and mean MAP was 100.1 ± 3.3 mmHg (p<0.001). BP 
gradually declined during the second half of HD treatments whereas BP 
was maintained during the second half of BFD sessions, accounting for 
the difference in mean BP values. BP data are summarised in figure 4-b. 
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Figure 4-b.  
Population blood pressure (systolic and diastolic) data during standard (HD) and 
biofeedback (BFD) dialysis. For clarity, mean arterial pressure is omitted, but this was 
also significantly higher during BFD. 
* p<0.001 by ANOVA. 
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IDH was defined as any SBP of less than 100mmHg, or a fall in SBP of 
>10% from baseline in association with the classical symptoms of 
hypotension (dizziness, cramps, flushing). There were no episodes of 
symptomatic hypotension during the 16 monitored sessions, but we 
observed 24 asymptomatic episodes of IDH with HD as compared with 12 
during BFD (OR 2.0, 95% CI 1.01 to 4.4). These findings were in context 
of a slightly greater volume of ultrafiltration (UF) during BFD (1.91 ± 1.38 
litres) as compared with HD (1.54 ± 1.19 litres), although this difference 
was not statistically significant. Individual UF volumes and body mass 
index are shown in table 4-b. 
 
 
Patient BMI (kg/m2) UF vol HD 
(l) 
Indexed UF 
vol HD  
UF vol BFD 
(l) 
Indexed UF 
vol BFD 
1 22 0.4 1.8 0.5 2.3 
2 24 1.3 5.4 2 8.2 
3 29 2.2 7.6 3.2 11.0 
4 21 1.2 5.7 1.8 8.5 
5 23 0.5 2.2 0.4 1.8 
6 24 2.7 11.1 3.3 14.1 
7 27 0.4 1.5 0.4 1.5 
8 29 3.6 12.4 3.7 12.6 
 
Mean ± SD 24.9 ± 3 
 
1.54 ± 1.19 
 
6.0 ± 4.2 
 
1.91 ± 1.38 
 
7.5 ± 5.1 
 
Table 4-b.  
Ultrafiltration (UF) volumes, body mass index (BMI) and UF volumes indexed to BMI for 
individual patients during both types of dialysis.  
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4.5.3 Echocardiographic data 
Throughout the study, all patients were in sinus rhythm and none had 
significant valvular disease or pulmonary hypertension. SF at baseline in 
all regions was compared on an individual basis for each type of dialysis. 
There were no significant differences in baseline SF in any of the 
patients. This was done to ensure repeatability of images and 
measurement technique, and also to ensure the RWMAs that persisted at 
30min post dialysis were not permanent.  
 
All eight patients developed RWMAs at peak stress during HD, as 
compared to seven patients during BFD. More RWMAs developed during 
HD as compared to BFD, with a total of 42 RWMAs occurring during HD 
as compared to 23 RWMAs during BFD (OR 1.8, 95% CI 1.1 to 3.0). 
There was also a difference when comparing the rate of unaffected 
regions between dialysis modalities (OR 0.60, 95% CI, 0.39 to 0.91). By 
30min post HD, 32 (76%) of the affected segments demonstrated a 
complete or partial resolution while after BFD 15 (65%) of the RWMAs 
improved. However, at 30min post HD 24 (30%) of affected regions still 
had SF >20% less than baseline, and following BFD this figure was 
similar at 23 (29%, OR 1.0, 95% CI 0.59 to 1.83). These data are 
summarised in figure 4-d and one representative patient’s regional wall 
motion is shown in figure 4-c.  
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Figure 4-c.  
Analysis of left ventricular wall motion (2 chamber view) of one representative patient (patient number 3) during standard 
(HD) and biofeedback controlled (BFD) dialysis. Wall motion is measured over each of 100 chords (red lines) around the 
ventricular wall. Baseline traces are similar. By 240min, 3 new regional wall motion abnormalities (RWMA, arrows) have 
developed during HD, but the same regions are unaffected during BFD. 30min post HD, 2 of the RWMAs have resolved 
and 1 persists (arrow). 
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Figure 4-d.  
a) Mean number of unaffected LV regions during standard (HD) and biofeedback 
dialysis (BFD). Only new RWMAs were counted and therefore all regions are scored as 
‘unaffected’ at baseline. Baseline is before start of dialysis, peak stress is the point at 
which most RWMAs were present during dialysis, and recovery is 30min post dialysis. 
Data are expressed as mean ± SE.  
 
b) Overall mean regional LV function (SF) during standard (HD) and biofeedback 
dialysis (BFD). Data are expressed as mean ± SE. 
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Table 4-c plus figures 4-d, 4-e and 4-f summarise the data for SF(mean), 
SF(WMA) and EF. SF(WMA) declined at peak stress during both types of 
dialysis and then improved in recovery. SF(WMA) did decrease by a larger 
percentage from baseline during HD  (-43 ± 15.1%) as compared to BFD 
(-37.8 ± 16.0%), but this difference did not reach statistical significance 
(p=0.19). In view of this trend towards a more severe reduction in SF(WMA) 
and also the greater number of RWMAs, SF(mean) declined to a 
significantly greater degree at peak stress during HD (-10.3 ± 48.4% from 
baseline) as compared to BFD (+13.5 ± 48.4%, p=0.022). At baseline and 
recovery there were no statistically significant differences in either 
SF(mean) or SF(WMA) between the two types of dialysis.  
 
 
 EF (%) SF(mean) (%) SF(WMA) (%) 
HD 
   
Baseline 50.1 ± 10.7 2.64 ± 1.5  2.98 ± 1.7 
Peak 48.7 ± 12.3 2.26 ± 1.4† 1.69 ± 1.0* 
Recovery 53.4 ± 13.3 2.64 ± 1.3 2.38 ± 1.3* ‡ 
 
   
BFD 
   
Baseline 46.1 ± 12.3 2.54 ± 1.4 3.12 ± 1.6 
Peak 53.1 ± 12.1  2.76 ± 1.3 1.90 ± 1.0* 
Recovery 54.4 ± 15.4 2.78 ± 1.6 2.67 ± 1.7* ‡ 
 
†
 p<0.05, * p<0.001 versus baseline by ANOVA ‡ p<0.001 versus peak by ANOVA  
 
Table 4-c.  
Global (EF) and regional (SF) LV function during standard (HD) and biofeedback dialysis 
(BFD). Baseline is before start of dialysis, peak stress is the point at which most RWMAs 
were present during dialysis, and recovery is 30min post dialysis. 
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Figure 4-e.  
Mean regional LV function (SF) in those regions that developed new RWMAs during 
standard (HD) and biofeedback dialysis (BFD). Data are expressed as mean ± SE. 
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Figure 4-f.  
Global LV function (EF) during standard (HD) and biofeedback dialysis (BFD). Data are 
expressed as mean ± SE. 
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At peak stress, EF was significantly lower during HD as compared to BFD 
(p=0.043), while no difference was found during recovery. Table 4-d 
shows the remaining LV and LA dimensions before and after HD and 
BFD. There were no differences in any of the measurements when 
comparing the dialysis modalities. 
 
 
 
 Pre dialysis  End dialysis p-value 
 HD BFD HD BFD  
LV major axis 
diastole (cm) 
8.4 ± 1.1 8.2 ± 1.0 8.1 ± 0.8 8.0 ± 0.6 0.79 
LV major axis 
systole (cm) 
7.1 ± 1.3 7.1 ± 1.0 7.0 ± 1.0 6.9 ± 0.6 0.97 
LV minor axis 
diastole (cm) 
5.2 ± 1.0 5.2 ± 0.8 5.1 ± 1.1 5.4 ± 0.8 0.92 
LV minor axis 
systole (cm) 
4.6 ± 1.0 4.3 ± 1.3 4.5 ± 0.7 4.3 ± 0.9 0.9 
LA diameter 
(cm) 
4.5 ± 0.7 4.5 ± 0.6 4.4 ± 0.6 4.4 ± 0.7 0.99 
LA indexed volume 
(ml/m2) 
33.0 ± 12 33.1 ± 11 30.5 ± 12 30.8 ± 11 0.95 
 
Table 4-d.  
Echocardiographic measurements of cardiac dimensions at the start and end of dialysis. 
LV = left ventricle, LA = left atrium. LA volume was calculated by Simpson’s rule from 
single plane (apical 4 chamber) and indexed for body surface area.  
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4.5.4 Haemodynamic data 
Baseline haemodynamic data were compared between the two dialysis 
modalities to ensure there were no systematic errors; no differences in 
any of the variables were observed.  
 
Pulse rate increased throughout the entire study period by a mean of +5.0 
± 2.5% above baseline during BFD, whereas pulse rate changed very 
little during HD (mean +0.4 ± 2.4%, p<0.01). Stroke volume declined 
during both treatments, but to a significantly lesser extent during BFD. 
Mean stroke volume for the entire HD session was -26.2 ± 7.2% from 
baseline, as compared to a mean of -20.2 ± 7.3% (p<0.001) during BFD. 
Cardiac output showed a similar pattern, declining during both treatments 
but less so during BFD. Mean cardiac output was -26.4 ± 7.2% during HD 
as compared to a mean of -18.2 ± 7.8 during BFD (p<0.001). Mean 
peripheral resistance during HD was +33.4 ± 11.2% above baseline, 
which was higher than the mean of +28.6 ± 12.2% during BFD (p<0.05). 
Mean baroreflex sensitivity was higher during HD at 7.3 ± 5.6ms/mmHg, 
as compared to a mean of 5.6 ± 3.4ms/mmHg during BFD (p<0.001). 
Baroreflex sensitivity also displayed more variability during HD 
(coefficient of variability 76.4%) as compared to BFD (coefficient of 
variability 60.7%) signifying increased autonomic activation during the 
former modality. Haemodynamic data are summarised in figure 4-g. 
 59
 
 
0 30 60 90 120 150 180 210 240
-40
-30
-20
-10
0
HD
BFD
Time (min)
SV
 
(%
 
ch
an
ge
 
fr
o
m
 
ba
se
lin
e)
0 30 60 90 120 150 180 210 240
-10
-5
0
5
10
HD
BFD
Time (min)
HR
 
(%
 
ch
an
ge
 
fr
o
m
 
ba
se
lin
e)
0 30 60 90 120 150 180 210 240
-40
-30
-20
-10
0 HD
BFD
Time (min)
CO
 
(%
 
ch
an
ge
 
fr
o
m
 
ba
se
lin
e)
0 30 60 90 120 150 180 210 240
0
10
20
30
40
50
60 HD
BFD
Time (min)
TP
R
 
(%
 
ch
an
ge
 
fr
o
m
 
ba
se
lin
e)
 
Figure 4-g.  
Systemic haemodynamics during standard (HD) and biofeedback (BFD) dialysis. During 
BFD, there was a greater increment in pulse (p<0.001) and a smaller decline in stroke 
volume and cardiac output (p<0.001 for each). As a result, peripheral resistance 
increased to a slightly lesser extent during BFD (p<0.05). 
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4.6 Discussion 
 
This study demonstrates that reversible reductions in LV regional wall 
motion occur during standard haemodialysis and to a significantly lesser 
extent during biofeedback dialysis. Although we did not measure blood 
flow before and after haemodialysis, we believe that regional LV 
dysfunction that develops during the procedure is most likely due to 
myocardial ischaemia. Previous studies have also suggested that dialysis 
can induce subclinical myocardial ischaemia [47, 52], but this is the first 
to suggest that this phenomenon can be ameliorated. 
 
The development of new LV RWMAs during physiological or 
pharmacological stress occurs in response to ischaemia and its onset 
precedes that of symptoms and electrocardiographic changes. This 
principle underlies dobutamine stress echocardiography [146]. Subclinical 
ischaemia is therefore the likely cause of the LV RWMAs that we have 
demonstrated in response to the stress of dialysis. The majority of 
affected regions demonstrated some degree of improvement by 30min 
after dialysis, and SF at baseline was similar in each individual when 
comparing the two dialysis sessions, which indicates that these regions 
do not sustain irreversible damage over a short timescale. However, 
around a third of regions had a persistent reduction in SF at 30min post 
dialysis. Transient myocardial ischaemia may lead to LV dysfunction that 
can persist despite the return of normal perfusion. This is known as 
myocardial stunning [53]. Stunned myocardium can take up to 24-48 
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hours to recover function following an ischemic insult (which matches the 
inter-dialytic interval) [57]. Therefore our results would be consistent with 
the hypothesis that stunning occurred in our patients, with RWMAs 
persisting despite conditions where any perfusion abnormalities would be 
expected to have resolved. However, for conclusive evidence of 
myocardial stunning, myocardial blood flow and LV function need to be 
measured simultaneously.  
 
The smaller number of RWMAs that occurred during BFD as compared 
with standard HD suggests less segmental myocardial ischaemia. BFD 
works on the principle of a negative feedback loop, designed to preserve 
blood volume to an extent that avoids hypotension [86]. Changes in 
ultrafiltration rate and dialysate conductivity are made when relative blood 
volume falls below a set limit, but in theory before blood pressure drops. 
Several studies have shown that BFD reduces IDH frequency in patients 
who are both prone and resistant to IDH, and this was also confirmed by 
our results [87, 88]. In our study, BP was significantly higher during BFD 
despite a trend towards higher ultrafiltration volume. This higher BP 
appeared to be due to a smaller decline in stroke volume and cardiac 
output and a higher pulse during BFD. One possible explanation for the 
higher stroke volume and cardiac output during BFD is a better-preserved 
blood volume, leading to improved cardiac filling. Baroreflex sensitivity 
was also lower and displayed less variability during BFD indicating less 
autonomic activity. This implies less haemodynamic stress during BFD. 
The higher BP, fewer IDH episodes or improved systemic 
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haemodynamics all have the capacity to lessen episodes of myocardial 
hypoperfusion as compared with standard HD.  
 
The large number of new RWMAs seen in our patients may reflect their 
demographics. All were prone to IDH, all had LVH and seven of the eight 
had documented atherosclerosis, although these are not uncommon 
findings in chronic dialysis patients. One weakness of our study is that the 
patients did not undergo coronary angiography, which would have 
provided information about the degree and extent of large vessel 
coronary disease to correlate with the echocardiographic data. However, 
there are plausible mechanisms other than large vessel obstructive 
coronary disease that may predispose to myocardial hypoperfusion. 
Coronary flow reserve is dependent on not only large vessel patency but 
on microvascular disease as well, which also reduces the ability to 
increase blood flow to myocardium during increased demand. Specific 
microvascular disease has been described in dialysis patients, likely due 
to the high prevalence of diabetes, hypertension, LVH and vascular 
calcification [152]. In addition, acute severe stress can induce stunning 
despite normal coronary anatomy [153] but although haemodialysis is 
associated with sympathetic activation and a hyperadrenergic state [81, 
154], none of our patients had a phenotype that resembled acute severe 
stress. Finally, it is possible that the autonomic nervous system may 
affect ventricular function during dialysis. Altered autonomic function, 
which is a common finding in dialysis patients, affects both IDH frequency 
and ventricular contractility [155, 156]. We observed differences in 
 63
baroreflex sensitivity between dialysis modalities, but this study did not 
assess the direct effect of the autonomic nervous system on LV function. 
 
There was a significant difference in percentage change from baseline in 
EF between the dialysis modalities, which was due to the trend for EF to 
fall at peak stress with HD and rise with BFD. The trend for EF to rise with 
BFD appeared to be due to the fact that SF in some unaffected LV 
regions increased during peak stress. This phenomenon was also seen 
during HD, but to a lesser extent. This corresponds to the better 
preservation of stroke volume and cardiac output during BFD. Again the 
reasons behind these changes are not explained, but may suggest that 
those regions without ischaemia are better able to increment function in 
the short term in response to the haemodynamic stress of dialysis.  
 
Our study does have some potential weaknesses. Patient numbers are 
small, so our results need to be replicated in a larger number of patients. 
In addition, ours was a short-term study and therefore any effect of 
dialysis-induced RWMAs on long-term cardiac dysfunction is at present 
purely speculative.  
 
In conclusion, this study demonstrates that reversible segmental 
myocardial dysfunction occurs during dialysis. We also show that by 
improving intradialytic BP with biofeedback dialysis this occurs less, 
thereby suggesting that this phenomenon may be a target for 
intervention.  
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5. Results: the effects of cooling the dialysate on regional 
left ventricular function and systemic haemodynamics 
 
5.1 Introduction 
 
In chapter 4, we demonstrated subclinical ischaemia occurring in 
response to the stress of haemodialysis. We also showed that it was 
possible to reduce the frequency and severity of this phenomenon by 
using biofeedback dialysis (Hemocontrol®) to improve the haemodynamic 
tolerability of dialysis. However, because of the relatively small study size 
we wanted to confirm the findings of dialysis induced LV RWMAs in an 
additional group of patients.  
 
We also wished to re-examine the hypothesis that maintaining 
intradialytic blood pressure and improving the haemodynamic tolerability 
of dialysis reduces the development of LV RWMAs. Hemocontrol® 
requires a relatively complicated prescription, is not widely available and 
works by reacting to changes in relative blood volume (RBV) that may not 
predict intradialytic hypotension (IDH) in all patients [85]. Although there 
have been many different strategies employed in an attempt to reduce 
IDH, reducing the temperature of the dialysate is one of the most simple 
[90]. Cooling the dialysate has been shown to be effective and is 
universally available at no additional cost.  
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Therefore, again using the development of reversible abnormalities in 
regional LV function as a marker of subclinical myocardial ischaemia, we 
performed a study to examine whether the improved haemodynamic 
tolerability of cool temperature dialysis leads to a reduction in the 
frequency of dialysis induced ischaemia, as compared to standard 
dialysis. 
 
 
5.2 Methods 
 
5.2.1 Patients 
10 patients on chronic haemodialysis who were prone to IDH were 
recruited for a randomised cross-over study. Four patients were male and 
all had been on dialysis for longer than six months. All patients dialysed 
via native arteriovenous fistulae and all were anuric. Remaining 
characteristics are shown in table 5-a. 
 
Patients were defined as IDH prone if they had episodes of IDH in more 
than 30% of dialysis sessions in the month before recruitment to the 
study. IDH was defined as systolic blood pressure (SBP) ≤ 100mmHg 
even in the absence of symptoms, or a fall in SBP > 10% of the pre 
dialysis reading in association with any of the classical symptoms of 
hypotension (headaches, cramps, light-headedness).  
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Patients were excluded if they had significant symptomatic cardiac failure 
(NYHA ≥ 3), had previously received a cardiac transplant or if it was not 
possible to obtain echocardiographic images of sufficient quality to allow 
meaningful analysis. 
 
 
 
 
Table 5-a.  
Patient demographics. APKD= adult polycystic kidney disease. IHD = ischemic heart 
disease, LVMI = LV mass index. 
* Angiogram result for patient 4: Diffuse three vessel disease, not suitable for 
intervention. 
†
 Patient 6 had had a dipyridamole stress test 12 months prior to entering the study 
which was negative. 
 
 
Patient Age  Months 
on 
dialysis  
Cause of 
ESRF 
Vascular 
disease 
IHD LVMI 
(g/m2.7) 
Angiogram BP lowering 
drugs 
1 83 11 Myeloma Y N 85.0 N  
2 
71 60 Unknown 
Y Y 
(angina) 52.1 
N Felodipine 10mg od, 
Atenolol 50mg od 
3 72 33 Diabetes N N 55.3 N Valsartan 160mg od 
4 71 19 Diabetes Y Y (MI) 96.7 Y* Diltiazem 90mg od 
5 42 44 Sarcoid N N 25.7 N 
  
6 
65 52 Diabetes 
N N    
52.1 
N† 
  
7 60 6 APKD N N 51.3 N 
  
8 
66 6 Diabetes 
Y N 
61.9 
N Diltiazem 300mg, 
Doxazosin 4mg od, 
Irbesartan 150mg od 
9 
55 17 Unknown 
N N 
55.8 
N Nifedipine 60mg od, 
Ramipril 10mg od 
10 
68 40 
Anti 
GBM 
N N 
46.3 
N  
Mean ± 
SD, or 
total 
number 
65 ± 
11 
29 ± 19  4 (40%) 2 (20%) 58.2 ± 
20 
1 (10%)  
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5.2.2 Study protocol 
Upon entry to the study, patients had their dry weight confirmed with 
reference to clinical examination. Following this, dry weight and anti-
hypertensive medications remained unchanged for the duration of the 
study. Patients were then randomised to two groups. Group A patients 
were commenced on standard thrice weekly bicarbonate-based dialysis 
with a dialysate temperature of 370C (HD37), whereas group B patients 
started thrice weekly dialysis with a dialysate temperature of 350C (HD35). 
Patients, but not dialysis unit staff, were blinded to the intervention. Both 
groups underwent one week of the dialysis therapy before undergoing a 
monitored session during one of the dialysis sessions during the second 
week. At the end of the second week, patients then crossed over to the 
other dialysis modality thereby acting as their own controls. After a further 
week on the alternate modality, patients underwent a second monitored 
session on the same day of the week as the first study session.  
 
For each monitored dialysis treatment, serial echocardiography was 
performed and non-invasive haemodynamic monitoring was undertaken 
using a Finometer (as described in chapter 3). The finger cuff was left in 
place for the entire session, and the non-fistula arm was used. To obtain 
baseline values, monitoring was commenced 30min prior to 
commencement of dialysis. Also before dialysis, patients had segmental 
multi-frequency bioimpedance performed (InBody BS20, Seoul, Korea) 
to assess intracellular (ICW), extracellular (ECW) and total body water 
(TBW). Body temperature was recorded before and after each session 
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using a digital tympanic thermometer (First Temp, Sherwood Davis & 
Geck, St Louis, USA) and ambient room temperature of the dialysis unit 
was also noted. Blood samples were collected before and after each 
session in lithium heparin and EDTA tubes, and biochemical analysis 
performed on a multichannel autoanalyser. Cardiac troponin-T (cTnT) 
analysis was performed using a third generation 
electrochemiluminescence assay (Roche diagnostics, Lewes, UK). Post 
dialysis cTnT values were corrected individually for haemoconcentration 
with reference to percentage change in haematocrit and blood volume 
using the formula: 
 
 Adjusted cTnT  =  cTnTpost     x  BVpost (1 – Hctpost) 
      BVpre (1 – Hctpre) 
 
where cTnTpost equals post dialysis cTnT, Hctpost equals post dialysis 
haematocrit, Hctpre equals pre dialysis haematocrit, BVpost equals end 
dialysis blood volume and BVpre equals start dialysis blood volume. Single 
pool Kt/Vurea values were calculated from pre and post urea levels [157]. 
Pre dialysis blood tests were drawn immediately after insertion of access 
needles, and post levels were taken from the arterial line 10sec after 
reducing blood pump speed to 50ml/min. An investigator was present for 
the entirety of every dialysis session to record intradialytic symptoms. We 
also performed quality of life scoring for both types of dialysis using the 
validated Short Form (SF-36) questionnaire [158], and developed a 
simple questionnaire to systematically evaluate symptoms of cold (see 
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appendix 15.1). This latter questionnaire was formulated according to 
similar scoring tools [159] and the questions assessing severe symptoms 
of cold were weighted to score more heavily. The lowest score signifying 
no thermal symptoms was 6 and the highest score indicating severe 
symptoms of cold was 24.  
 
The primary endpoint was the frequency of new LV regional wall motion 
abnormalities during HD37 and HD35 in relation to their effects on BP and 
systemic haemodynamics. 
 
All patients gave informed consent prior to commencement, and ethical 
approval for the project was granted by Derbyshire Research Ethics 
Committee. 
 
5.2.3 Echocardiography 
Echocardiography and subsequent analysis were performed as described 
in chapters 3 and 4. Images were recorded prior to commencing dialysis 
(baseline), at 120min and 240min during dialysis and 30min after dialysis 
was finished (recovery). 10 regions of the left ventricle were assessed for 
the development of new RWMAs at each time point. We calculated mean 
SF for all ten segments (SFMEAN) and for those segments that developed 
new RWMAs (SFWMA). Peak stress was defined for each patient as the 
point during the first monitored dialysis session when most RWMAs were 
present (either 120min or 240min). When comparing dialysis modalities, 
the same time point was used in the second dialysis session.  
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5.2.4 Haemodialysis details 
Haemodialysis was performed as described in chapter 3. For each 
session, net fluid removal was set on an individual basis according to 
ideal dry weight. However, if there was >20% difference in programmed 
UF volume from the first session, the second monitored session was 
rescheduled.  
 
 
5.3 Statistical analysis 
 
Results are expressed as mean ± SD if parametric or median 
(interquartile range, IQR) if non-parametric unless otherwise stated. 
Echocardiographic, BP and haemodynamic data were analysed using 
one-way analysis of variance (ANOVA) with a design for repeated 
measures and Bonferroni’s test to correct for multiple comparisons. The 
frequencies of IDH and of new RWMAs occurring during each dialysis 
modality were compared using Poisson regression. For other data, either 
the paired t-test or Wilcoxon rank sum test was used depending on 
normality of the distribution. An alpha error at P<0.05 was judged to be 
significant. 
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5.4 Results 
 
5.4.1 Blood pressure 
During HD37, mean systolic BP (SBP) was 141.6 ± 17mmHg, mean 
diastolic BP (DBP) was 69.4 ± 5mmHg and mean of the mean arterial 
pressure (MAP) was 92.6 ± 10mmHg. During HD35, BP was significantly 
higher with mean SBP of 158.8 ± 14mmHg, mean DBP of 78.6 ± 4mmHg 
and mean MAP of 110.9 ± 7mmHg (p<0.001 for all comparisons). The 
lower mean BP with HD37 was the result of a fall in BP after the first hour 
of dialysis, whereas with HD35 BP was maintained until the last third of 
the treatment. These data are summarised in figure 5-a. 
 
There were two episodes of symptomatic hypotension during HD37 as 
compared to one with HD35 (p=ns), all of which required administration of 
normal saline plus temporary cessation of UF. However, there was a 
significant difference in the number of asymptomatic IDH between the 
treatments, which occurred with a frequency of 0.4 episodes per session 
with HD35 as compared to a rate of 6.2 episodes per session with HD37 
(OR 15.5, 95% CI 5.6 to 14.2). 
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Figure 5-a.  
Overall mean BP for HD37 and HD35. BP was significantly higher during HD35 (p<0.001 
for all comparisons). 
 
 
5.4.2 Echocardiographic data 
Throughout the study, all patients were in sinus rhythm and none had 
significant valvular disease or pulmonary hypertension. SF at baseline in 
all regions was compared on an individual basis for each type of dialysis; 
there were no significant differences in baseline SF in any of the patients.  
 
A total of 49 new RWMAs occurred in nine patients during HD37. In 
contrast, only 13 new RWMAs occurred in four patients during HD35 (OR 
3.8, 95% CI 2.1 to 6.9). By 30min post dialysis, 24 (49%) of the affected 
areas with HD37 had recovered normal motion whilst with HD35 8 (62%) of 
RWMAs had improved (OR 4.9, 95% CI 1.9 to 12.1). Therefore, with both 
types of dialysis but to a greater extent with HD37, a significant proportion 
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of affected regions still had SF >20% less than baseline at 30min post 
dialysis. These data are summarised in figure 5-b. 
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Figure 5-b. 
i) Mean number of unaffected LV regions during HD37 and HD35. Data are expressed as 
mean ± SE. Comparison at peak stress, OR 3.8 (95% CI 2.1 to 6.9), in recovery OR 4.9 
(95% CI 1.9 to 12.1). 
 
ii) Overall mean regional LV function (SF) during HD37 and HD35. Data are expressed as 
mean ± SE.  
* p <0.001 by ANOVA. 
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SFWMA declined with both types of dialysis at peak stress before 
improving in recovery. There were no differences in SFWMA between HD37 
and HD35 at any of the time points, showing that the areas that did 
develop new RWMAs were affected to a similar magnitude. However, due 
to difference in the overall number of new RWMAs, SFMEAN at peak stress 
was significantly lower with HD37 (2.5 ± 1.6%) as compared with HD35 
(3.9 ± 1.9%, p<0.001). This pattern of lower SFMEAN with HD37 was also 
seen in recovery (p<0.001). Complete SFWMA and SFMEAN data are shown 
in table 5-b, figure 5-b and figure 5-c.  
 
 
 
 EF (%) SF(MEAN) (%) SF(WMA) (%) 
HD37    
Baseline 61 ± 14 3.0 ± 1.8 3.7 ± 2 
Peak 61 ± 10* 2.5 ± 1.6** 1.7 ± 1.2 
Recovery 60 ± 12 2.7 ± 1.5** 2.8 ± 1.6 
    
HD35    
Baseline 57 ± 10 2.5 ± 1.2 3.2 ± 1.3 
Peak 72 ± 9* 3.9 ± 1.9** 1.8 ± 0.9 
Recovery 69 ± 11 3.7 ± 1.9** 3.1 ± 1.7 
* p<0.05 by ANOVA comparing HD37 and HD35  
** p<0.001 by ANOVA comparing HD37 and HD35 
 
Table 5-b.  
Global (EF) and regional (SF) LV function during HD37 and HD35. Baseline is before start 
of dialysis, peak stress is the point at which most RWMAs were present during dialysis, 
and recovery is 30min post dialysis. 
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Figure 5-c.  
Mean regional LV function (SF) in those regions that developed new RWMAs during 
HD37 and HD35. Data are expressed as mean ± SE. 
 
 
With HD35, EF rose during dialysis and was higher than baseline at peak 
stress and in recovery. However, EF did not change during HD37 and 
therefore there was a significant difference in EF at peak stress when 
comparing dialysis modalities (p<0.05). Data for EF are shown in table 5-
b and figure 5-d. We observed no differences in LV dimensions when 
comparing the two types of dialysis; these data are displayed in table 5-c.  
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Figure 5-d.  
Global systolic function (EF) during HD37 and HD35. Data are expressed as mean ± SE.  
* p<0.05 by ANOVA 
 
 
 
 
HD37 HD35 
Pre dialysis 
  
LVDd (cm) 4.7 (4.3, 5.4) 5.0 (4.3, 5.5) 
LVDs (cm) 3.2 (3.0, 3.8) 3.6 (3.0, 4.2) 
   
120min 
  
LVDd (cm) 4.7 (4.1, 5.3) 4.5 (4.0, 5.6) 
LVDs (cm) 3.1 (2.6, 3.9) 3.2 (2.7, 3.8) 
   
240min 
  
LVDd (cm) 4.4 (3.9, 5.5) 4.8 (4.0, 5.5) 
LVDs (cm) 2.8 (2.2, 4.0) 3.2 (2.8, 4.2) 
   
30min post 
  
LVDd (cm) 4.9 (4.2, 5.5) 4.6 (4.4, 5.7) 
LVDs (cm) 3.3 (2.9, 3.9) 3.4 (2.9, 4.0) 
 
Table 5-c.  
Echocardiographic measurements of cardiac dimensions before, during and after 
dialysis. LVDd = left ventricle diameter in diastole, LVDs = left ventricle diameter in 
systole. There were no significant differences in any of the dimensions when comparing 
the two dialysis modalities. Data are shown as median (interquartile range). 
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5.4.3 Haemodynamic data 
Haemodynamic data are summarised in figure 5-e. SV declined 
throughout both dialysis modalities to a similar degree, with means of -19 
± 5% during HD37 and -23 ± 13% with HD35 (p=ns). Peripheral resistance 
(TPR) rose to a significantly greater extent with HD35. Overall mean TPR 
for the entire HD35 dialysis session was +42 ± 18% above baseline as 
compared to a mean of +10 ± 8% during HD37 (p<0.001). Heart rate (HR) 
was lower with HD35 with a mean of 69 ± 2bpm representing a -4 ± 3% 
change from baseline. Mean HR with HD37 was 78 ± 2bpm, a change of 
+5 ± 3% from baseline (p<0.05). As a product of HR and SV, cardiac 
output (CO) was therefore lower during HD35 with an overall mean of -26 
± 14% as compared to a mean of -15 ± 5% with HD37 (p<0.01). 
 
0 30 60 90 120 150 180 210 240
-50
0
50
100
HD37
HD35
Time (min)
Pe
rip
he
ra
l r
e
si
s
ta
n
ce
(%
 
ch
a
n
ge
 
fro
m
 
ba
se
lin
e)
0 30 60 90 120 150 180 210 240
-75
-50
-25
0
25
HD37
HD35
Time (min)
SV
 
(%
 
ch
an
ge
 
fro
m
 
ba
s
el
in
e
)
p=ns
0 30 60 90 120 150 180 210 240
-60
-50
-40
-30
-20
-10
0
10
HD37
HD35
Time (min)
CO
 
(%
 
c
ha
n
ge
 
fro
m
 
ba
s
el
in
e
)
0 30 60 90 120 150 180 210 240
-25
0
25
HD37
HD35
Time (min)
HR
 
(%
 
c
ha
n
ge
 
fro
m
 
ba
s
e
lin
e
)
 
 
Figure 5-e.  
Systemic haemodynamics during HD37 and HD35. There was no difference in mean SV 
between the two dialysis modalities, but TPR was significantly higher during HD35. HR 
was also lower with HD35 as was CO. Data are expressed as mean ± SE. 
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5.4.4 Thermal symptoms and quality of life assessments 
Temperature score was higher (representing a greater sensation of cold) 
with HD35, with a median of 12 (IQR 7 to 14) as compared to a median of 
8 (IQR 6 to 12) with HD37 (p=0.01). Of the 10 patients, three experienced 
cold symptoms to a degree that made them uncomfortable during 
dialysis, two were able to detect the difference between modalities but did 
not feel uncomfortable or felt better with HD35, and five were unable to 
differentiate between the treatments. During HD35, the median 
temperature score for the patients that experienced unpleasant 
symptoms of cold was 14 (range 12 to 16) as compared to 10 (IQR 6 to 
12) for those that tolerated the intervention (p=0.066). There were no 
obvious differences that distinguished the patients that did not tolerate 
HD35; in particular, there were no correlations between temperature score 
and either pre dialysis body temperature or delta body temperature. In 
addition, there was no difference between the two types of dialysis in 
quality of life score as rated by the SF-36 questionnaire, with median 
values of 61 (IQR 39 to 78) with HD37 and 62 (IQR 50 to 73) with HD35 
(p=ns). 
There were no differences in body temperature pre dialysis but body 
temperature post dialysis was lower and delta body temperature was 
negative with HD35. Ambient room temperature was also similar between 
the two types of dialysis and varied by less than 10C from the median for 
all study sessions. Complete temperature data are displayed in table 5-d.  
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 HD37 HD35 
Temperature score 
 
8 (IQR 6 to 12)* 12 (IQR 7 to 14)* 
Body temp pre dialysis (0C) 
 
35.3 (IQR 34.9 to 36.3) 35.6 (IQR 35.1 to 36.6) 
Body temp post dialysis (0C) 
 
36.5 (IQR 35.3 to 36.3)** 35.5 (IQR 35.0 to 35.9)** 
Delta body temp (0C) 
 
+0.7 (0.05 to 1.3)*** -0.6 (IQR-1.35 to 0.05)*** 
Ambient room temp (0C) 
 
25.1 (24.3 to 25.5) 24.7 (IQR 24.5 to 25.4) 
* p=0.01, **p=0.02, ***p<0.001 by Wilcoxon rank sum HD37 versus HD35 
 
Table 5-d.  
Temperature data. Temperature score rates how cold a patient is feeling during the 
dialysis treatment, with the lowest score of 6 signifying no thermal symptoms and the 
highest score of 24 indicating severe symptoms of cold.  
 
 
5.4.5 Fluid status and bioimpedance 
Volume status of the patients was similar when the two dialysis modalities 
were compared. Equally there were no differences in body weight pre and 
post dialysis or in programmed ultrafiltration volume. These data are 
shown in table 5-e.  
 
 
HD37 HD35 
Body weight pre dialysis (kg) 71.8 (60 to 86.4) 71.6 (60 to 87.3) 
Body weight post dialysis (kg) 69.7 (59 to 84.4) 69.8 (59.3 to 84.7) 
UF volume (ml) 2.0 (1.4 to 2.3) 2.1 (1.6 to 2.4) 
Relative blood volume (%) -4.1 (-8 to -2) -6.3 (-10 to -4) 
ECW (l) pre dialysis 14.5 (12.4 to 16.7) 14.4 (12.7 to 16.6) 
ICW (l) pre dialysis 22 (17.9 to 24.3) 21.5 (18.4 to 24) 
ECW/TBW 0.41 (0.4 to 0.41) 0.41 (0.4 to 0.42) 
 
Table 5-e.  
Bioimpedance data and pre and post dialysis body weights. Data are shown as median 
(interquartile range). There were no significant differences between HD37 and HD35 for 
any of the parameters. 
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5.4.6 Laboratory data 
There were no differences in any of the biochemical parameters when the 
two types of dialysis were compared. In particular, Kt/Vurea was almost 
identical between HD37 and HD35. In addition, cTnT levels were similar 
between the two modalities and did not change significantly post dialysis 
after correction for haemoconcentration. Laboratory data are shown in 
table 5-f. 
 
 
HD37 
 
HD35 
 
Pre dialysis Post dialysis Pre dialysis Post dialysis 
Haemoglobin 
(g/dl) 
10.6  
(9.6 to 12) 
10.9  
(9.7 to 12.1) 
11.2  
(10 to 12.6) 
11.3  
(10.1 to 12.9) 
Bicarbonate 
(mmol/l) 
23.5  
(22 to 26) 
28  
(28 to 29.5) 
24.5  
(19.5 to 25.5) 
28  
(27 to 29) 
Na+ (mmol/l) 
 
138  
(135 to 140) 
137  
(136 to 138) 
138  
(136 to 140) 
138 
(137 to 138) 
Corr. Ca2+ 
(mmol/l) 
2.42  
(2.19 to 2.53) 
2.39  
(2.25 to 2.45) 
2.44  
(2.12 to 2.55) 
2.38  
(2.22 to 2.52 
Phosphate 
(mmol/l) 
1.65  
(1.24 to 1.92) 
0.79  
(0.6 to 0.92) 
1.52  
(1.26 to 2.03) 
0.79  
(0.67 to 0.91) 
Albumin (g/l) 
 
34.5  
(32.5 to 37) 
33.5  
(32 to 40) 
34  
(33 to 38.5) 
36.5  
(33 to 39.5) 
CRP (mg/l) 
 
5  
(4 to 16.5) 
5  
(5 to 16.5) 
8.5  
(4 to 16) 
8  
(4 to 17) 
cTnT (µg/l) 
 
0.05  
(0.02 to 1.0) 
0.05  
(0.05 to 0.076) 
0.05  
(0.02 to 0.12) 
0.06  
(0.02 to 0.13) 
PTH (ng/l) 
 
290  
(120 to 532) 
 302  
(140 to 589 
 
Kt/Vurea 
 
1.49  
(1.2 to 1.73) 
 1.48  
(1.1 to 1.73) 
 
 
Table 5-f.  
Biochemical data. Data are shown as median (interquartile range). There were no 
significant differences between HD37 and HD35 for any of the parameters. 
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5.5 Discussion 
 
This study shows that a significant number of new reversible LV regional 
wall motion abnormalities occur during standard dialysis, confirming the 
findings described in chapter 4. We have also demonstrated that by 
improving intradialytic BP and reducing IDH by cooling the dialysate, it is 
possible to achieve a significant reduction in the development of RWMAs.  
 
There is an increasing body of evidence suggesting that subclinical 
myocardial ischaemia develops during haemodialysis. The results 
showing development of new RWMAs during dialysis from this current 
study and chapter 4 are similar, and together are strongly suggestive of 
subclinical ischaemia. In addition to the work from our centre, one study 
has demonstrated dialysis induced perfusion defects using single photon 
emission computed tomography (SPECT) [52] and there are 10 reports of 
silent intradialytic ST depression detected by Holter monitoring [28, 43-
51]. Although initially there was concern that some ECG changes 
observed during dialysis were related to changes in electrolyte 
concentrations as opposed to myocardial hypoperfusion, the 
demonstration of dialysis induced ischaemia by electrocardiographic, 
echocardiographic and isotopic techniques certainly suggests that such 
findings are attributable to ischaemia. 
 
In patients with coronary artery disease but without chronic kidney 
disease, transient myocardial ischaemia may lead to LV dysfunction that 
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can persist after the return of normal perfusion. This prolonged 
dysfunction is known as myocardial stunning [53]. Myocardial stunning 
has been demonstrated in humans after exercise and dobutamine stress 
in patients with coronary artery disease, and recent studies have provided 
evidence that repetitive episodes of ischaemia can be cumulative and 
lead to prolonged left ventricular dysfunction (myocardial hibernation) [53-
59]. Myocardial stunning is therefore increasingly thought to be a 
causative mechanism for heart failure, with stunning and hibernation 
existing as part of a single spectrum.  In our studies, a significant number 
of RWMAs persisted at 30min post dialysis when the conditions favouring 
the development of ischaemia during dialysis had been removed; this 
could be interpreted as preliminary evidence of dialysis induced 
myocardial stunning. Therefore, the occurrence of subclinical ischaemia 
in response to dialysis with sustained but reversible abnormalities in 
regional function could potentially contribute to the genesis of uraemic 
cardiac failure, particularly if the ischaemic insult is repeated up to three 
times per week. In support of this there is only circumstantial evidence. 
The fibrosis that characterises uraemic cardiomyopathy shares some 
common histological features with areas of hibernating myocardium in 
non-dialysis patients (harvested from affected areas during coronary 
artery bypass surgery) [160-162]. In addition, patients who receive a 
kidney transplant have significantly reduced all cause and cardiovascular 
death rates as compared to similar patients who remain on dialysis on the 
waiting list [163, 164]. In conjunction with this, it is also known that renal 
transplantation in patients with established heart failure improves left 
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ventricular (LV) ejection fraction and symptoms [165]. The reasons for 
this remain unclear and are generally attributed to reversal of the uraemic 
state. However, an alternative explanation is that some of this benefit 
seen following transplantation may be due to the avoidance of dialysis 
that has a negative impact on the myocardium. Importantly, a longer 
duration of dialysis before transplantation (greater than one year) reduces 
the benefit seen in terms of improvement in LV function, which is also 
consistent with the concept of repetitive ischaemic insults leading to more 
prolonged or even permanent reductions in myocardial performance 
[165]. However, our short term studies do not assess the long term 
sequelae of the presence of new RWMAs on systolic function, which at 
present remain speculative. 
 
RWMAs developed to a much lesser degree during HD35, implying less 
dialysis induced ischaemia. In addition, a greater proportion of affected 
regions had recovered by 30min post dialysis with HD35. This latter 
finding may also suggest less of an ischaemic burden, as more severe 
episodes of myocardial hypoperfusion cause more prolonged reductions 
in regional LV function [166]. There was clear separation seen in terms of 
BP and haemodynamic response between HD37 and HD35. BP was 
maintained at a higher overall level with less change throughout the HD35 
dialysis session. In addition, there were fewer episodes of IDH. With no 
difference in SV, these differences were explained by a greater rise in 
TPR with HD35, signifying vasoconstriction in response to the cooler 
temperature. These changes, including the lower HR with HD35, are 
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consistent with the published studies [167, 168], but this favourable 
haemodynamic and BP response to HD35 may result in improved 
coronary artery perfusion during diastole and therefore explain why fewer 
RWMAs developed. It is possible that either the higher mean BP or the 
reduction in IDH may be responsible for the reduction in the incidence of 
RWMAs, although it is also conceivable that the effects of both of these 
factors are synergistic, with IDH that occurs at a lower mean BP 
potentially having a greater detrimental affect on myocardial perfusion. In 
summary, the results from this current study and in chapter 4 have shown 
that two different dialysis techniques that both improve the intradialytic BP 
profile reduce the incidence of new RWMAs in two different groups of 
patients. 
 
EF increased during HD35 but remained unchanged during HD37, resulting 
in a significant difference between the dialysis modalities at peak stress. 
The effect of haemodialysis on EF remains controversial, with different 
studies reporting increases, no change and also decreases [169-172]. 
The effect of dialysis upon EF is in part related to changes in volume 
status as are the changes in SV, so EF may increase whilst there is a 
concurrent decrease in SV. However, there is some evidence that the 
degree of cardiac disease may also influence the change in EF [171], 
possibly determining the degree to which myocardial contractility can be 
increased. In our study, in the absence of any differences in UF volume, 
fluid status or LV dimensions between the two types of dialysis, the 
greater number of RWMAs with HD37 could potentially explain why EF did 
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not increment in the same way as during HD35. This is consistent with the 
work of Levy et al who also found an improvement in LV contractility with 
cooler dialysate [173], which is the only other study of which we are 
aware that examines LV function in response to cool dialysis. 
 
Reducing the temperature of the dialysate improves IDH and our results 
show for the first time that it has a beneficial effect on intradialytic 
regional LV function. Furthermore, cooling the dialysate is possible on all 
dialysis monitors and is extremely simple to perform. However, concerns 
regarding unpleasant symptoms of cold and negative effects on small 
solute clearance due to increased peripheral sequestration have 
persisted. Although it is clear from the published literature and from this 
current study that there is no adverse affect on Kt/Vurea [167], the effects 
on patients' symptoms are less clear. In this study we found that the 
patient response to HD35 was heterogeneous, with three patients finding 
a dialysate temperature of 350C too cold (although no patients found it 
intolerable in the short term). The majority of patients were unable to 
detect a difference between the two types of dialysis and some patients 
who normally experience hot flushes with a dialysate temperature of 37oC 
preferred HD35. Our study design may have magnified any symptoms of 
cold by switching directly from 370C to 350C as opposed to a gradual 
reduction in temperature. However, there were no obvious features that 
predicted which patients did and did not tolerate the cooler dialysate; in 
particular tolerability was not predicted by pre dialysis body temperature. 
Therefore, a practical approach would be to gradually reduce dialysate 
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temperature in steps of 0.50C, stopping if the patient experiences 
excessive symptoms or when 350  is achieved [174]. This approach is 
necessary as there are no data concerning the optimal dialysate 
temperature to maximise potential benefits whilst avoiding excessive 
thermal symptoms. An alternative strategy is isothermic dialysis, in which 
a biofeedback device constantly adjusts dialysate temperature to keep 
patient body temperature constant. Isothermic dialysis has also been 
shown to reduce IDH effectively, and causes thermal symptoms in only 
5% of treatments [175]. However, isothermic dialysis has not been 
evaluated in terms of its effects on regional LV function and has the 
disadvantage that it is less widely available as it requires specific dialysis 
monitors with a dedicated BTM® module (Fresenius, Bad Homburg, 
Germany). 
 
cTnT is often elevated in dialysis patients and predicts mortality [61]. 
Furthermore, cTnT levels are higher in patients prone to IDH as 
compared to stable patients. However, there is continuing debate as to 
whether cTnT rises acutely following dialysis [63, 67]. In our current study 
we found no difference in cTnT levels between HD37 and HD35, and also 
no acute rise in cTnT after correction for haemoconcentration. In addition, 
there were no correlations between cTnT levels and the frequency of 
RWMAs. However, all of the studies examining pre and post dialysis 
cTnT levels collected the post dialysis sample at the end of the session, 
but it is well recognised that plasma cTnT levels may only become 
elevated after 6 to 12 hours following an episode of ischaemia. Therefore, 
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although our findings in respect to cTnT do not refute that myocardial 
ischaemia develops in response to dialysis, they do mean that the 
development of RWMAs cannot be determined by measuring plasma 
cTnT levels in this way. It remains to be seen if cTnT levels prior to the 
subsequent dialysis session correlate with the frequency of RWMAs; one 
study found a significant increase in troponin I levels 44 hours post 
dialysis sessions complicated by IDH as compared to sessions in which 
patients were stable [78]. 
 
Our study does have some potential weaknesses. Patient numbers are 
relatively small and measurements were taken from only one dialysis 
session, but the results do replicate those of our previous study. There is 
some debate as to whether tympanic temperature accurately reflects 
body temperature, and although there are several studies supporting its 
accuracy we did not have the facility to measure blood line temperature 
[176, 177]. Finally, we did not perform coronary angiography upon these 
patients, so we cannot tell to what extent the degree of large vessel 
epicardial disease underlay our results.  
 
In conclusion, we have confirmed our previous findings that reversible 
reductions in regional LV function occur in response to standard 
haemodialysis. We suggest that these are most likely to represent 
subclinical myocardial ischaemia and may be a potential aetiological 
factor in the development of cardiac dysfunction in this patient group. 
Reducing the temperature of the dialysate is an effective intervention to 
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lessen the development of RWMAs, and is also associated with improved 
haemodynamics and less IDH.  
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6.  Results: the effects of acetate-free double chamber 
haemodiafiltration and standard dialysis on systemic 
haemodynamics and troponin-T levels  
 
6.1 Introduction 
 
Following the demonstration of left ventricular regional wall motion 
abnormalities during haemodialysis that were ameliorated by techniques 
that reduce IDH, we examined other novel modifications of the dialysis 
method that are purported to improve haemodynamic stability. These 
studies are described in the following two chapters. 
 
In this chapter, we aimed to investigate whether an acetate free dialysis 
technique is capable of abrogating the changes in systemic 
haemodynamics and in biomarkers of myocardial damage seen with 
conventional haemodialysis. Historically, acetate was used as the sole 
buffer in haemodialysis. However, it was recognised that acetate was an 
aetiological factor in IDH, and switching from acetate to bicarbonate as 
the principle buffer improved cardiovascular stability and reduced 
intradialytic symptoms [5]. However, standard bicarbonate based dialysis 
is not acetate free and can still result in significant transfer of acetate to 
the patient, which can make up as much as 25-49% of the buffer load 
[113, 114]. Paired haemodiafiltration (PHF, Bellco, Mirandola, Italy) is a 
novel online convective technique that has been designed to be used with 
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dialysate that is completely acetate free. In place of acetate, the dialysate 
concentrate contains hydrochloric acid to prevent calcium precipitation 
(this is converted to water and sodium chloride during online dialysate 
preparation) and there is no requirement for a sterile bicarbonate infusion. 
 
In addition to its potential haemodynamic effects, acetate has also been 
cited as a possible pro-inflammatory stimulus [178]. Inflammation has 
also been linked to cardiovascular risk in the dialysis population so as a 
secondary endpoint we also sought to evaluate the effects of acetate free 
PHF upon the systemic inflammatory response. We decided not to 
examine the effect of acetate on the genesis of myocardial stunning until 
we had elucidated whether PHF had real benefits in terms of reducing 
IDH and improving systemic haemodynamics during dialysis. 
 
 
6.2 Subjects and Methods 
 
6.2.1 Patients 
We recruited 12 patients on chronic haemodialysis for a prospective 
randomised crossover study. Two patients were female and all had been 
on dialysis for more than six months. 10 patients had native arteriovenous 
fistulae and two dialysed via tunnelled internal jugular catheters. All but 
one patient was anuric. Remaining baseline patient information is shown 
in table 6-a. 
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A mixture of hypotension-prone and hypotension-resistant patients were 
recruited. Six patients were defined as ‘unstable on dialysis’; they had 
episodes of IDH in more than 30% of dialysis sessions in the month 
before recruitment to the study. IDH was defined as systolic blood 
pressure (SBP) ≤ 100mmHg even in the absence of symptoms, or a fall in 
SBP > 10% of the pre dialysis reading in association with any of the 
classical symptoms of hypotension (headaches, cramps, light-
headedness). The remaining six patients were defined as ‘stable on 
dialysis’. 
 
Patients were excluded if they had haemoglobin (Hb) <10g/dl, or if they 
had significant co-morbidity which, in the opinion of the investigator, 
would make completion of the study unlikely. 
 
6.2.2 Study protocol 
All patients gave informed consent prior to commencement, and ethical 
approval for the project was granted by Derbyshire Research Ethics 
Committee. Upon entry to the study, patients had their dry weight 
confirmed with reference to clinical examination, serial blood pressure 
readings and relative blood volume monitoring. Following this, dry weight 
and anti-hypertensive medications remained unchanged for the duration 
of the study. Patients were then randomised to group A or B. Group A 
patients were commenced on standard thrice weekly HD, whereas group 
B patients started thrice weekly PHF treatment. Both groups underwent 1 
week of stabilisation before one of the dialysis sessions during the 
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second week was monitored. At the end of the second week, patients 
then crossed over to the other dialysis modality thereby acting as their 
own controls. After a further week of stabilisation, patients underwent a 
second monitored session.   
 
 
Patient Age  Months on 
dialysis 
Epo 
(U/wk) 
Anti-hypertensive 
medication 
Cause of ESRF Vascular 
disease? 
IHD? 
1 
58 52 25000   
Obstructive 
uropathy 
N N 
2 81 18 8000   Unknown  Y N 
3 66 51 14000 Lisinopril 5mg od Unknown N N 
4 
66 19 20000   
Anti-GBM 
disease 
N N 
5 
74 35 8000 
Nifedipine 60mg od, 
Doxazosin 6mg od 
FSGS Y N 
6 
80 34 16000   
Diabetic 
nephropathy 
Y Y 
7 41 67 2000 Lisinopril 5mg od APKD Y Y 
8 72 62 25000   Lupus nephritis N N 
9 64 53 12000   APKD N Y
*
 
10 
78 28 7000 Diltiazem 120mg bd 
Renovascular 
disease 
Y Y 
11         62 8 9000 Lisinopril 20mg od, 
Nifedipine 60mg od, 
Moxonidine 200mcg od 
Diabetic 
nephropathy 
Y N 
12 
74 47 30000   
Obstructive 
uropathy 
N N 
 
Mean ± 
SD 68 ± 11.2 39.5 ± 18.7 
14667 
± 8669 
 
   
 
Table 6-a.  
Baseline characteristics of randomised patients. Epo = epoetin. All patients were being 
administered intravenous Eprex. Epo doses and anti-hypertensive medications were 
left unchanged for the duration of the study. ESRF = end stage renal failure, FSGS = 
focal segmental glomerulosclerosis, APKD = adult polycystic kidney disease. IHD = 
ischemic heart disease, and refers to a diagnosis of angina or previous myocardial 
infarction.  
* Coronary angiogram result for patient 9. Mild disease of LAD, good RCA, recannulised 
an occluded branch of LAD. 
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For each monitored dialysis treatment, non-invasive haemodynamic 
monitoring was undertaken using a Finometer (full description in chapter 
3). The finger cuff was left in place for the entire session, and the non-
fistula arm was used. To obtain baseline values, monitoring was 
commenced 30min prior to commencement of dialysis. Body temperature 
was recorded before and after each session using a digital tympanic 
thermometer (First Temp, Sherwood Davis & Geck, St Louis, USA). 
Blood samples were collected before and after each session in lithium 
heparin and EDTA tubes, and biochemical analysis performed on a 
multichannel autoanalyser. Cardiac troponin-T (cTnT) analysis was 
performed using a third generation electrochemiluminescence assay 
(Roche diagnostics, Lewes, UK). Post dialysis cTnT values were 
corrected individually for haemoconcentration with reference to 
percentage change in haematocrit and blood volume using the formula: 
 
 Adjusted cTnT  =  cTnTpost     x  BVpost (1 – Hctpost) 
      BVpre (1 – Hctpre) 
 
where cTnTpost equals post dialysis cTnT, Hctpost equals post dialysis 
haematocrit, Hctpre equals pre dialysis haematocrit, BVpost equals end 
dialysis blood volume and BVpre equals start dialysis blood volume. Single 
pool Kt/Vurea values were calculated from pre and post urea levels [157]. 
In addition, blood samples were collected pre and post dialysis in EDTA 
tubes for measurement of plasma C-reactive protein (CRP), tumour 
necrosis factor (TNFα) and interleukin-6 (IL6). Samples were centrifuged 
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at 3500rpm for 15min to separate the plasma, which was immediately 
frozen at -800C until time of analysis. CRP, TNFα and IL6 were 
subsequently measured using commercially available enzyme linked 
immunosorbent assays (ELISA, described in chapter 3). Pre dialysis 
blood tests were drawn immediately after insertion of access needles, 
and post levels were taken from the arterial line 10sec after reducing 
blood pump speed to 50ml/min. An investigator was present for the 
entirety of every dialysis session to record intradialytic symptoms.  
 
Primary endpoints were percentage change in blood pressure (BP), 
stroke volume (SV), cardiac output (CO) and total peripheral resistance 
(TPR) in response to HD and PHF. Secondary endpoints were changes 
in cTnT in response to the two dialysis modalities. 
 
6.2.3 Bicarbonate Dialysis and Paired Haemodiafiltration 
All dialysis treatments were performed using Formula 2000 monitors 
(Bellco, Mirandola, Italy). HD was performed using low-flux polysulphone 
dialysers either 1.8m2 or 2.0m2 as per individual patients’ usual 
prescription (LOPS 18/20, Braun Medical Ltd, Sheffield, UK. PHF is a 
novel on-line HDF technique and was performed using Diapes 
polyethersulphone double chamber dialysers consisting of a combined 
1.9m2 dialyser and 0.7m2 ultrafilter (Bellco, Mirandola, Italy). This 
arrangement allows reinfusion to occur inside the dialyser, as previously 
described [117]. PHF was employed in predilution mode with the 
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ultrapure infusion rate set at 10l/hr. For both treatments, dialysate 
contained sodium 138mmol/l, potassium 1mmol/l, calcium 1.5mmol/l, 
magnesium 0.5mmol/l, bicarbonate 32mmol/l and glucose 1g/l. For HD 
treatments, dialysate contained acetate 3mmol/l whereas for acetate free 
PHF, the dialysate concentrate contained hydrochloric acid at 3g/l.  
Ultrapure water was used for dialysate preparation. For HD, sodium 
conductivity was set at 13.6mS/cm. To ensure equivalent sodium removal 
during PHF, during the stabilising week intradialytic sodium levels were 
monitored using a bedside analyser (AVL analyser, Roche diagnostics, 
Lewes, UK) and conductivity set to ensure identical end dialysis plasma 
sodium levels. Other aspects of dialysis treatments did not differ between 
groups. All treatments were of four hours duration and anti-coagulation 
was achieved with unfractionated heparin. Dialysate flow was 500ml/min 
and dialysate temperature was set at 360C. For each session, net fluid 
removal was set on an individual basis according to dry weight. Blood 
pump speed varied between 250ml/min and 450ml/min depending on 
patients’ vascular access but each individual patient had the same blood 
flow for their two monitored sessions. 
 
6.2.4 Troponin analysis in the general dialysis population 
To supplement the cTnT data, we recruited a further 54 patients to obtain 
cTnT, creatinine kinase (CK) and creatinine kinase MB (CK-MB) profiles 
in a representative group of our centre’s haemodialysis population. All of 
these patients had been established on dialysis for more than six months. 
40 were defined as ‘stable’ and the remaining 14 ‘unstable’ as per the 
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above definition. Less than 10% in each group had documented 
ischaemic heart disease. A single pre-dialysis blood sample was 
collected in each of the 54 patients. Blood collection and analysis was 
performed as above. 
 
 
6.3 Statistical analysis 
 
Results are expressed as the mean ± SD, or for non-parametric data as 
the median with the interquartile range (IQR) within parentheses. Data for 
cTnT underwent logarithmic transformation prior to analysis due to the 
distribution of the data points. For statistical analysis the paired t-test for 
parametric data and Wilcoxon analysis for non-parametric data were 
used. An alpha error at P<0.05 was judged to be significant.  
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6.4 Results 
 
6.4.1 Blood pressure 
Mean BP was higher during HD as compared to PHF. During HD, mean 
systolic BP (SBP) for the entire session was 145.5 ± 8.0mmHg, mean 
diastolic BP (DBP) was 80.8 ± 3.5mmHg and mean of the mean arterial 
pressure (MAP) was 104.1 ± 5.2mmHg. During PHF, mean SBP for the 
entire session was 7.7mmHg lower at 137.8 ± 5.3 mmHg (p<0.0001), 
mean DBP was 1.6mmHg lower at 79.2 ± 1.9mmHg (p=0.005) and mean 
MAP was 3.6mmHg lower at 100.5 ± 2.9mmHg (p<0.0001). As is 
apparent from the wider ranges and larger SDs, there was more variation 
in BP during HD. Blood pressure data are summarised in figure 6-a. 
 
The total number of IDH episodes during HD was 37, as compared with 
23 episodes during PHF. There were relatively few symptomatic episodes 
of IDH - two during both HD and PHF. The remaining IDH episodes were 
asymptomatic SBP recordings <100mmHg. The difference in mean 
number of IDH episodes between HD and PHF did not reach statistical 
significance. For the asymptomatic episodes no corrective action was 
taken. For two of the four symptomatic episodes, UF was temporarily 
stopped and 200ml of saline or online reinfusate were delivered 
(depending on modality). For the other two episodes, symptoms resolved 
with temporary cessation of UF. 
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Figure 6-a.  
Mean BP for HD and PHF. During PHF, BP was lower (SBP p<0.0001, MAP p<0.0001, 
DBP p=0.005) but there was less variation in BP. BP is seen to fall in the last 15min of 
HD but is maintained during the same period of PHF. For clarity, only SBP and DBP are 
shown. Data are expressed as mean ± SEM. 
 
 
6.4.2 Haemodynamic data 
Haemodynamic and BP measurements at baseline were compared to 
ensure repeatability of measurement technique and conditions. There 
were no significant differences in any of the parameters between HD and 
PHF.  
 
HR did not differ between HD and PHF treatments, with mean values for 
the entire session of +2.1 ± 3.2 % and +2.9 ± 3.9 % respectively 
(p=0.199). During both treatments there was a trend for HR to increase 
slightly.  
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SV progressively declined during both treatments relative to baseline, but 
to a greater extent during HD. Mean SV for the entire HD session was      
-24.8 ± 8.4% and mean SV during PHF was -18.5 ± 8.6% (p=0.003). SV 
at the end of HD had fallen by -47.9% of baseline, and by -30.9% of 
baseline at the end PHF. As a product of HR and SV, CO showed similar 
changes. During HD, CO declined by -37.4% from baseline, with a mean 
value for the entire session of -24.8 ± 6.6%. During PHF, CO declined by          
-24.6% from baseline and the mean value was significantly higher at        
-15.2 ± 6.3% (p<0.0001).  
TPR rose progressively during both treatments. However, in light of the 
changes in CO, TPR rose to a greater degree during HD. TPR rose by 
71% from baseline during HD, with a mean value for the entire session of 
+39.3 ± 14.5%. During PHF, TPR rose by 47.9% with a mean value of 
+19.4 ± 10.3%. The difference in mean TPR values was statistically 
significant (p<0.0001). All haemodynamic data are summarised in figure 
6-b. 
The above data pertains to the population as a whole. Examining 
haemodynamic and blood pressure data for individual patients, 9/12 
demonstrated similar changes although two patients exhibited a greater 
increase in HR during PHF as compared with HD. One patient 
demonstrated no differences between HD and PHF. The remaining two 
patients exhibited opposite findings to the overall data, with greater 
decline in CO and a greater rise in TPR during PHF as compared with 
HD.  
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Figure 6-b.  
Haemodynamic changes during HD and PHF. Data are shown as mean ± SEM. 
 
 
6.4.3 Biochemical results 
There were significant differences in cTnT between the two treatments. 
Pre PHF median cTnT levels were lower at 0.03 (IQR 0.03 to 0.16)µg/l as 
compared with HD with a median of 0.05 (IQR 0.03 to 0.12)µg/l 
(p=0.031). Post HD median cTnT levels (adjusted for 
haemoconcentration) rose to 0.06 (IQR 0.035 to 0.17)µg/l, whereas 
adjusted post PHF median cTnT levels fell to 0.02 (IQR 0.01 to 0.07)µg/l 
(p<0.0001). There was also a statistically significant difference between 
median pre and adjusted post values for HD (p=0.01) and for PHF 
(p=0.0008). cTnT data are summarised in figure 6-c. 
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Figure 6-c.  
Cardiac troponin T levels pre and post HD and PHF. Post levels are corrected for 
hemoconcentration.  
 
 
The cTnT data for the general dialysis population is summarised in table 
6-b. Pre dialysis median serum cTnT was significantly higher in the 
unstable group of patients, but there were no significant differences 
between the median CK or CK-MB levels.  
 
 Stable  
 
Unstable p-value 
Age 
(years) 
56 ± 14 59 ± 16 0.26 
Pre dialysis 
cTnT (µg/l) 
0.01 (0.01 to 0.04) 0.1 (0.05 to 0.8) <0.0001 
Pre dialysis CK 
(iu/l) 
84  98  0.28 
Pre dialysis CK 
MB (iu/l) 
0.5  1.2  0.12 
 
Table 6-b.  
General dialysis population pre-dialysis cTnT, CK and CK-MB levels, with patients 
divided into ‘stable’ or ‘unstable’ on dialysis. Biochemical data are expressed as 
medians with IQR within parentheses. 
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Other biochemical results from pre and post blood samples are shown in 
table 6-c. Most blood tests were similar between the two treatments, 
including pre and post plasma sodium levels. Equally, there were no 
differences between dialysis treatments for mean intradialytic sodium 
levels at 1 and 3 hours (p=0.53 and 0.49 respectively). Median serum 
bicarbonate levels were 3.0mmol/l lower pre PHF as compared with pre 
HD levels (p=0.031) but post treatment levels were similar between the 
two.  
 
 
Pre HD Pre PHF p-value Post HD Post PHF p-value 
Hb (g/dl) 10.9  
(10.4-12) 
10.7  
(9.5-11.8) 
0.77 11.3  
(10.7-12.9) 
11.8  
(10.8-12.9) 
0.47 
HCO3 (mmol/l) 25  
(23.5-27) 
22  
(20-24) 
0.016  29  
(26.5-31) 
27  
(25-29) 
0.156 
Na (mmol/l) 138  
(138-141) 
139  
(138-141) 
0.625 137  
(135-139) 
137  
(136.5-139) 
0.33 
Urea (mg/dl) 63.3 
(48.2-76.5) 
61.9 
(47.1-75.9) 
0.47 19.8 
(13.4-19.9) 
21.3 
(13.4-24.6) 
0.365 
Creatinine (mg/dl) 9.6 
(7.5-10.2) 
9.2 
(7.8-10.3) 
0.97 3.6  
(2.9-4.2) 
3.7 
(3.2-4.8) 
0.831 
Adj calcium 
(mmol/l) 
2.43  
(2.36-2.51) 
2.48  
(2.36-2.55) 
0.148 2.35  
(2.33-2.42) 
2.29  
(2.28-2.44) 
0.16 
P04 (mmol/l) 1.81  
(1.39-2.03) 
1.62  
(1.37-1.88) 
0.73 0.78  
(0.64-0.87) 
0.75  
(0.65-0.89) 
0.13 
Albumin (g/dl) 3.3  
(3.1-3.7) 
3.4  
(3.3-3.5) 
0.90 3.8  
(3.6-4.0) 
3.7  
(3.2-4.0) 
0.44 
PTH (ng/l) 236  
(138-382) 
173  
(122-310) 
0.637    
 
Table 6-c.  
Pre and post biochemical and haematological results for HD and PHF. Values shown 
are medians with the interquartile range within parentheses. The majority of results were 
similar between treatments. There was a significantly lower serum bicarbonate level pre 
PHF as compared to pre HD, although post levels were compatible.  
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6.4.4 Cytokine and CRP levels 
There were no differences between any of the measured cytokines when 
comparing HD and PHF, either before or after dialysis. CRP and albumin 
levels were also similar between modalities. TNFα tended to rise 
following HD (+1.9 ± 3.3pg/ml) and fall following PHF (-0.9 ± 2.6pg/ml), so 
delta TNF was different between the two modalities (p<0.05). This may 
reflect greater clearance due to the convective element of PHF. IL6 and 
CRP were strongly correlated (r=0.54, p<0.0001), but there were no 
correlations between TNFα and either CRP or IL6. These data are shown 
in table 6-d. 
 
 
 IL6 (pg/ml) TNFα (pg/ml) CRP (mg/l) Albumin (g/l) 
Pre HD 11.2 
(7.5 – 14.8) 
1.1 
(0 – 2.7) 
9.2 
(3.7 – 14.9) 
33 
(30.5 – 36.5) 
Pre PHF 9.9  
(9.4 – 14.5) 
2.7 
(0 – 5.2) 
10.6  
(4.0 – 36) 
34 
(32.5 – 35) 
Post HD 10.2 
(7.7 – 16.9) 
2.9 
(0 – 2.7) 
8.2  
(4.3 – 15.8) 
38 
(36 – 40) 
Post PHF 10.6  
(7.4 – 14.5) 
1.6 
(0 – 1.8) 
11.2 
(3.4 – 37) 
36 
(32 – 39.5) 
 
Table 6-d.  
Levels of cytokines (TNFα, IL6), CRP and albumin before and after standard dialysis 
and acetate free PHF. There were no significant differences in any of the values. 
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6.4.5 Dialysis details 
Pre-dialysis body weight was 76.2 ± 12.6kg for HD and 76.3 ± 12.7 for 
PHF (p=0.93). There were no differences between the two treatments in 
relative blood volume reduction, ultrafiltration (UF) rate, single-pool Kt/V 
or change in body temperature. Fluid removal and reduction in plasma 
sodium were also the same for each modality. In all patients, the 
prescribed dry weight was achieved. These data are shown in table 6-e. 
During the stabilising week of PHF, dialysate sodium conductivity was 
tailored to deliver the same end dialysis plasma sodium level as HD. In 
predilution mode, this resulted in PHF sodium conductivity being set 
2mS/cm higher than HD in all patients. 
 
  
HD PHF p-value 
 Mean ± SD Range Mean ± SD Range  
Weight loss (% of 
body wgt) 
1.9 ± 0.7 0.6 to 2.8 1.9 ± 0.8 0.4 to 3.1 0.8 
Delta RBV (%) 
 
-9.24 ± 7.56 -21 to -1.1 -9.46 ± 7.59 -22.1 to 2.6 0.94 
UF rate (l/hr) 
 
0.42 ± 0.17 0.22 to 0.67 0.45 ± 0.17 0.1 to 0.65 0.75 
Delta serum Na 
(mmol/l) 
-2.17 ± 1.95 -5.0 to 1.0 -2.10 ± 2.62 -6.0 to 4.0 0.94 
Delta patient 
temperature (0C) 
0.18 ± 0.69 -0.8 to 1.5 0.28 ± 0.49 -0.7 to 1.0 0.69 
Kt/V 
 
1.38 ± 0.32 0.67 to 1.88 1.37 ± 0.28 0.81 to 1.77 0.91 
 
Table 6-e.  
Comparison of dialysis parameters between HD and PHF. RBV = relative blood volume 
reduction, UF = ultrafiltration. Kt/Vurea was a single pool value. 
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6.5 Discussion 
 
Acetate transfer is significant during bicarbonate-based HD and may be a 
factor in the aetiology of IDH. This study demonstrates that acetate free 
PHF is associated with improved haemodynamics, a lower BP but with a 
trend towards less IDH and lower cTnT levels as compared to HD. 
 
The haemodynamic response to PHF was characterised by attenuation of 
the characteristic decline in SV and CO seen with HD, and as a result a 
smaller increase in TPR was observed. These differences were present 
despite identical fluid removal, relative blood volume change and pre, 
intra and post dialysis plasma sodium levels. It remains contentious as to 
whether acetate transfer during dialysis causes myocardial depression - 
although several studies do show that acetate causes a reduction in 
myocardial contractility, there are other studies that do not confirm this 
[109-112]. Acetate may directly affect myocardial contractility [113, 114], 
although it is also possible that increased endothelial NO production 
stimulated by acetate affects the baroreflex arc [112, 179]. In terms of the 
findings of our study, it is possible that the lack of acetate transfer during 
PHF treatments resulted in less suppression of myocardial contractility 
and therefore a smaller decline in SV and CO. 
 
An alternative explanation for our results would be that the improved 
haemodynamics seen with PHF are due to the comparison of a 
predominantly convective with a diffusive technique. However, there is 
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accumulating evidence that the acute benefit of convective therapies on 
improved stability during dialysis is due to increased patient cooling, 
which is mediated by a greater rise in TPR. When the therapies are 
matched for extracorporeal energy balance, low flux dialysis is equivalent 
in terms of IDH frequency and changes in systemic haemodynamics to 
both pre and post dilution HDF [93, 94]. These results also show that 
differences in solute clearance cannot explain the improved 
haemodynamics of HDF. In our study, we appear to have avoided 
significantly greater cooling during PHF by reducing the dialysate 
temperature during HD. Change in patients’ body temperature did not 
differ between the two modalities, and TPR was lower during PHF. 
However, one potential weakness of our study is that we did not have 
access to thermal energy measurement equipment to formally document 
energy transfer during dialysis treatments. Other suggested mechanisms 
to explain improved stability with convective therapies include differences 
in sodium removal and improved biocompatibility. In our study, treatments 
were matched for changes in plasma sodium, and the membranes and 
lines were of sufficient similarity to make a difference in biocompatibility 
unlikely. Therefore, it seems more likely that the lack of acetate as 
opposed to the difference in convection explains our results, although the 
design of this study cannot exclude other, as yet undiscovered, 
advantages of convective therapies.  
 
Vasodilatation, another well-recognised effect of acetate did not seem to 
be predominant as TPR was higher during HD. The higher TPR seen with 
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HD may have occurred in response to the greater fall in SV and CO, 
suggesting that a greater degree of vasoconstriction was required during 
HD to prevent hypotension. These observations were unexpected, as 
many studies have shown that acetate can cause vasodilatation, although 
most of this work is in respect to acetate dialysis where acetate transfer 
would be higher as compared to standard bicarbonate HD. If acetate is 
responsible for the observed differences in our study, then this might 
suggest that the myocardial depressant effects of acetate are the 
predominant influence at the levels experienced during bicarbonate 
dialysis.   
 
Overall BP was lower during PHF, but was preserved with fewer 
fluctuations as compared to HD. This was especially evident in the last 
15min of the treatments when BP during HD dropped but during the same 
period of PHF was maintained. In addition, there was a trend towards 
fewer episodes of IDH during PHF treatments. This study was not 
powered to detect a significant difference in IDH episodes and it may be 
that this trend towards less IDH would have been statistically significant if 
participant numbers were larger or more sessions studied. In support of 
this, acetate free biofiltration (AFB), a technique that employs base free 
dialysate and a post-dilution infusion of ultra sterile bicarbonate, has been 
shown to reduce IDH as compared to standard dialysis [112]. 
Furthermore, one longer-term study showed AFB to provide improved 
control of pre-dialysis BP that is consistent with our findings of lower 
blood pressure during PHF, but without increased instability [116]. The 
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results from our study show that the higher BP with HD was due to an 
excessive rise in TPR (greater than that required to compensate for the 
larger fall in CO), but the mechanisms behind this remain obscure. 
 
We observed significant differences between HD and PHF in serum cTnT 
levels both pre and post dialysis. Levels were lower pre PHF as 
compared to HD, and after PHF the levels fell further. Following HD, cTnT 
levels rose, and one explanation for this is that the BP fluctuations and 
change in volume status seen during HD may be sufficient to induce 
subclinical myocardial cell damage. This is supported by our finding of 
higher cTnT levels in IDH prone patients in our general dialysis 
population, who are more at risk of myocardial hypoperfusion. These 
results differ from those reported in chapter 5 when cTnT did not rise 
following dialysis, even in the presence of echocardiographic evidence of 
ischaemia. Therefore, because cTnT may take up to 12 hours to rise 
following an ischaemic insult, measuring levels immediately following 
dialysis may only intermittently detect acute, dialysis induced rises in 
cTnT. However, if dialysis does cause subclinical myocardial ischaemia, 
then this may have the potential to impair cardiac performance. The lower 
pre dialysis cTnT levels (possibly signifying reduced overall release) and 
the improved myocardial performance may indicate that this effect is less 
with PHF.  
Alternatively, it is possible that the fall in cTnT levels with PHF was due to 
increased clearance across the high flux membrane. High flux 
membranes clear molecules up to 15kDa by diffusion and can clear larger 
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molecules up to 25kDa by convection. However, cTnT is a charged 
molecule that is 38kDa in size, and some individual patients 
demonstrated as much as a 50% reduction in cTnT levels. It has been 
shown that smaller cTnT fragments (8 to 25kDa) are also present in the 
serum of dialysis patients [180], and these might be cleared significantly 
by PHF. However, recent work has shown that these fragments are not 
responsible for the elevated readings seen in many dialysis patients when 
the current third generation assay is used [64]. Therefore, to determine 
the mechanism of the reduced cTnT levels seen with PHF, it would be 
necessary to compare pre and post dialysis cTnT levels with PHF versus 
a standard haemodiafiltration technique that provides similar clearance. 
 
Pre PHF bicarbonate levels were noted to be slightly lower than pre HD 
levels, although there was no difference in post dialysis levels. This may 
reflect the fact that acetate will continue to be converted to bicarbonate in 
the immediate post dialysis period, and as a result, serum bicarbonate 
levels can initially continue to rise. In contrast, the post dialysis serum 
bicarbonate with acetate free dialysis represents the maximum level 
achieved. Our results suggest that bicarbonate conductivity should be set 
3-4 mS/cm higher for PHF than HD to achieve equivalent overall acid-
base control. Sodium balance during predilution haemodiafiltration (HDF) 
remains a matter of debate, with different authors reaching different 
conclusions. We took a pragmatic approach to ensure the dialysis 
modalities were matched in terms of change in plasma sodium 
concentrations but did not perform detailed sodium balance studies. 
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However, our findings of slightly higher conductivity settings during PHF 
have been previously reported during predilution HDF [181]. We can only 
speculate as to possible causes, but this may be due to large infusion 
volumes added before the dialyser leading to a reduction in the Donnan 
effect. Therefore, despite the relative hypotonicity of the reinfusate, the 
ultrafiltrable sodium fraction may have been increased. 
 
We did not find any significant differences in inflammatory effects 
between standard dialysis (using a biocompatible membrane and 
ultrapure dialysate) and acetate free PHF, with similar levels of CRP and 
cytokines with both treatments. These results are similar to one other 
report comparing these two treatments [182], and suggest that the levels 
of acetate transfer during standard bicarbonate dialysis are insufficient to 
stimulate an inflammatory response. The fall in TNFα following PHF may 
represent greater clearance of this molecule as compared to standard 
dialysis, either due to convection or to the higher flux membrane.  
 
In conclusion this study demonstrates that acetate-free PHF is associated 
with a lower BP without increased instability and significantly less 
deterioration in systemic haemodynamics as compared to cool 
temperature low-flux bicarbonate-based dialysis. We suggest that one 
possible explanation for this is the absence of acetate that may be 
important in maintaining myocardial contractility. The rise in troponin with 
standard dialysis and the higher readings seen in IDH prone patients 
provide further evidence that subclinical myocardial damage may occur 
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during the procedure. PHF may be associated with a reduction in 
myocardial cell injury, increased clearance of cTnT across a high flux 
membrane or a combination of both. However, there was no evidence 
that PHF reduced systemic inflammation. This study provides initial 
evidence that PHF may be a superior treatment in selected patient 
groups. However, given the relative expense and complexity of this 
treatment compared to standard dialysis and lack of clear separation in 
terms of IDH between the treatments, it is remains doubtful that PHF 
would be the most efficient technique to reduce dialysis induced 
myocardial stunning. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 112
7. Results: a comparison of progressive dialysate 
conductivity reduction with Diacontrol and standard 
dialysis 
 
7.1 Introduction 
 
Empirical reduction of dialysate sodium to below plasma water sodium 
enhances sodium removal by diffusion, and may lead to a reduction in 
total body sodium. Some studies, including previous work from our centre 
have shown that progressively reducing dialysate sodium results in 
significant improvements in pre and post dialysis blood pressure, 
matched by a fall in IDWGs (figure 7-a, [102]). This approach leads to 
dialysis with lower UF rates, which may in turn be important in avoiding 
IDH and therefore myocardial hypoperfusion during dialysis. The 
drawback of this approach is that in the early period of dialysis an 
excessive reduction in plasma tonicity may result, leading to rapid falls in 
circulating volume with resultant symptoms and hypotension. Therefore, 
in an ideal situation dialysate sodium should be as low as possible, 
providing this can be achieved without excessive intradialytic symptoms.  
 
In an attempt to achieve this, a novel biofeedback dialysis technique has 
been developed (Diacontrol®, DC described in chapter 1) that returns a 
patient to a prescribed plasma sodium level by the end of dialysis. It is 
programmed to avoid rapid drops in plasma tonicity early in dialysis and 
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therefore may confer a benefit in terms of reducing IDH (figure 1-e), 
although clinical evaluation of DC remains limited. 
 
Within a protocol of progressive dialysate conductivity reduction, we 
sought to further investigate whether using DC would lead to improved 
haemodynamic tolerability and less IDH as compared to conventional 
dialysis (with a fixed dialysate sodium), thereby allowing maximisation of 
potential benefits of sodium reduction. 
 
 
Figure 7-a. 
Interdialytic weight gains progressively fall as dialysate conductivity is reduced [102]. 
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7.2 Subjects and Methods 
 
7.2.1 Patients 
We recruited 10 patients on chronic haemodialysis for a prospective 
randomised single-blind crossover study. Patients were characterised by 
a low incidence of IDH, defined as less than three episodes of IDH in the 
month before recruitment. Three patients were female and all had been 
on dialysis for more than six months. Eight patients had native 
arteriovenous fistulae and two dialysed via tunnelled internal jugular 
catheters. All but one patient was anuric, and the remaining patient had a 
residual 24-hour urine volume of only 300ml. Seven patients were not 
taking anti-hypertensive medication. At the outset of the study, mean 
haemoglobin was 11.7 ± 0.7g/dl (range 10.3 – 12.6) and serum albumin 
was 36.3 ± 3g/l (range 32 – 42). Remaining baseline patient information 
is shown in table 7-a. 
 
Patients were excluded if they had experienced three or more episodes of 
IDH, if their target weight had been altered in the month before 
recruitment or if they were treated with any modality other than standard 
bicarbonate-based haemodialysis. All patients gave informed consent 
prior to commencement, and ethical approval for the project was granted 
by Derbyshire Research Ethics Committee. 
 
 
 115
Patient Age 
(years) 
Months on 
dialysis 
Anti-hypertensive 
medication 
Cause of ESRF 
1 69 17 Lisinopril 20mg od APKD 
2 42 240   Reflux nephropathy 
3 66 6   Vasculitis 
4 66 72   TIN 
5 55 6 Nifedipine 60mg od 
Ramipril 2.5mg od 
Unknown 
6 73 6 Lisinopril 2.5mg od 
Atenolol 50mg od 
Amlodipine 10mg od 
Unknown 
7 76 67   Anti-GBM disease 
8 65 81   APKD 
9 79 38   ARVD 
10 74 33  Obstructive uropathy 
 
Mean ± SD 66.5 ± 11 57 ± 71  
 
 
Table 7-a.  
Patient characteristics. ESRF = end stage renal failure; APKD = adult polycystic kidney 
disease, ARVD = atherosclerotic renovascular disease, TIN = tubulo-interstitial nephritis. 
 
 
7.2.2 Study protocol 
Upon entry to the study, patients had their dry weight confirmed with 
reference to clinical examination and serial blood pressure readings. 
Standard low sodium diet (<6g per day) was reinforced with additional 
dietetic interactions, but no additional dietary interventions were 
performed. Patients were then randomised to group A or B. Group A 
patients were commenced on standard thrice-weekly HD and group B 
were started on DC. After each two week period (six dialysis treatments) 
conductivity settings were progressively reduced as shown in figure 7-b. 
For HD, initial fixed dialysate conductivity was 13.6mS/cm (HD13.6), 
reducing to 13.4mS/cm (HD13.4) then to 13.2mS/cm (HD13.2). We have 
previously demonstrated the average end dialysis plasma conductivities 
obtained at these settings [102]. Therefore, initial prescribed end dialysis 
plasma conductivity with DC was 13.7 (DC13.7), reducing to 13.6mS/cm 
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(DC13.6) and then 13.5mS/cm (DC13.5). 13.5mS/cm is the lowest target 
conductivity allowed by DC when inputting the prescription into the 
dialysis monitor due to software programming. At the end of the sixth 
week, patients returned to their usual dialysis prescription for two weeks 
washout. At the start of the ninth week patients crossed over to the other 
dialysis modality thereby acting as their own controls, and the same 
conductivity reduction was performed. If intradialytic symptoms or IDH 
attributable to a reduction in conductivity developed, patients were 
returned to the last conductivity level at which they has been stable. 
Study duration was 14 weeks and data were collected from a total of 360 
dialysis sessions. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7-b.  
Flow diagram of study design. 
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7.2.3 Dialysis details 
Dialysis was performed as described in chapter 3. Technical aspects and 
validation of Diascan and Diacontrol (DC) have been described 
previously [104-106, 108]. DC is a biofeedback system that uses single 
pool kinetic modelling, and in response to plasma conductivity (measured 
by ionic dialysance, Diascan) automatically adjusts dialysate 
conductivity throughout the dialysis session to achieve the prescribed 
plasma conductivity by the end of dialysis.  
 
7.2.4 Data collection 
For every treatment dialysis run data were automatically collected and 
downloaded to a database (Exalis, Gambro-Hospal, Mirandola, Italy). 
This included pre, post and intradialytic BP, start and end plasma 
conductivities, dialysate conductivity (during DC a time averaged mean 
was subsequently calculated), ionic mass balance (IMB) and relative 
blood volume (RBV).  Conductivities and IMB were estimated by 
Diascan every 15min and RBV continuously measured using an optical 
measure of haemoglobin concentration (Hemoscan, Gambro-Hospal, 
Mirandola, Italy). An investigator interviewed patients at each dialysis 
session to monitor symptoms and episodes of IDH, defined as systolic 
blood pressure (SBP) ≤ 100mmHg even in the absence of symptoms, or 
a fall in SBP > 10% of the pre dialysis reading in association with any of 
the classical symptoms of hypotension (headaches, cramps, 
lightheadedness). In addition, each patient completed a validated thirst 
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score on a weekly basis (see appendix 15.2). Absence of thirst is 
represented by a minimum score of 7 and most thirsty represented by a 
maximum score of 35.  
 
During the second week of each conductivity setting, both before and 
after a mid-week dialysis session, patients had segmental multi-frequency 
bioimpedance measurements using tactile electrodes (InBody BS20, 
Seoul, Korea) to assess intracellular (ICW) and extracellular water that 
was then corrected for body weight (ECW). Before and after the same 
dialysis session blood samples were collected in lithium heparin and 
EDTA tubes. Biochemical analysis of the blood samples was performed 
on a multichannel autoanalyser. Plasma sodium concentration was 
determined by indirect ionometry, and the diffusible concentration was 
obtained by using a correction factor of 0.94 [183]. Single pool Kt/Vurea 
values were calculated from pre and post urea levels according to 
Daugirdas II. 
 
At the highest and lowest conductivity settings with each dialysis modality 
(weeks 2, 6, 10 and 14) patients had ambulatory BP monitors fitted 
(OSCAR2, SunTech Medical, Eynsham, UK) for the first 24 hour period 
immediately following dialysis. The initial reading was taken at the same 
time as the post dialysis BP. This monitor has been shown to meet the 
accuracy criteria of the European Society of Hypertension International 
Protocol. 
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7.3 Statistical analysis 
 
Two separate analyses were planned to take account of the fact that 
individual patients display varying pre dialysis sodium and conductivity 
levels, and therefore empirical reduction of fixed dialysate conductivity will 
result in differing end dialysate plasma conductivity in different patients. 
Therefore, a direct comparison between HD and DC may compare 
dialysis sessions with different sodium balance. The first analysis 
(‘conductivity reduction’) was designed to compare the different variables 
within each dialysis modality at the different conductivity settings and all 
treatment sessions were included.  
The second analysis was designed to compare HD with DC. For each 
individual, data were paired and analysed when end dialysis plasma 
conductivity was equal for both dialysis modalities. Pairs will be referred 
to as DCH or HDH corresponding to those with end dialysis plasma 
conductivity of 13.7mS/cm, DCM or HDM corresponding to those pairs with 
end dialysis plasma conductivity of 13.6mS/cm, and DCL or HDL 
corresponding to those pairs with end dialysis plasma conductivity of 
13.5mS/cm. 
 
Results are expressed as mean ± SD unless otherwise stated. Data were 
analysed using one-way ANOVA with Bonferroni’s test to correct for 
multiple comparisons after confirmation of a normal distribution and equal 
variance. The IDH rate for each setting was compared using Poisson 
regression. An alpha error at P<0.05 was judged to be significant. 
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7.4 Results 
 
Table 7-b shows the number of patients at each level of fixed dialysate 
conductivity that had end dialysis plasma conductivity equal to each 
setting of DC. 10 pairs of data were excluded from the second analysis; 
with HD end dialysate plasma conductivity was <13.5mS/cm in nine 
cases, and was >13.7 mS/cm in one case.  
 
 DC13.7 DC13.6 DC13.5 
HD13.6 6 2 0 
HD13.4 1 5 2 
HD13.2 0 0 4 
 
Table 7-b.  
Table to demonstrate number of patients at each level of fixed dialysate conductivity 
(HD) that had end dialysis plasma conductivity equal to each setting of Diacontrol (DC). 
 
 
7.4.1 BP and intradialytic symptoms 
BP data are shown in table 7-c. BP at the outset of the study was largely 
well controlled, and during conductivity reduction with both HD and DC 
there were no significant changes in pre, intra or post dialysis BP. Equally 
there was no difference in IDH frequency between the conductivity 
settings, with rates of 0.14, 0.28 and 0.22 events/session at HD13.6, HD13.4 
and HD13.2 respectively and IDH rates of 0.29, 0.3 and 0.34 
events/session with DC13.7, DC13.6, and DC13.5 (p=ns for all). Reduction of 
conductivity was well tolerated during both types of dialysis, and only one 
of the ten patients experienced unacceptable symptom levels (muscle 
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cramps) during HD13.2 for which the dialysate conductivity was returned to 
13.4mS/cm.  
 
 
 
HD 
 
 DC 
 
Pre-dialysis SBP DBP Pre-dialysis SBP DBP 
HD 13.6 140.5 ± 20.2 76.8 ± 15.3 DC 13.7 146.4 ± 20.3 80.1 ± 13.2 
HD 13.4 143.6 ± 19.5 79.1 ± 17.0 DC 13.6 143.1 ± 16.4 78.3 ± 14.0 
HD 13.2 138.4 ± 22.6 75.8 ± 11.2 DC 13.5 141.8 ± 24.1 76.5 ± 10.6 
Intra-dialysis 
  
Intra-dialysis 
  
HD 13.6 126.5 ± 16.5 70.7 ± 9.9 DC 13.7 126.9 ± 17.6 70 ± 10.4 
HD 13.4 125.1 ± 18.2  70.9 ± 10.2 DC 13.6 124 ± 16.4 69.9 ± 9.9 
HD 13.2 127.8 ± 19.1 68.5 ± 10.0 DC 13.5 123.5 ± 16.7 68 ± 8.9 
Post-dialysis 
  
Post-dialysis 
  
HD 13.6 126.7 ± 18.6 71.3 ± 12.0 DC 13.7 133.6 ± 26.6 70.4 ± 12.7 
HD 13.4 128.8 ± 23.8 69.6 ± 13.1 DC 13.6 124.2 ± 18.9 68.8 ± 13.4 
HD 13.2 126.9 ± 18.5 68.9 ± 11.9 DC 13.5 125 ± 18.5 72.5 ± 16.7 
 
Table 7-c.  
Blood pressure during conductivity reduction with fixed dialysate conductivity (HD) and 
Diacontrol (DC). Comparisons were made only within each modality (i.e. HD and DC 
were not directly compared) and p>0.05 for all. 
 
 
There were few differences in pre, intra or post dialytic BP between HD 
and DC when matched for end dialysis plasma conductivity. The only 
difference was seen in post dialysis SBP when comparing HDL that had a 
mean of 130.5 ± 25mmHg with DCL with a mean of 118 ± 17mmHg 
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(p<0.05). Equally there were no differences in IDH frequency, with rates 
of 0.2 events/session and 0.4 events/session for HDH and DCH, 0.2 
events/session and 0.1 events/session for HDM and DCM respectively and 
0.3 events/session and 0.6 events/session for HDL and DCL respectively 
(p=ns for all). BP data for matched sessions are shown in table 7-d. 
 
 Pre SBP Post SBP Pre DBP Post DBP Intra-dialysis 
SBP 
Intra-dialysis 
DBP 
HDH 145 ± 20 133 ± 27 80 ± 16 76 ± 16 129 ± 22 72 ± 15 
DCH 150 ± 21 139 ± 18 83 ± 19 75 ± 13 132 ± 19 73 ± 11 
       
HDM 145 ± 24 131 ± 29 81 ± 10 71 ± 14 132 ± 20 76 ± 12 
DCM 151 ± 23 130 ± 22 82 ± 16 75 ± 21 134 ± 26 76 ± 17 
       
HDL 141 ± 17 130 ± 23* 74 ± 16 70 ± 16 130 ± 18 70 ± 11 
HDL 142 ± 22 118 ± 17* 75 ± 10 67 ± 19 124 ± 19 65 ± 11 
 
Table 7-d.  
BP data for those sessions when end dialysis plasma conductivity was matched for HD 
and DC. * p<0.05 by ANOVA. 
 
 
7.4.2 Ambulatory BP 
One patient did not tolerate ABPM and therefore only nine patients were 
included in this part of the analysis. ABPM data are summarised in figure 
7-c and table 7-e. Again, baseline BP was low at the outset. Overall 
24hour, daytime and night time BP did appear lower when comparing 
HD13.6 to HD13.2 and when comparing DC13.7 to DC13.5; however, none of 
these differences reached statistical significance (p=ns).  
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The number of patients displaying night time dipping (defined as a 
reduction in daytime SBP of >10%) did not change with conductivity 
reduction. Three patients displayed dipping during HD13.6, HD13.2 and 
DC13.7 and four patients displayed dipping during DC13.5. Also, there were 
no differences between night-day SBP ratios at the different conductivity 
settings. 
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Figure 7-c.  
Overall interdialytic ambulatory BP data.  
 
 
 HD13.6 HD13.2 DC13.7 DC13.5 
Overall 24hr SBP 125 ± 16 119 ± 15 128 ± 16 120 ± 11 
Daytime SBP 126 ± 17 121 ± 14 131 ± 16 123 ± 10 
Night time SBP 119 ± 14 115 ± 16 119 ± 17 116 ± 17 
     
Overall 24hr DBP 68 ± 10 65 ± 9 70 ± 11 65 ± 6 
Daytime DBP 69 ± 10 67 ± 9 71 ± 11 66 ± 6 
Night time DBP 64 ± 8 62 ± 10 67 ± 10 62 ± 8 
 
Table 7-e. 
Interdialytic ambulatory BP data. There were no differences when comparing ABPM 
results for any of the dialysis settings. 
 124
7.4.3 Sodium balance 
During conductivity reduction with HD, start dialysis plasma conductivity 
was significantly lower with HD13.2 (13.8 ± 0.28mS/cm) as compared with 
HD13.6 (14.0 ± 0.23mS/cm, p<0.05). This was also reflected in pre-dialysis 
plasma sodium concentration, which was 138.3 ± 2.6mmol/l with HD13.6 
as compared to 135.9 ± 2.1mmol/l with HD13.2 (p<0.05). During 
conductivity reduction with DC, there was a non-significant trend for start 
dialysis plasma conductivity to fall as conductivity was reduced. Start 
dialysis plasma conductivity was 14.0 ± 0.27mS/cm with DC13.7, 14.0 ± 
0.21mS/cm with DC13.6 and 13.9 ± 0.25mS/cm with DC13.5 (p=ns). 
However, there was a difference between pre-dialysis plasma sodium 
concentration with DC13.7 (139 ± 2.2mmol/l) and DC13.5 (136.6 ± 
2.0mmol/l, p<0.05). 
 
End dialysis plasma conductivity fell during conductivity reduction with 
both types of dialysis. With HD13.6, HD13.4 and HD13.2, end dialysis plasma 
conductivity was 13.7 ± 0.1mS/cm, 13.6 ± 0.2mS/cm and 13.4 ± 
0.14mS/cm respectively (p<0.001 for each comparison). Diacontrol 
successfully achieved prescribed end dialysis plasma conductivity with a 
mean difference of 0.019 ± 0.03mS/cm between prescribed and achieved 
values (p=ns). End dialysis plasma conductivity was significantly lower 
following HD13.2 as compared to DC13.5 (p<0.001), but there were no 
differences between HD13.6 and DC13.7, or between HD13.4 and DC13.6 
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(p=ns). Start and end dialysis plasma conductivity data are summarised 
in figure 7-d. 
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Figure 7-d.  
Pre and post dialysis plasma conductivity (Γ) data for HD and DC. *p<0.05 by ANOVA, 
** p<0.001 by ANOVA. There were no statistically significant differences between start 
conductivity at different DC settings. The dotted line in the start dialysis plasma 
conductivity graph shows that a proportion of patients have start dialysis plasma 
conductivity less than 13.5mS/cm, the lowest allowed target with DC. 
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Post-dialysis mean plasma sodium concentration was 137.3 ± 1.0mmol/l 
with HD13.6, which was significantly higher than with HD13.4 (135.9 ± 
1.3mmol/l, p<0.05) or HD13.2 (135.7 ± 1.0mmol/l, p<0.05). However, the 
trend for post-dialysis plasma sodium to fall with conductivity reduction 
with DC did not reach statistical significance. Mean post dialysis plasma 
sodium concentrations were 137.5 ± 1.2mmol/l with DC13.7, 136.5 ± 
1.9mmol/l with DC13.6 and 136.8 ± 3 with DC13.5. Equally the differences 
when comparing HD13.6 and DC13.7, HD13.4 and DC13.6 or HD13.2 and 
DC13.5 did not reach significance, although the trend was for lower post 
dialysis plasma sodium concentrations with fixed dialysate conductivity in 
the latter two comparisons. 
 
Start dialysis plasma conductivities were also very similar when 
modalities were matched for end dialysis plasma conductivity. Mean start 
dialysis plasma conductivities for HDH and DCH were 14.0 ± 0.2mS/cm 
and 14.0 ± 0.2mS/cm respectively, for HDM and DCM were 13.9 ± 
0.2mS/cm and 14.0 0.3mS/cm respectively and for HDL and DCL were 
14.0 ± 0.2mS/cm and 14.0 ± 0.3mS/cm respectively (p=ns for all). This 
was reflected in similar pre and post dialysis plasma sodium 
concentrations. 
 
There were no differences in IMB during either conductivity reduction or 
when modalities were matched for end dialysis plasma conductivity. IMB 
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values at the different conductivity settings are shown in tables 7-f and 7-
g. 
 
Thirst score 
 
Thirst score 
 
HD13.6 10.8 ± 3 DC13.7 10.3 ± 2.5 
HD13.4 10.5 ± 4.5 DC13.6 9.8 ± 2.1 
HD13.2 9 ± 1.4 DC13.5 9.6 ± 2.0 
    
Relative blood vol. (%) 
 
Relative blood vol. (%) 
 
HD13.6 -5.8 ± 4.4 DC13.7 -5.9 ± 4.7 
HD13.4 -5.8 ± 3.6 DC13.6 -6.7 ± 3.6 
HD13.2 -5.7 ± 3.5 DC13.5 -5.2 ± 4.4 
    
Ionic mass balance 
(mmol) 
 
Ionic mass balance 
(mmol) 
 
HD13.6 331 ± 117 DC13.7 390 ± 173 
HD13.4 369 ± 106 DC13.6 411 ± 139 
HD13.2 347 ± 125 DC13.5 398 ± 125 
 
   
Kt/Vurea  Kt/Vurea  
HD13.6 1.4 ± 0.3 DC13.7 1.4 ± 0.2 
HD13.4 1.4 ± 0.2 DC13.6 1.5 ± 0.3 
HD13.2 1.4 ± 0.2 DC13.5 1.5 ± 0.2 
 
Table 7-f.  
Dialysis details for HD and DC during conductivity reduction. Comparisons were made 
only within each modality (i.e. HD and DC were not directly compared) and p>0.05 for 
all. 
 
 
7.4.4 Volume status 
With conductivity reduction during HD, there was a reduction in pre-
dialysis ECW and a trend towards a reduction in IDWG. Mean ECW was 
0.22 ± 0.04l/kg during HD13.6 as compared to 0.21 ± 0.09l/kg during 
HD13.2 (p<0.05). Mean weight gain was 2.0 ± 0.7kg during HD13.6 as 
compared with 1.9 ± 0.6kg during HD13.2 (p=0.06). However, during 
conductivity reduction with DC, these differences were not apparent. 
Weight gain and ECW were 1.90 ± 0.8kg and 0.21 ± 0.04l/kg during 
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DC13.7. During DC13.5 mean weight gain was 2.0 ± 0.8kg and pre dialysis 
ECW was 0.21 ± 0.04l/kg (p=ns). There were no differences in pre 
dialysis ICW, post-dialysis weight or in thirst score in any of the 
comparisons. Post dialysis BIA measurements were found to be 
inaccurate and displayed a large degree of variation. 
 
When HD and DC were matched for end dialysis plasma conductivity, 
there were no differences in IDWG, post dialysis weight, thirst score or 
pre-dialysis ECW at any of the three end dialysis conductivity levels. 
These data are shown in table 7-g. 
 
7.4.5 Dialysis details 
There were no differences during conductivity reduction with either 
modality in relative blood volume or Kt/V. Equally, there were no 
differences in any of these outcomes when HD and DC were matched for 
end dialysis plasma conductivity. These data during conductivity 
reduction are displayed in table 7-f and for the matched analysis in table 
7-g. 
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 HDH DCH HDM DCM HDL DCL 
Thirst 
score 
11 ± 4 10 ± 2 11 ± 5 10 ± 2 9 ± 1 9 ± 2 
Rel. blood 
vol. (%) 
-4.2 ± 3 -4.8 ± 5 -5.9 ± 4 -7.9 ± 4 -7.3 ± 4 -4.4 ± 6 
ECW pre 
(l/kg) 
0.22 ± 0.03 0.21 ± 0.03 0.22 ± 0.04 0.21 ± 0.04 0.21 ± 0.04 0.20 ± 0.04 
IMB 
(mmol/l) 
324 ± 83 350 ± 170 344 ± 124 428 ± 165 414  ± 
108 
447 ± 158 
Kt/Vurea 1.5 ± 0.3 1.4 ± 0.2 1.3 ± 0.2 1.4 ± 0.2 1.4 ± 0.2 1.5 ± 0.3 
 
Table 7-g.  
Dialysis details for those sessions when end dialysis plasma conductivity was matched 
for HD and DC. ECW = extracellular water corrected for body weight, measured before 
dialysis. There were no differences in any of the parameters between the paired groups. 
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7.5 Discussion 
 
We have demonstrated that in stable haemodialysis patients, empirical 
reduction of dialysate sodium is safe, practicable and does not 
significantly reduce dialysis tolerability. Using this approach, reduction of 
end dialysis plasma conductivity with biofeedback dialysis has no 
significant short-term clinical benefit over fixed dialysate conductivity. 
 
Although it is intuitive that reducing dialysate sodium will have beneficial 
effects on thirst, IDWG and blood pressure, available data on this issue 
are conflicting. Several studies show that pre dialysis BP is improved as 
dialysate conductivity is reduced [97, 100, 102] and one study suggests 
an improvement in interdialytic ambulatory BP [99]. Other studies 
however found that sodium reduction does not affect BP [98, 101]. 
Equally, it is controversial whether dialysate sodium reduction reduces 
IDWG [98-100, 102, 103] or improves thirst [98, 102, 103]. However, the 
majority of the observed benefit in these studies was in those patients 
who were hypertensive at the outset, or had large IDWG [97, 98, 100, 
103]. Patients in our study demonstrated good baseline BP control and 
low IDWG. Equally, average systolic ambulatory BP at the outset was 
over 15mmHg less than the study by Farmer et al in which conductivity 
reduction improved ABPM readings [99]. This may explain why we did not 
demonstrate any significant change in these parameters with conductivity 
reduction. However, conductivity reduction was well tolerated in our 
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patients, did not increase IDH rates and was practicable in the setting of a 
busy outpatient haemodialysis unit.  
 
Plasma osmolality, which is largely determined by plasma sodium 
concentration, is the major stimulus to drink and therefore reducing the 
plasma conductivity and sodium concentration should theoretically 
improve thirst. Although other studies have reported an improvement in 
thirst scores with conductivity reduction [98, 102], another study reported 
a paradoxical increase [103]. However, in the latter study higher overall 
thirst scores were due to increased thirst on dialysis days, and thirst 
scores were lower in the interdialytic period, with resultant lower weight 
gains. We did not demonstrate any statistically significant change in thirst 
score as conductivity was reduced. However, in our patients thirst score 
at the outset was remarkably low, which may reflect good compliance 
with dietary sodium restriction and also may explain why we failed to 
demonstrate a significant impact of conductivity reduction on IDWG. This 
is similar to the results of Kooman et al who enforced an extremely strict 
dietary sodium restriction, and found that conductivity reduction did not 
lead to any reductions in BP or IDWG [101]. 
 
DC is a biofeedback system that returns a patient to a prescribed plasma 
conductivity by the end of every dialysis session. Our results further 
confirm that DC accurately achieves the prescribed conductivity, even at 
levels <14.0mS/cm. By doing so, DC will completely remove the 
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interdialytic sodium load independently of variations in pre dialysis 
plasma sodium. In the long term this should prevent chronic sodium and 
therefore fluid overload. Initial work suggested that DC may also provide 
short-term benefit by improving haemodynamic stability during dialysis. It 
was postulated that this was due to the avoidance of rapid reductions in 
plasma tonicity and therefore circulating volume as shown in figure 1-e 
[106, 107]. However, when matched for end dialysis plasma conductivity, 
we observed no differences in pre, post or intra dialytic BP, or in IDH 
frequency between the HD and DC. When so matched, sodium balance 
appeared similar between modalities as manifest by equal pre and post 
dialysis plasma conductivity and sodium concentrations, similar IMB, 
equal post dialysis weights and IDWG. In one of the previous studies that 
reported improved intradialytic stability with DC, it was not clear if 
standard dialysis and DC had equal sodium balance, and in the other 
study in which sodium balance was matched, the authors demonstrated a 
smaller fall in BP during DC but IDH frequency was not altered. Other 
studies have, like us, failed to demonstrate any advantage in intradialytic 
stability [108, 184, 185]. Furthermore, we did not observe a difference in 
relative blood volume between HD and DC when end dialysis plasma 
conductivity was matched.  
 
When comparing HD and DC at the lower conductivity settings, we found 
the range of DC to be limited. The lowest target plasma conductivity 
setting allowable with DC is 13.5mS/cm, which may be higher than initial 
plasma conductivity in a proportion of patients. Therefore intra-dialytic 
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sodium loading can still occur with DC in those patients with low pre 
dialysis plasma sodium concentrations [184]. Certainly significantly lower 
end dialysis plasma conductivities and sodium concentrations were 
achieved with a fixed dialysate conductivity of 13.2mS/cm as compared to 
DC13.5 without a reduction in dialysis tolerability. This may explain why 
ECW was reduced during conductivity reduction with HD but not with DC. 
Furthermore, we have previously shown that fixed dialysate conductivity 
can be safely set as low as 13.0mS/cm, and although only tolerated by 
approximately 40% of stable patients, maximal benefits in terms of BP 
and IDWG were seen in this group [102]. Therefore, within a strategy 
aiming to reduce total body sodium, DC may be a less effective tool than 
dialysis with fixed dialysate sodium [96, 184]. 
 
During conductivity reduction with HD, we observed a progressive fall in 
pre dialysis plasma sodium concentrations and in start dialysis plasma 
conductivity, whereas with DC we saw a fall in plasma sodium but without 
a fall in plasma conductivity. Start dialysis plasma conductivity is 
measured after the commencement of dialysis in contrast to plasma 
sodium for which the blood is drawn prior to the treatment commencing. 
With HD, the largest plasma dialysate concentration gradient for sodium 
is likely to occur early in the treatment and therefore rapid falls in plasma 
tonicity can occur. In the early stages of DC, dialysate sodium tends to be 
high to prevent this. Therefore, the progressive reduction in pre dialysis 
plasma sodium concentrations (with stable weight and IDWG) reflects 
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both modalities reducing the sodium pool, despite the lack of change in 
start dialysis plasma conductivity with DC. 
 
Our study does have some limitations. As the first study to compare HD 
and DC with a strategy of dialysate sodium reduction, we selected stable 
patients. We may well have observed greater benefits of conductivity 
reduction if hypertensive patients or those with large IDWG were studied. 
In addition, it is possible that if DC does have any short-term benefits 
over fixed dialysate sodium, they may only be apparent in such patients. 
Conductivity reduction was performed every two weeks, and it is 
conceivable that greater benefit may have been seen if patients remained 
at each setting for longer periods, as BP can lag behind changes in 
volume status [186].  
 
In conclusion, we have shown that empirical reduction of dialysate 
sodium in stable patients is practicable and well tolerated. In this setting, 
DC did not appear to have any short tem clinical advantage over fixed 
dialysate sodium, and indeed was not able to reduce plasma conductivity 
to as great a degree. Further work is required to compare the effects of 
HD and DC during conductivity reduction in those patients with large 
IDWGs or uncontrolled hypertension. Also, it is not yet clear if DC has 
any impact on long-term patient outcomes in either stable or unstable 
populations. 
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8. Results: a comparison of the effects of hypertonic 
glucose-based peritoneal dialysate and Icodextrin on 
blood pressure and systemic haemodynamics 
 
8.1 Introduction 
 
Little is known about the haemodynamic response to CAPD. The next 
three chapters describe studies designed to characterise this, and also to 
examine the varying effects of the different commercially available 
dialysate solutions.  
  
It is becoming increasingly recognised that glucose has limitations as the 
osmotic agent in peritoneal dialysate. Glucose and glucose degradation 
products (GDPs) are toxic to the peritoneum [12], and glucose is also 
systemically absorbed leading to hyperinsulinaemia plus weight gain [13]. 
This has driven the development of other dialysate solutions, including 
Icodextrin (Extraneal), which is a large molecular weight glucose 
polymer that is not systemically absorbed. Icodextrin reduces systemic 
glucose absorption and achieves equivalent ultrafiltration as compared 
with hypertonic glucose fluids during prolonged intraperitoneal dwells 
[187].  
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This chapter describes an initial study to examine the hypotheses that 
CAPD is associated with significant haemodynamic change, and that 
1.36% glucose, 3.86% glucose and Icodextrin containing-dialysate fluids 
exert differing haemodynamic effects. 
 
 
8.2 Subjects and methods 
 
8.2.1 Patients 
We recruited eight patients on CAPD for a prospective crossover study. 
Baseline characteristics and CAPD prescriptions are shown in table 8-a. 
All patients had been on CAPD for more than six months (mean 40.5 
months, range 18-73). All had a weekly Kt/V of greater than 2.0 of which 
less than 50% was provided by residual renal function. One patient was 
anuric.  
 
Patients were eligible only if their blood pressure had been stable (BP 
<140/85 mmHg with no changes in anti-hypertensive medications) over 
the four weeks prior to recruitment, and if less than 50% of their PD 
regime was made up of 3.86% glucose solution or Icodextrin. Patients 
were excluded if they had severe peripheral vascular disease, of if they 
had an arterio-venous fistula or renal transplant in situ.  
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All patients underwent clinical examination prior to commencing the study 
to ensure that they were at their optimal weight. All patients underwent 
standard peritoneal equilibration testing (PET) and assessment of dialysis 
adequacy (Adequest 2.0 program, Baxter Healthcare, Norfolk, UK). 
 
 
 
Patient  Sex Age PD 
regime 
Cause of ESRF Transporter 
status 
Epo dose 
(mcg/wk) 
Antihypertensive 
drugs 
1 M 70 LLLL Type 2 diabetes LA 0 Lisinopril 10mg od 
2 F 60 LLL I * Type 2 diabetes LA 10  
3 
M 57 
LLLLL 
Malignant 
hypertension 
HA 
10 
Lisinopril 40mg od 
4 M 77 LLLN Unknown HA 0  
5 F 66 LLL I * Type 2 diabetes HA 10 Amlodipine 10mg 
6 
M 77 
LLL I 
ARVD HA 
30 
Diltiazem 300mg od, 
Moxonidine 0.3mg od, 
Lisinopril 2.5mg od 
7 M 74 LLLLL TIN LA 40  
8 
M 83 
LLL I 
IgA nephropathy HA 
20 
Doxazosin 4mg od, 
Felodipine 10mg od 
Mean ± 
SD 
 70.5 ± 
9.0  
  
15 ± 14.1 
 
 
Table 8-a.  
Baseline patient characteristics.  
L= 1.36% glucose, I=Icodextrin, N=Nutrineal. 4 patients were using Icodextrin regularly 
as their nighttime dwell, where as 4 patients were Icodextrin naïve. * denotes patients 
that used 3.86% glucose dialysate regularly three times per week. All other patients 
used 3.86% glucose on an as required basis.  TIN = tubulointerstitial nephritis, ARVD = 
atherosclerotic renovascular disease. Transporter status refers to peritoneal membrane 
transporter characteristics, with LA = low average transporter and HA = high average 
transporter. Epo = erythropoeitin; all patients were self-administering darbepoetin alfa. 
Anti-hypertensive medications were left unchanged for the duration of the study. 
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8.2.2 Study protocol 
All patients gave informed consent prior to commencement, and ethical 
approval for the project was granted by Derbyshire Research Ethics 
Committee. Patients were asked to attend for two study days (A and B), 
the order of which was randomly determined. For each investigatory 
session, patients were admitted to a clinical investigations unit where 
CAPD was performed. All fluids were manufactured by Baxter Healthcare 
(Norfolk, UK) and were warmed to 370C before instillation. Non-invasive 
haemodynamic monitoring was undertaken using a Finometer (chapter 
3), which was fitted for the entirety of each session. To obtain baseline 
values, monitoring commenced 30min prior to draining the nighttime 
dwell. On day A, patients underwent CAPD with 2.5L of low osmolar 
Physioneal (bicarbonate/lactate-based pH neutral fluid containing 1.36% 
glucose) followed by high osmolar Physioneal (3.86% glucose). Dwell 
times were 150min and each drain/dwell cycle was planned to last 
approximately three hours, although this was not absolute due to variable 
draining times of different patients. On day B, 2.5L Icodextrin was 
substituted for the 3.86% Physioneal but the protocol was otherwise 
identical. There was at least a week’s washout period between the two 
study days. Patients were allowed a light breakfast two hours before the 
first CAPD exchange, and were supplied with a standardised midday 
meal that was consumed one hour before the second CAPD exchange. 
Blood samples were collected before and after each session in lithium 
heparin and EDTA tubes, and biochemical analysis performed on a 
multichannel autoanalyser. The volume and electrolyte concentration of 
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the peritoneal waste fluid was also assessed. Primary endpoints were 
percentage change in blood pressure (BP), stroke volume (SV), cardiac 
output (CO) and total peripheral resistance (TPR) in response to different 
PD dialysate fluids. 
 
 
8.3 Statistical analysis 
 
Results are expressed as mean ± SD. For BP and haemodynamic data, 
the mean refers to the complete dwell period, and these data were 
compared using one-way ANOVA with a design for repeated measures 
and Bonferroni’s test to correct for multiple comparisons. For other data, 
the paired t-test was used after significant deviations from a normal 
distribution were excluded with the Kolmogorov-Smirnov test. Correlation 
coefficients were calculated using Pearson’s test. An alpha error at 
P<0.05 was judged to be significant.  
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8.4 Results 
 
8.4.1 Blood pressure during dwell periods 
We found BP to be significantly higher during 3.86% glucose dwells as 
compared to both 1.36% glucose and Icodextrin dwells (p<0.001). The 
mean systolic BP (SBP) for the entire dwell with 1.36% glucose was 
149.8 ± 4mmHg, the mean diastolic BP (DBP) 86.6 ± 3mmHg and the 
mean of the mean arterial pressure (MAP) 109.5 ± 3mmHg. During the 
3.86% glucose dwells all three BP parameters were higher; the mean 
SBP for the entire dwell was 159.9 ± 6mmHg (p<0.001), mean DBP was 
93.9 ± 4mmHg (p<0.001) and mean MAP was 117.5 ± 5mmHg (p<0.001). 
During the Icodextrin dwells, SBP and MAP did not differ significantly 
from the 1.36% glucose dwells with means of 150.9 ± 7mmHg (p=0.44) 
and 108.0 ± 4mmHg (p=0.14) respectively. However, mean DBP was 2.4 
± 1mmHg lower during the Icodextrin dwells at 84.3 ± 2mmHg (p=0.003). 
Comparing mean BP during 3.86% glucose dwells with Icodextrin dwells, 
readings were significantly higher during the former for SBP, DBP and 
MAP (p<0.001 for each). BP data are summarised in figure 8-a. 
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Figure 8-a.  
Mean BP changes during CAPD dwells with different fluids. BP rises marginally during 
each dwell, but is significantly higher during 3.86% glucose dwell as compared to both 
1.36% glucose and Icodextrin dwells (p <0.001).  
 
 
8.4.2 Haemodynamic data during dwell periods 
We also found significant differences in HR between 3.86% glucose 
dwells and both the 1.36% glucose and Icodextrin dwells (p<0.001). 
Mean HR for the entire 1.36% glucose and Icodextrin dwell periods were 
not significantly different at -4.3 ± 2% and -4.2 ± 1% respectively 
(p=0.74). The mean HR during 3.86% glucose dwell was -2.3 ± 3% and 
this was significantly greater than either the 1.36% glucose (p<0.01) or 
Icodextrin dwell periods (p<0.01). These data are summarised in figure 8-
b. 
 
SV and CO were also found to be significantly higher during 3.86% 
glucose dwells (p<0.001). During 1.36% glucose dwell, mean SV for the 
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whole period was -5.7 ± 6%. After an initial increase, SV during the 
Icodextrin dwell was stable with a mean for the entire period of -8.1 ± 4%, 
which was not statistically different from 1.36% glucose dwell (p=ns). 
During 3.86% glucose dwell, mean SV for whole period was -1.2 ± 7%, 
which was significantly higher than both 1.36% glucose (p<0.001) and 
Icodextrin dwell periods (p<0.001).  
 
As the product of SV and HR, CO showed similar changes. Mean CO for 
whole dwell period with 1.36% glucose was -10.5 ± 7%. CO increased 
initially for both Icodextrin and 3.86% glucose fluids, but to a much 
greater extent with 3.86% glucose. For the Icodextrin dwell the mean for 
the entire period was -12.6 ± 4%. The mean CO for 3.86% glucose dwell 
was -4.2 ± 8%, which was significantly higher than 1.36% glucose 
(p<0.001) and Icodextrin dwells (p<0.001).  
 
TPR increased progressively during all three dwell phases at a similar 
rate and by a similar magnitude. Mean TPR for the entire dwell period 
was +25.7 ± 13% for 1.36% glucose, +30.6 ± 16% for 3.86% glucose and 
+28.1 ± 11% for Icodextrin. There were no significant differences between 
these mean values (p=ns). All haemodynamic data are summarised in 
figure 8-b. 
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Figure 8-b.  
Haemodynamic changes during CAPD dwells. TPR during all three dwells was similar; 
however, a higher HR (p<0.001), SV (p<0.001) and therefore CO (p<0.001) were 
observed during 3.86% glucose dwells. 
 
 
The haemodynamic and BP patterns described above are population 
means. Analysing patients individually, 7/8 exhibited similar patterns for 
BP. 2/3 of the diabetic patients were insulin treated and they did not 
display a higher SV and CO during 3.86% glucose dwell, as compared to 
the non-insulin treated patient who did behave in a similar overall fashion. 
No insulin was administered during the study periods.  
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8.4.3 Ultrafiltration volumes and sodium removal 
The mean ultrafiltration (UF) volume during the 3.86% glucose dwell was 
500 ± 290ml. This value was significantly higher than both Icodextrin 
dwell with a mean of 243.8 ± 111ml (p=0.028) and the 1.36% glucose 
dwell with a mean of 143.8 ± 96.3ml (p=0.001). The difference between 
the mean UF volumes with Icodextrin versus 1.36% glucose was of 
borderline statistical significance (p=0.057). There was no correlation 
between BP and UF volume. These data are summarised in figure 8-c. 
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Figure 8-c.  
Mean UF volumes for CAPD dwells with different fluids. Mean UF volume is significantly 
greater after 3.86% glucose dwell as compared to both icodextrin and 1.36% glucose 
dwells. Icodextrin does result in a greater UF volume as compared to 1.36% glucose 
dwell although this is only of borderline statistical significance. The modest UF volume 
seen with the icodextrin is likely to be due to the relatively short dwell time.  
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There were no significant differences in sodium loss between Icodextrin 
and 3.86% glucose dwells (p=ns), with means of -10.8 ± 14mmol and       
-12.5 ± 31mmol respectively. During 1.36% glucose dwell, sodium was 
retained with a mean value of +5.7 ± 12mmol. This value was significantly 
lower than Icodextrin dwell (p<0.01), but of borderline significance 
compared with 3.86% glucose dwell (p=0.055). 
 
8.4.4 Peritoneal transport characteristics and urea kinetic modelling  
All patients had a weekly Kt/V of greater than 2.0 (mean 2.5, range 2.0 to 
3.4). Mean weekly creatinine clearance was 78.1l/wk (range 61.8 to 
115.5) with mean residual renal function 3.2ml/min (range 0 to 7.7). There 
were no correlations between BP and residual renal function, weekly 
creatinine clearance or Kt/V. Individuals’ overall haemodynamic response 
did not differ depending on peritoneal membrane transporter 
characteristics (shown in table 8-a), nor did this influence the speed in 
which the haemodynamic response occurred following instillation of 
dialysate. 
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8.5 Discussion 
 
Although CAPD is generally regarded as being better tolerated than 
haemodialysis from a cardiovascular point of view, this study 
demonstrates that CAPD is associated with significant haemodynamic 
changes. We have also shown that there are disparities in the 
haemodynamic effects of different dialysate fluids, with significant 
differences between 3.86% glucose dialysate and both 1.36% glucose 
and Icodextrin. To our knowledge, there are no previous reports 
describing similar changes. 
 
Mean BP was higher during the 3.86% glucose dwells, as were HR, SV 
and therefore CO. The higher BP during the 3.86% glucose dwells was 
present despite larger UF volumes and greater sodium removal. It is 
known that glucose, systemically absorbed from peritoneal dialysate 
leads to hyperinsulinaemia [13], and it is possible that this has direct 
effects on myocardial function and BP. Certainly hyperinsulinaemia has 
been described as causing a rise in SV and CO coupled to a fall in TPR 
in healthy subjects [131, 188] whilst an increase in aortic systolic BP in 
response to insulin infusion has also been reported [189]. The fact that 
there were no significant differences in TPR between dialysate fluid types 
suggests that the higher BP seen with 3.86% glucose was due to 
increased myocardial performance. This would be consistent with work by 
Khoury, who has shown that a glucose/insulin/potassium infusion can 
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stimulate an increase in myocardial performance in patients with left 
ventricular dysfunction [190].  
 
In association with the slight rise in BP, TPR rose throughout each dwell 
phase. The mechanisms behind this rise in TPR remain unexplained, but 
one explanation for this would be mesenteric vasoconstriction in 
response to the cooling effect of instilling dialysate. Haemodialysis 
patients experiencing progressive UF demonstrate a rise in TPR in 
association with an increase in peripheral sympathetic nerve activity [81], 
so an alternative explanation would be that UF and the subsequent 
volume contraction cause a compensatory rise in TPR [191].  
 
In our study, when comparing 1.36% glucose and Icodextrin, we 
observed differences with a lower DBP and trend towards lower SV 
during Icodextrin dwells. With regard to the relative amount of glucose in 
the two fluids these differences may be less than expected, although 
some authors have found minimal effects on systemic haemodynamics 
with lower amounts of glucose and insulin. This raises the possibility of 
‘dose-response’ or ‘threshold’ effects and that the amount of glucose 
absorbed is important in determining the magnitude of hyperinsulinaemia 
and haemodynamic response. 
 
Three of our study patients were type II diabetics, two on insulin and one 
on sulphonylurea treatment. These patients were not analysed separately 
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due to small numbers, but the patient on sulphonylurea treatment 
appeared to behave in a similar fashion to non-diabetics. The two 
patients on insulin treatment however did not display higher SV and CO 
during 3.86% glucose dwells. It is possible that the patient on 
sulphonylurea treatment had some degree of preserved residual insulin 
secretion to explain the changes in haemodynamics, although without 
further work measuring glucose and insulin levels in addition to 
haemodynamics this is conjecture.  
Other than the difference in glucose content, Icodextrin contains lactate 
as a buffer whereas Physioneal contains bicarbonate/lactate mix and 
has a neutral pH. It is therefore possible that the difference in lactate 
content or in intraperitoneal pH might be responsible for some of the 
observed difference in haemodynamic effects. However, this seems 
unlikely because there were still significant differences between 1.36% 
and 3.86% Physioneal which both have identical buffer. Furthermore, 
there are no changes in systemic pH as a result of using either buffer 
system [192]. Another difference between the fluid types is the lower 
amounts of glucose degradation products (GDPs) in Icodextrin. Despite 
an extensive literature search no published work on the potential 
haemodynamic effects of GDPs was found.  
 
In conclusion, these data demonstrate that CAPD is associated with 
significant haemodynamic disturbance. We have also demonstrated that 
BP, HR, SV and CO are significantly higher during 3.86% glucose dwells 
compared to both 1.36% glucose and Icodextrin dwells. BP 
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measurements taken during 3.86% glucose dwells may therefore not be 
representative of overall BP. However, the design of this initial study did 
not allow elucidation of the mechanisms underlying the diverse responses 
to the differing dialysate types.  
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9. Results: the systemic haemodynamic and metabolic 
effects of hypertonic glucose and amino-acid based 
peritoneal dialysis fluids 
 
9.1 Introduction 
 
Our initial study showed that BP rose during CAPD with 3.86% glucose 
dialysate due to higher HR, SV and CO (chapter 8); however, it was not 
possible to determine the mechanisms underlying these changes. One 
possible explanation was that the changes were due to the effects of 
greater systemic absorption of glucose from the 3.86% glucose solution, 
leading to hyperglycaemia and hyperinsulinaemia. Certainly, both 
hyperglycaemia and hyperinsulinaemia are recognised to elevate BP and 
exert independent effects on systemic haemodynamics [129, 130]. 
Alternatively, the greater UF and therefore intraperitoneal volumes with 
3.86% glucose may have increased venous return and therefore cardiac 
filling. In addition, the fluids differed not only in glucose content but also in 
buffer type and in the amount of glucose degradation products (GDPs). 
 
We therefore performed a further study to address the limitations of the 
previous study. We sought to re-examine the acute effects of CAPD on 
BP and haemodynamics in a different group of fasted, non-diabetic 
patients. We also wanted to relate BP and haemodynamic changes to the 
degree of systemic absorption of glucose and subsequent 
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hyperinsulinaemia. In addition, we planned to examine whether any 
haemodynamic changes observed were due to differences in cardiac 
filling as assessed by echocardiography. Finally, we wanted to confirm 
the differential haemodynamic effects of a glucose sparing regime, this 
time using an alternative glucose free solution (Nutrineal®, which contains 
1.1% amino acids as the osmotic agent). 
 
 
9.2 Methods 
 
9.2.1 Patients 
We recruited ten non-diabetic patients on CAPD for a prospective 
crossover study. Baseline characteristics and CAPD prescriptions are 
shown in table 9-a. All patients had been on CAPD for more than six 
months (mean 26 ± 26months, range 6 to 89).  
 
Patients were eligible only if their blood pressure had been stable (BP 
<140/85 mmHg with no changes in anti-hypertensive medications) over 
the four weeks prior to recruitment, and if less than 50% of their PD 
regime was made up of 3.86% glucose solution or Icodextrin. Patients 
were excluded if they had diabetes mellitus, severe peripheral vascular 
disease, of if they had an arterio-venous fistula or renal transplant in situ.  
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All patients underwent clinical examination prior to commencing the study 
to ensure that they were at their optimal weight, and had standard 
peritoneal equilibration testing (PET) and assessment of dialysis 
adequacy (Adequest 2.0 program, Baxter Healthcare, Norfolk, UK). 
 
 
Patient  Sex Age PD regime Cause of 
ESRF 
Transporter 
status 
Epo dose 
(mcg/wk) 
Antihypertensive 
drugs 
1 F 63 LLLL* 
Chronic 
pyelonephritis HA 30.0 
 
2 M 59 LLLHI 
Malignant 
hypertension HA 10.0 
Lisinopril 40mg od, 
Nifedipine 90mg od, 
Doxazosin 16mg od 
3 F 62 LLL 
Chronic 
pyelonephritis LA 10.0 
Doxazosin 4mg od, 
Atenolol 50mg od 
4 M 33 LLLL* MCGN HA 30.0 
Lisinopril 20mg od, 
Amlodipine 10mg od 
5 M 68 LLLI 
Chronic GN 
(type 
undefined) HA 7.5   
6 M 39 LLLL* 
IgA 
nephropathy LA 30.0 Lisinopril 20mg od 
7 F 52 LLL Myeloma HA 10.0   
8 M 66 LLLI Unknown HA 0.0 Nifedipine 90mg od 
Mean ± 
SD 
  
55 ± 13  
  
16 ± 12 
 
 
  
 
  
 
 
Excluded patients 
9 F 55 LLLL Chronic TIN L 10 Amlodipine 10mg od 
10 M 62 LLL Unknown LA 0 Lisinopril 10mg od 
 
Table 9-a.  
Baseline characteristics of study patients. L = low osmolar (1.36%) glucose, H = high 
osmolar (3.86%) glucose, I = Icodextrin. * denotes patients who used 3.86% glucose on 
a regular basis, all other patients used 3.86% glucose on an as required basis. MCGN = 
membrano proliferative glomerulonephritis, TIN = tubulointerstitial nephritis. Transporter 
status – HA = high average, LA = low average, L = low. Epo = erythropoietin, all patients 
were taking subcutaneous Aranesp®.  Patients 9 and 10 did not complete the study and 
were excluded from the analysis. 
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9.2.2 Study protocol 
Patients attended for three study days (A, B and C), the order of which 
was randomly determined. For each investigatory session, patients were 
admitted to a clinical investigations unit where CAPD was performed. All 
fluids were manufactured by Baxter Healthcare (Norfolk, UK) and were 
warmed to 370C before instillation. Non-invasive haemodynamic 
monitoring was undertaken using a Finometer (described in chapter 3) 
that was fitted for the entirety of each session. To obtain baseline values, 
monitoring commenced 30min prior to draining the night-time dwell.  
On day A, conventional bioincompatible fluids (PDFCONV) were used 
(Dianeal®, lactate buffered, acidic pH). Patients underwent CAPD with 
2.5L of 1.36% glucose solution followed by fluid containing 3.86% 
glucose. On day B, patients received dialysis with pH neutral 
bicarbonate/lactate buffered fluid low in GDPs (Physioneal®, PDFBIO); 
patients again received 1.36% glucose followed by 3.86% glucose based 
solutions. On day C, patients had PDFCONV with 1.36% glucose followed 
by 1.1% amino acid solution (PDFAA - Nutrineal®, lactate buffer, acidic pH, 
no GDPs). Dwell times were 120min and each drain/dwell cycle was 
planned to last approximately 2.5 hours, although this was not absolute 
due to variable draining times of different patients. There was at least a 
week’s washout period between the study days. Patients were fasted 
from the midnight before and throughout the study period.  
 
M-mode echocardiography was performed using commercially available 
equipment at the start and end of each dwell period to measure left 
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ventricular dimensions (1.5-3.6 MHz 3S probe, Vivid 3®, GE medical 
systems, Sonigen, Germany). The volume of the peritoneal waste fluid 
from each dwell was also recorded. Blood samples were collected before 
and after each session in lithium heparin and EDTA tubes, and 
biochemical analysis performed on a multichannel autoanalyser. In 
addition, blood samples were collected at baseline and then at 10min, 
30min and 60min of each dwell phase for analysis of plasma glucose 
(fluoride oxidase tubes) and at 10min and 60min for measurement of 
insulin (EDTA tubes). Samples for insulin analysis were centrifuged at 
3500rpm for 15min to separate the plasma, which was immediately 
frozen at -800C. Insulin was subsequently measured using a 
commercially available enzyme-linked immunosorbent assay kit as 
described in chapter 3 (Insulin ELISA, DRG diagnostics, Marburg, 
Germany). Insulin resistance was assessed by calculating the 
homeostasis model of assessment index (HOMA-IR) using the following 
equation [193]: 
HOMA IR = Baseline glucose (mmol/l) x baseline insulin (µ/IU/l)/22.5 
in which a value > 3.8 indicates insulin resistance. This measure has 
been validated in renal patients [194]. 
 
Primary endpoints were percentage change in blood pressure (BP), 
stroke volume (SV), cardiac output (CO) and total peripheral resistance 
(TPR) in relation to plasma glucose and insulin levels and cardiac 
dimensions.  
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All patients gave informed consent prior to commencement, and ethical 
approval for the project was granted by Derbyshire Research Ethics 
Committee. 
 
 
9.3 Statistical analysis 
 
Results are expressed as mean ± SD unless otherwise stated. For BP 
and haemodynamic data, the mean refers to the complete dwell period. 
After demonstration of a normal distribution, all data were compared 
using one-way ANOVA with a design for repeated measures and 
Bonferroni’s test to correct for multiple comparisons. An alpha error at 
P<0.05 was judged to be significant.  
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9.4 Results 
 
Two patients did not complete the study – one became ill after attending 
for only the first study day, and the second patient had an inaccurate 
Finometer trace (intermittent detection of pulse wave resulting in 
unacceptable data quality). These patients were excluded from the 
analysis. Analysis of baseline measurements showed that there were no 
differences in BP or in any of the haemodynamic variables between the 
three different study days.  
 
9.4.1 Blood pressure, PDFCONV versus PDFAA 
BP was higher during 3.86% PDFCONV dwells as compared to PDFAA. 
During 3.86% PDFCONV, mean systolic BP (SBP) for the entire dwell was 
163.5 ± 5mmHg, mean diastolic BP (DBP) was 92.8 ± 3mmHg and mean 
arterial pressure (MAP) 118.9 ± 3mmHg, as compared to a mean SBP of 
158.9 ± 6mmHg (p<0.01), DBP of 87.1 ± 6 (p<0.001) and MAP of 113.2 ± 
5mmHg (p<0.001) during PDFAA dwells. The higher overall BP with 
3.86% PDFCONV was due to differences in first half of the dwell, and 
systolic readings were similar during the last third of the dwell. These 
data are summarised in figure 9-a. No differences were observed when 
comparing BP during 1.36% PDFCONV and PDFAA dwells (BP data for 
1.36% PDFCONV dwells are shown in table 9-b). 
 
 157
0 30 60 90 120 150 180 210 240 270
50
100
150
200
1.36% PDFCONV
 PDFAA
3.86%  PDFCONV
Time (min)
BP
 
(m
m
Hg
)
 
Figure 9-a.  
BP during PDFCONV and PDFAA dwells. BP was significantly higher during 3.86% 
PDFCONV as compared to either 1.36% PDFCONV or PDFAA (p<0.001 for all comparisons). 
1.36% PDFCONV data points are combined value for both days as values were extremely 
similar. Data are shown as mean ± SEM. 
 
 
9.4.2 Blood pressure, PDFCONV versus PDFBIO 
BP was similar when comparing PDFCONV and PDFBIO during both 1.36% 
and 3.86% dwells. These data are shown in table 9-b. However, when 
comparing 1.36% and 3.86% glucose dwells, BP was significantly higher 
with 3.86% glucose for both PDFCONV and PDFBIO (p<0.001 for all 
comparisons). BP tended to decline throughout 3.86% PDFCONV dwells, 
which was in contrast to the pattern seen with all other fluids where BP 
rose progressively. These data are summarised in figure 9-b. 
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Figure 9-b.  
BP during PDFCONV and PDFBIO dwells. There were no differences in mean BP when 
comparing the two fluid types, but mean BP was higher when comparing 3.86% glucose 
fluids with the corresponding 1.36% glucose fluid (p<0.001 for both comparisons). Data 
are shown as mean ± SEM. 
 
 
 
 
1.36% PDFCONV 1.36% PDFBIO 3.86% PDFCONV 3.86% PDFBIO 
SBP (mmHg) 157.3 ± 5 155.3 ± 5 163.5 ± 5 164.7 ± 6 
DBP (mmHg) 87.2 ± 2 86.6 ± 2 92.8 ± 3 94.4 ± 4 
MAP (mmHg) 113.1 ± 4 113.4 ± 3 118.9 ± 3 121.1 ± 5 
 
Table 9-b.  
Blood pressure during 1.36% and 3.86% PDFCONV and PDFBIO dwells. There were no 
differences when comparing fluid types, but BP was significantly higher when comparing 
3.86% to 1.36% (p<0.001 for all comparisons). 
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9.4.3 Haemodynamics, PDFCONV versus PDFAA 
Mean HR for the entire dwell period was 69 ± 8bpm with 3.86% PDFCONV, 
which reflected a rise of +2 ± 5% from baseline. This was not significantly 
different from a mean HR of 71 ± 13bpm with PDFAA (+5 ± 6% from 
baseline, p=ns). However, SV and CO were both higher during PDFCONV 
dwells. SV for entire dwell period was -9 ± 4% from baseline with 3.86% 
PDFCONV and was -20 ± 7% with PDFAA (p<0.001). CO for entire dwell 
was -7 ± 5% beneath baseline with 3.86% PDFCONV as compared with -15 
± 6% with PDFAA (p<0.001). TPR also differed significantly between 
3.86% PDFCONV and PDFAA. With the former, TPR rose to a mean of +12 
± 8% above baseline for the entire dwell period, and with PDFAA mean 
TPR was +25 ± 11% above baseline (p<0.001). These data are 
summarised in figure 9-c. 
 
9.4.4 Haemodynamics, PDFCONV versus PDFBIO 
There were no differences in any of the haemodynamic variables when 
comparing PDFCONV and PDFBIO during 1.36% glucose dwells. These 
data are shown in table 9-c. However, as compared to 3.86% PDFBIO, 
TPR was significantly lower with 3.86% PDFCONV, with a mean for the 
entire 3.86% PDFBIO dwell of +31 ± 18% from baseline (p<0.001). As a 
result, SV and CO were therefore higher during 3.86% PDFCONV; mean 
values during the PDFBIO dwell were -17 ± 8% (p<0.05) and -13 ± 6% 
(p<0.01) respectively. These data are summarised in figure 9-d. 
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Figure 9-c.  
Haemodynamics during PDFCONV and PDFAA dwells. SV and CO were significantly 
higher during PDFCONV dwells and TPR was significantly lower, as compared to PDFAA. 
1.36% PDFCONV data points are combined value for both days as values were extremely 
similar. Data are shown as mean ± SEM. 
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Mirroring the trend for BP to increase during dwell periods, TPR also 
increased throughout all dwell periods (although TPR did fall during the 
last 30min of PDFAA dwell). The exception was during 3.86% PDFCONV 
dwell, when TPR progressively fell, which resulted in a smaller decline in 
CO as compared to the other fluid types. 
 
 
 
 
1.36% PDFCONV 1.36% PDFBIO 
HR (% change from 
baseline) 
-1 ± 1 -1 ± 1 
SV (% change from baseline) -7 ± 3 -8 ± 3 
CO (% change from 
baseline) 
-9 ± 3 -9 ± 3 
TPR (% change from 
baseline) 
+11 ± 7 +9 ± 8 
 
Table 9-c.  
Systemic haemodynamics during 1.36% PDFCONV and PDFBIO dwells. HR = heart rate, 
SV = stroke volume, CO = cardiac output, TPR = total peripheral resistance. All data are 
shown as percentage change from baseline. There were no differences in any of the 
variables when compared between fluid types. 
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Figure 9-d.  
Haemodynamics during PDFCONV and PDFBIO dwells.  Parameters were very similar 
during 1.36% glucose dwells. SV and CO were significantly higher during 3.86% 
PDFCONV dwells and TPR was significantly lower, as compared to 3.86% PDFBIO. Data 
are shown as mean ± SEM. 
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9.4.5 Plasma glucose and insulin levels 
Mean fasting glucose at baseline was 5.4 ± 1.1mmol/l. Plasma glucose 
did not change significantly during 1.36% PDFCONV, 1.36% PDFBIO or 
PDFAA dwells. Highest mean glucose was 5.8 ± 0.7mmol/l during 1.36% 
PDFCONV dwells, 5.6 ± 0.7mmol/l during 1.36% PDFBIO dwells and 5.1 ± 
0.6mmol/l PDFAA dwells (p=ns for all comparisons). However, during 
3.86% glucose dwells, plasma glucose rose significantly. Glucose was 
significantly higher than baseline by 10min during 3.86% PDFCONV and 
PDFBIO dwells, with mean levels of 7.5 ± 1.3mmol/l (p<0.01 versus 
baseline) and 7.7 ± 1.1mmol/l (p<0.001 versus baseline) respectively. By 
60min, mean plasma glucose had risen to 9.1 ± 2.1mmol/l during 3.86% 
PDFCONV and 9.1 ± 1.9mmol/l during 3.86% PDFBIO. These values were 
significantly higher than baseline (p<0.001), and higher than the peak 
levels during PDFAA and 1.36% glucose dwells (p<0.001 for all 
comparisons).  
A similar pattern was seen with plasma insulin levels. Mean fasting 
plasma insulin was 16.9 ± 6.7µIU/ml, and did not change significantly 
during 1.36% PDFCONV (plasma insulin 18.1 ± 6.3µIU/ml at 60min), 1.36% 
PDFBIO dwells (18.43 ± 6.7µIU/ml at 60min) or PDFAA dwells (16.7 ± 
6.1µIU/ml at 60min, p=ns for all comparisons). However, insulin did rise 
significantly in response to the hyperglycaemia of the 3.86% glucose 
dwells. Mean plasma insulin was 22.9 ± 8.8µIU/ml at 10min (p=ns versus 
baseline) and 31.6 ± 14.4µIU/ml at 60min during 3.86% PDFCONV dwells 
(p<0.05 versus baseline). During 3.86% PDFBIO, mean plasma insulin 
 164
was 29.0 ± 11.1µIU/ml at 10min (p=ns versus baseline) and 35.6 ± 
16.2µIU/ml at 60min (p<0.01 versus baseline). For PDFCONV and PDFBIO, 
both 10min and 60min plasma insulin levels were significantly higher than 
the corresponding values for PDFAA (p<0.05 for 10min comparison, 
p<0.001 for 60min comparison PDFCONV versus PDFAA, p<0.01 for 60min 
comparison PDFBIO versus PDFAA). Plasma glucose and insulin data are 
summarised in figure 9-e. 
At baseline, there were only two fasting glucose readings of greater than 
7.0mmol/l, and in both these patients readings were less than 7.0mmol/l 
on the other two study days. Mean HOMA IR was 4.6 ± 2.7 and four 
patients had values suggestive of insulin resistance (>3.8).  
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Figure 9-e.  
Plasma glucose (a) and insulin (b) levels during PDFCONV, PDFBIO and PDFAA dwells. 
Plasma glucose and insulin rose significantly during 3.86% glucose dwells as compared 
to both baseline and the corresponding values during PDFAA dwells. The two data points 
for 1.36% PDFCONV represent values for PDFCONV and PDFAA study days. Data are 
shown as mean ± SD. * p<0.001 versus baseline, corresponding measurements during 
1.36% glucose and PDFAA by ANOVA. ** p<0.05 versus PDFAA. *** p<0.05 versus 
baseline, p<0.001 PDFCONV versus PDFAA and p<0.01 PDFBIO versus PDFAA 
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9.4.6 Ultrafiltration volumes 
UF volumes were similar during PDFAA, 1.36% PDFCONV and 1.36% 
PDFBIO dwells, with means of 177 ± 167ml, 116 ± 129ml and 134 ± 138ml 
respectively (p=ns for all comparisons). UF volumes however were 
significantly higher with 3.86% glucose dwells, with means of 736 ± 
180ml with PDFCONV and 649 ± 232 with PDFBIO (p<0.001 for all 
comparisons versus 1.36% glucose and p<0.05 for all comparisons 
versus PDFAA). There was no difference when comparing UF volumes 
between 3.86% glucose PDFCONV and PDFBIO (p=ns). These data are 
shown in figure 9-f. 
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Figure 9-f.  
Ultrafiltration volumes during PDFCONV, PDFBIO and PDFAA dwells. 1.36% PDFCONV data 
represent the combined value for both days as values were extremely similar. Data are 
shown as mean ± SD. * p<0.001 versus 1.36% glucose, p<0.05 versus PDFAA by 
ANOVA. 
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9.4.7 Echocardiographic measurements 
At the outset of the study, only two patients had LV hypertrophy (defined 
as LVMI >51g/m2.7 or interventricular septal thickness >1.1cm) and all 
had normal ejection fractions. Despite the differences in ultrafiltration 
volume (and therefore in intraperitoneal volume during the dwell periods) 
there were no significant differences in LV dimensions throughout the 
study period. Equally, ejection fraction remained constant throughout all 
dwell periods. These data are shown in table 9-d. 
 
 
 
LVDd 
start (cm) 
LVDd 
end (cm) 
LVDs 
start (cm) 
LVDs 
end (cm) 
EF start 
(%) 
EF end 
(%) 
1.36% 
PDFCONV 
4.0  ± 0.6 4.1 ± 0.5 2.4 ± 0.6 2.4 ± 0.5 72 ± 9 72 ± 9 
1.36% 
PDFBIO 
3.8 ± 0.6 4.1 ± 0.5 2.3 ± 0.5 2.4 ± 0.4 70 ± 8 73 ± 6 
3.86% 
PDFCONV 
4.2 ± 0.5 4.1 ± 0.4 2.3 ± 0.3 2.2 ± 0.4 76 ± 5 77 ± 8 
3.86% 
PDFBIO 
4.0 ± 0.5 4.0 ± 0.6 2.2 ± 0.4 2.2 ± 0.6 75 ± 8 75 ± 9 
PDFAA 3.9 ± 0.5 4.1 ± 0.5 2.3 ± 0.5 2.2 ± 0.5 73 ± 9 77 ± 12 
 
Table 9-d.  
Echocardiographic measurements of left ventricular (LV) diameter. LVDd = LV diameter 
in diastole, LVDs = LV diameter in systole, EF = ejection fraction, start = start of dwell 
immediately after fluid instillation, end = end of dwell immediately before fluid is drained 
out. 
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9.4.8 Biochemical parameters 
Biochemical data from the start and end of each study session are shown 
in table 9-e. There were no differences in any of the variables. In 
particular, mean post PDFCONV bicarbonate was 28.3 ± 6mmol/l and did 
not differ from either post PDFBIO bicarbonate (29.8 ± 5mmol/l) or post 
PDFAA bicarbonate (mean of 27.4 ± 5mmol/l, p=ns for both comparisons). 
 
 
 
Pre  
PDFCONV 
Post 
PDFCONV 
Pre 
PDFBIO 
Post 
PDFBIO 
Pre  
PDFAA 
Post 
PDFAA 
Haemoglobin 
(g/dl) 
12.6 ± 1 12.4 ± 1 12.4 ± 1 12.2 ± 2 12.9 ± 1 12.3 ± 1 
Bicarbonate
 
(mmol/l) 
26.3 ± 5 28.3 ± 6 26.4 ± 5 29.8 ± 5 26.2 ± 6 27.4 ± 5 
Sodium 
(mmol/l) 
139 ± 4 140 ± 2 138 ± 4 140 ± 3 139 ± 4 139 ± 3 
Potassium 
(mmol/l) 
4.3 ± 0.5 3.9 ± 0.5 4.4 ± 0.6 4.0 ± 0.6 4.3 ± 0.5 4.1 ± 0.6 
Corr calcium 
(mmol/l) 
2.47 ± 0.1 2.47 ± 0.1 2.45 ± 0.2 2.53 ± 0.1 2.47 ± 0.2 2.47 ± 0.2 
Phosphate 
(mmol/l) 
1.5 ± 0.4 1.3 ± 0.5 1.6 ± 0.5 1.4 ± 0.5 1.7 ± 0.4 1.4 ± 0.3 
Albumin (g/dl) 
 
33 ± 3 33 ± 3 31 ± 3 31 ± 3 32 ± 4 31 ± 4 
PTH (ng/l) 
 
356 ± 244  352 ± 234  371 ± 232  
CRP (mg/l) 
 
4 ± 4 4 ± 4 7 ± 11 8 ± 14 5 ± 6 4 ± 6 
 
Table 9-e.  
Biochemical parameters for each of the study days. PTH = parathormone, CRP = C 
reactive protein. There were no differences in any of the parameters when comparing 
PDFCONV and PDFAA, or PDFCONV and PDFBIO. 
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9.4.9 Peritoneal transport characteristics and urea kinetic modelling  
All patients had a weekly Kt/Vurea of over 2.0 (mean 2.57 ± 0.5, range 
2.09 to 3.46). Mean weekly creatinine clearance was 94 ± 19l/wk (68 to 
127) and residual renal function was 4.8 ± 3ml/min (0.2 to 10.2). 
Peritoneal transport characteristics for each patient are listed in table 9-a. 
Transport characteristics did not appear to affect the haemodynamic 
response to the different fluid types, or the magnitude or rate of change in 
plasma glucose during the 3.86% glucose dwells.  
 
 
9.5 Discussion 
 
This study confirms that hypertonic glucose dialysate results in an acute 
elevation of BP as compared to low osmolar glucose or amino acid 
containing solutions. The elevation in BP was associated with 
hyperglycaemia and hyperinsulinaemia, but was not due to differences in 
cardiac filling. We also observed differences between the haemodynamic 
response to conventional and biocompatible hypertonic glucose solutions. 
 
In accordance with results from chapter 8 in which we demonstrated 
higher BP with 3.86% glucose as compared to Icodextrin, results from 
this study also show a rise in BP with hypertonic glucose solutions as 
compared with either 1.36% glucose or PDFAA, the latter being entirely 
glucose free. This rise in BP occurred with both hypertonic PDFBIO and 
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PDFCONV and did not appear dependent on buffer type. The higher BP 
also occurred despite the largest UF volumes, but the absence of change 
in LV diameters indicates the effects on BP were not caused by increased 
cardiac filling due to the larger intraperitoneal volume. Equally, the stable 
LV dimensions argue against the study patients being volume overloaded 
at baseline, in which situation an improvement in cardiac function may be 
seen in response to ultrafiltration. Therefore, the hyperglycaemia and 
hyperinsulinaemia demonstrated in our study during 3.86% glucose 
dwells seem the most likely cause of the rise in BP.  
BP has been shown to rise in response to hyperglycaemia in several 
studies in both non diabetic and diabetic patients, while glucose and 
insulin exert independent effects on systemic haemodynamics [129, 130, 
195, 196]. Marfen et al demonstrated a rise in BP during hyperglycaemia, 
during both normal and elevated insulin levels [130]. BP was returned to 
baseline with a glutathione infusion, suggesting the direct effect of 
hyperglycaemia on haemodynamics may be mediated by free radical 
production leading to reductions in nitric oxide. Equally, 
hyperinsulinaemia during euglycaemic clamp studies has been shown to 
cause elevations in HR, SV and CO whilst also causing a fall in TPR 
[131]. These changes would be consistent with those observed when 
comparing the haemodynamic response to PDFAA and PDFCONV, with SV 
and CO significantly higher and TPR lower in the presence of 
hyperinsulinaemia during 3.86% PDFCONV.  
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Despite a similar rise in BP, the underlying haemodynamic response 
differed between PDFCONV and PDFBIO 3.86% solutions. These two fluids 
produced equal changes in plasma insulin and glucose, similar UF 
volumes and the fluids were warmed to exactly the same temperature 
before instillation. Although the fluids differ in buffer, there was no 
significant difference in plasma bicarbonate at the end of the study 
period. In addition, there were no differences between 1.36% PDFCONV 
and PDFBIO, so it seems unlikely that the buffer type alone exerted a 
significant effect on systemic haemodynamics. However, as the 
metabolism of glucose and lactate are linked in both skeletal muscle and 
hepatocytes [197], it is possible to speculate that the difference in buffer 
type resulted in differences in subsequent glucose metabolism. 
Alternatively, PDFBIO does contain significantly fewer glucose degradation 
products (GDPs) as compared to PDFCONV. The amount of GDPs 
generated during heat sterilisation depends on both dialysate pH and the 
amount of glucose present, and therefore 3.86% PDFCONV contains more 
GDPs than 1.36% PDFCONV [11]. This may explain why 1.36% PDFBIO 
and PDFCONV behaved in a similar fashion, but why 3.86% fluids differed. 
One report describes mesenteric artery vasodilatation in the rat in 
response to acidic buffered, 4.25% glucose fluid with high GDP content, 
and abrogation of this effect with similar fluid low in GDPs [198]. These 
data would be consistent with our observation of lower TPR during 3.86% 
PDFCONV dwells. Although very difficult to isolate from biological fluids, 
indirect measurements suggest that systemic absorption of GDPs occurs 
during CAPD with conventional solutions [124, 125]. However, there are 
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no available data on whether or not GDPs can affect systemic 
haemodynamics.  
In short, the haemodynamic response during CAPD is affected by 
multiple different factors. In addition to the possible effects of 
hyperglycaemia and hyperinsulinaemia, cooling due to the dialysate fluid 
plus the effects of ultrafiltration are likely explanations for the rise in TPR 
and BP throughout the dwell periods (seen with all fluids except 3.86% 
PDFCONV). In addition, autonomic function and baroreflex sensitivity can 
be altered by all of the above factors. Therefore, it is only possible to 
speculate as to the exact cause of the haemodynamic changes that we 
observed, particularly when comparing PDFCONV and PDFBIO. 
 
In contrast to the findings in chapter 8, we did not observe significant 
differences in HR between the fluid types during this current study. Only 
one patient was taking a rate limiting drug (atenolol) so it may be that our 
patients, as with many dialysis patients, had impaired autonomic function 
[41]. However, this was not formally assessed. 
 
We observed a relatively high degree of insulin resistance in our patients 
at baseline. This, in combination with the large amount of glucose 
delivered during 3.86% dwells explains the magnitude of hyperglycaemia 
seen in some of these non-diabetic patients. Patients were fasted 
throughout, yet plasma glucose exceeded 11mmol/l in three patients. 
These data are consistent with other work that shows patients on CAPD 
have a higher prevalence of insulin resistance and therefore display 
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higher plasma glucose levels in response to a glucose load compared 
with normals [13, 199]. Furthermore, the hyperinsulinaemia seen in 
response to glucose may be abnormally prolonged in CAPD patients 
[199]. Although not assessed in our short term study, the frequent use of 
hypertonic glucose solutions resulting in repeated excursions of glucose 
and insulin to outside of their normal ranges may well have the potential 
to exert negative long term metabolic effects. Certainly, several large 
prospective studies in non-diabetics have shown that a hyperglycaemic 
response to a glucose load is a strong predictor of cardiovascular death. 
[122, 123]. This may be important in the context of the extremely high 
cardiovascular mortality rates in dialysis patients that are not explained by 
conventional risk factors alone. Crucially, this may be modifiable as 
preliminary data show that a PD regime employing Icodextrin to reduce 
glucose exposure can improve insulin resistance after a period of nine 
months [13].  
 
In conclusion, we have demonstrated that the hyperglycaemia and 
hyperinsulinaemia observed during CAPD with hypertonic glucose 
dialysate is associated with an acute rise in BP. CAPD with 1.1% amino 
acid solution did not cause any such derangements. In addition, a 
differing haemodynamic response to conventional and newer 
biocompatible PD solutions was observed, the cause of which is at 
present unclear. We suggest that these adverse haemodynamic and 
metabolic effects may have the potential to negatively impact on 
cardiovascular outcomes. As cardiovascular risk reduction is key to 
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ensuring optimal outcome in CAPD patients, manipulation of these 
haemodynamic and metabolic consequences by using low glucose, 
biocompatible fluids should be the subject of longer term, outcome-based 
studies.  
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10. Results: the acute effects of automated peritoneal 
dialysis on systemic haemodynamics 
 
10.1 Introduction 
 
Automated peritoneal dialysis (APD) is an increasingly utilised modality in 
the treatment of CKD stage 5. It is often used in preference to continuous 
ambulatory peritoneal dialysis (CAPD) to improve dialysis adequacy or for 
lifestyle reasons. To date, there are no published data examining the 
haemodynamic effects of APD. 
 
Residual renal function (RRF) is crucial in maintaining adequacy in many 
peritoneal dialysis patients, and also in helping maintain fluid and 
electrolyte balance. In addition, maintenance of RRF has been shown to 
affect survival [134, 135]. Debate continues as to whether APD increases 
the rate of decline of RRF as compared to CAPD, and the published 
literature in this area is quite discrepant [136-138, 200-204]. Some 
authors have postulated that APD causes greater shifts in osmotic load 
and exerts more intensive ultrafiltration as compared to CAPD, and this in 
turn may potentially cause adverse haemodynamic effects [136, 139]. 
Other work demonstrates that episodes of dehydration are associated 
with greater decline of RRF in CAPD patients, analogous to the 
association of episodes of intradialytic hypotension (IDH) with an 
increased loss of RRF in HD patients [203]. 
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Following our demonstration of significant haemodynamic changes in 
response to CAPD, we undertook a study to examine the BP and 
haemodynamic response to APD. 
 
 
10.2 Subjects and Methods 
 
10.2.1 Patients 
The same eight patients as described in chapter 8 were studied. Baseline 
characteristics, RRF, transporter status and CAPD prescriptions are 
shown in table 8-a.  
 
10.2.2 Study protocol 
All patients gave informed consent prior to commencement and ethical 
approval for the project was granted by Derbyshire Research Ethics 
Committee. Patients were admitted to a clinical investigations unit where 
APD was performed using Homechoice APD machines (Baxter 
Healthcare, Norfolk, UK). APD was carried out during daylight hours and 
patients were awake throughout. Non-invasive haemodynamic monitoring 
was undertaken using a Finometer that was fitted for the entirety of the 
investigatory session (described in chapter 3). To obtain baseline values, 
monitoring started 30min prior to commencing APD. The APD 
prescription stipulated a treatment time of four hours, consisting of three 
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drain/instillation cycles each using 2.5L of dialysate fluid. The dwell time 
for each cycle was 76mins. 1.36% glucose-based Physioneal 
(bicarbonate/lactate-based pH neutral fluid, Baxter Healthcare, Norfolk, 
UK) was used for the first and third exchanges and 3.86% glucose 
Physioneal for the second exchange. The APD prescription ensured that 
1.36% glucose and 3.86% glucose fluids did not mix in the reservoir bag. 
Dialysate fluid was warmed by the Homechoice machine prior to 
instillation. Due to the physical constraints of continuous monitoring, 
patients remained semi-recumbent throughout. 
 
Blood samples were collected before and after each session in lithium 
heparin and EDTA tubes, and biochemical analysis performed on a 
multichannel autoanalyser. Peritoneal waste fluid was also assessed 
(volume, electrolyte concentration). Primary endpoints were percentage 
change in blood pressure (BP), stroke volume (SV), cardiac output (CO) 
and total peripheral resistance (TPR) in response to the APD cycle.  
 
 
10.3 Statistical analysis 
 
Results are expressed as mean ± SD (where given, values in 
parentheses represent the range). BP and haemodynamic data were 
compared using one-way ANOVA with a design for repeated measures 
and Bonferroni’s test to correct for multiple comparisons. For other data, 
the paired t-test was used after significant deviations from a normal 
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distribution were excluded with the Kolmogorov-Smirnov test. Correlation 
coefficients were calculated using Pearson’s test. An alpha error at 
P<0.05 was judged to be significant.  
 
 
10.4 Results 
 
10.4.1 Blood pressure and heart rate 
For the entire study period, overall mean systolic BP (SBP) was 148 ± 
5mmHg, mean diastolic BP (DBP) was 87 ± 3mmHg and mean of the 
mean arterial pressure (MAP) was 108 ± 5mmHg. Initial BP was not 
significantly different from end BP (for SBP p=0.32, for DBP p=0.87, and 
for MAP p=0.97). There were no statistically significant differences 
between the mean BP values for the dwell periods with 1.36% and 3.86% 
glucose. Mean SBP during 1.36% glucose dwell was 149 ± 3mmHg, 
mean DBP 87 ± 1mmHg and mean MAP 108 ± 2mmHg. Mean SBP 
during 3.86% glucose dwell was 149 ± 6mmHg, mean DBP 89 ± 4mmHg 
and mean MAP 110.7 ± 4.7mmHg.  As can be seen from the larger SDs 
and ranges, BP varied more during the 3.86% dwell, falling at 20min 
(SBP fell by 14mmHg) and then plateauing. BP data are summarised in 
figure 10-a. 
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Figure 10-a.  
Mean BP data for entire study period. All 3 BP parameters drop during the 1st and 3rd 
drainage periods and then rise upon dialysate fluid instillation. This is not seen in the 2nd 
drain/fill period. There is no significant difference between mean BP values at the start 
and end of the investigatory period. 
 
 
Mean SBP, DBP and MAP dropped during drainage and rose on 
instillation of dialysate in two of the three drain/fill periods. The largest 
magnitude of change occurred during the third drain/fill period, where 
mean SBP fell from 150mmHg to 142mmHg during drainage (p=0.029), 
before rising to 148mmHg on instillation. Mean DBP fell from 85mmHg to 
80mmHg (p=0.01) before climbing to 86mmHg, while mean MAP fell from 
107mmHg to 102mmHg (p=0.01) and then rose to 108mmHg. The falls in 
BP parameters during the first and second drainage periods were smaller 
and did not reach statistical significance.  
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10.4.2 Haemodynamic parameters 
Throughout the entire study period, HR remained relatively stable. There 
was no significant difference between mean HR at the start and end of 
the study period (p=0.28). Mean percentage change from baseline was    
-1.9 ± 2%. Data for HR are summarised in figure 10-b. 
 
Throughout the study period, SV and CO both fell. The fall in SV to           
-21.1% from baseline was of borderline statistical significance (p=0.060). 
Mean SV for entire period was -9.3 ± 6%. CO fell to -22.4% from baseline 
(p=0.037) and overall mean CO was -11.1 ± 6%. During all three 
drainage periods SV and CO rose, and on instillation of fluid both then 
fell. The largest changes occurred during the third drain/fill phase, with 
SV varying between -4.7% and -19.5% and CO varying between -22.4% 
and -5.3%.  
 
Contrary to the changes in SV and CO, TPR progressively rose 
throughout the study period to +53.4% above baseline (p=0.016). Mean 
TPR for the study period was +19.7 ± 18%. During drainage periods, 
mean TPR fell but then rose during fluid instillation. Again, changes were 
greatest during drain/fill phase 3 with TPR varying between -1.7% and 
+50.2%. A similar pattern of response (fall in TPR with an inadequate rise 
in SV and CO) was also seen to explain the fall in BP at 20min during the 
3.86% glucose dwell. Haemodynamic data are summarised in figure    
10-b.  
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Figure 10-b.  
Haemodynamic data. SV and CO progressively decline throughout the study period 
(p=0.060, p=0.037 respectively). During each drain/fill phase, SV and CO rise as fluid is 
drained out of the peritoneal space and fall upon instillation of fluid. TPR progressively 
rises during the study period (p=0.032). During dialysate fluid drainage, TPR falls and 
then rises again upon instillation of dialysate. HR remains constant, with no significant 
change comparing start and end mean values (p=0.28). 
 
 
The haemodynamic and BP patterns described above are population 
means. Analysing patients individually, 6/8 patients showed similar trends 
with respect to BP, HR, SV, and TPR. The three diabetic patients were 
not demonstrably different from the non-diabetics. Of the two that differed 
from the population mean, one patient did not display a pronounced rise 
in TPR and fall in CO throughout the overall study period. The other 
patient did display a similar overall pattern but had a higher SV/CO and 
therefore a higher BP during the 3.86% glucose dwell. This latter finding 
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was similar to our previous work showing a similar pattern during 
hypertonic glucose CAPD dwells (chapters 8 and 9). The two patients 
who differed from the group did display the same haemodynamic 
changes during the drain/fill phases with a rise in SV and CO coupled to a 
fall in TPR during drainage, and a rise in TPR plus a fall in SV and CO 
during instillation. These two patients were not examined on the same 
study day, did not have the same peritoneal transporter status and both 
had UF volumes that were similar to the group mean. 
 
10.4.3 Ultrafiltration volumes and sodium removal 
Mean ultrafiltration (UF) volume for the overall dwell period was 542 ± 
232ml. Overall, sodium was retained with a mean of +12.8 ± 38mmol. 
There was no correlation between BP, SV or TPR and either UF volume 
or sodium loss. Mean serum sodium at the start of the study period was 
133.8 ± 4mmol/L and did not change post study, with a mean of 133.8 ± 
3mmol/L. 
 
10.4.4 Peritoneal transport characteristics and urea kinetic modelling  
All patients had a weekly Kt/V of greater than 2.0 (mean 2.5, range 2.0 to 
3.4). Mean weekly creatinine clearance was 78.1l/wk (range 61.8 to 
115.5), with mean residual renal function 4.4 ± 3.6ml/min. There were no 
correlations between BP and residual renal function, weekly creatinine 
clearance or Kt/V. 
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10.5 Discussion 
 
This study reports significant systemic haemodynamic effects during 
APD. Changes were seen in CO and TPR over the entire study period 
and in BP, SV, CO and TPR during drain/instillation periods. To our 
knowledge, this is the first report examining the haemodynamic response 
to APD. 
 
The most significant changes in BP were seen during drain/fill phases. 
During the first and third drain phases, BP fell when dialysate was 
drained out of the peritoneal cavity. Mirroring this fall in BP, TPR fell 
whilst SV and CO both rose. For two of the drain phases the rise in CO 
was inadequate and did not prevent BP falling. Conversely, BP and TPR 
rose when dialysate was instilled into the peritoneal cavity, and 
associated with this there was a fall in SV and CO. This is likely to be a 
‘volume effect’ due to mesenteric capacitance vessel compression by the 
dialysate fluid. This effect may have been greatest in the third drain/fill 
phase as this followed the dwell period with 3.86% glucose dialysate 
during which UF is likely to have been greater. Intravascular volume 
would therefore be more contracted, and the volume drained would be 
larger. 
TPR rose progressively throughout the APD treatment by more than 50% 
from baseline. In response to this, a progressive fall in CO was 
demonstrated (with a trend towards a fall in SV). These changes however 
did not significantly affect overall BP. The rise in TPR may be due to a 
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cooling effect, with each drain/fill cycle further cooling the mesenteric 
vessels and leading to vasoconstriction. A greater cooling effect may 
occur during APD as compared with CAPD due to the increased number 
of drain/fill cycles with the former, as the method of warming the APD 
dialysate in the reservoir bag on top of the Homechoice machine may 
not deliver a fully mixed and accurate fluid temperature. Potentially, the 
temperature of instilled dialysate could be more accurately measured and 
manipulated with online sensors and heating, which may provide a way of 
modulating the haemodynamic response to APD. Haemodialysis patients 
experiencing progressive UF demonstrate a rise in TPR in association 
with an increase in peripheral sympathetic nerve activity [81]. Therefore, 
an alternative explanation for the rise in TPR during our study would be 
sympathetic activation in response to the UF of APD. This latter 
explanation seems less likely as there were no correlations between UF 
volume and BP, SV or TPR. 
 
The data from the experiments described in chapters 8 and 9 
demonstrate a differential haemodynamic response to 1.36% and 3.86% 
glucose-based dialysate fluids, with higher BP, HR and SV (but similar 
TPR) seen with 3.86% glucose dialysate. This was not seen our current 
study (except for in one patient). During our previous studies with CAPD 
patients, the protocol ensured that all conditions (including dialysate fluid 
temperature) were identical except for the dialysate fluid type. However, 
the progressive rise in TPR during this current study may reflect that 
there was a significant cooling effect as APD progressed. This may have 
 185
exerted a more powerful effect on systemic haemodynamics than the 
effects of dialysate glucose. Furthermore, dwell times were much shorter 
during this current study and a similar UF volume was removed over a 
shorter period of time. Fluid shifts, plasma refill rate and therefore 
effective blood volume may therefore have been affected differently. 
 
The link between APD and a faster rate of decline in RRF remains 
controversial. Some authors have found that APD is associated with a 
faster decline in RRF [136-138], whereas others have not [200-205]. An 
adverse haemodynamic response to APD as compared with CAPD has 
been postulated as a possible factor in speeding decline of RRF but has 
never before been documented. We have demonstrated significant 
changes in BP and haemodynamics during drain/fill periods, and it is 
possible that the increased number of drain/fill cycles with APD (up to 10 
per night) as compared to CAPD may impact on RRF. Dehydration 
episodes in PD patients have also been shown to increase the decline of 
RRF [203]. Therefore the shorter dwell phases with more rapid 
ultrafiltration that are seen with APD may explain the fall in BP a third of 
the way through the 3.86% glucose dwell, and are also a potential factor 
that may affect RRF. Equally, the haemodynamic changes seen over the 
entire study period (possibly mediated by systemic cooling) may be 
important. In health, the kidneys receive 20-25% of CO, and many 
conditions that cause a fall in CO also lead to reduction in renal blood 
flow [206]. Systemic cooling in rats has been demonstrated to cause 
renal vasoconstriction and reduce renal blood flow, although it is not 
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known whether the same phenomenon occurs in humans [207]. In 
addition, diseased kidneys have additional impairment of autoregulation, 
and may therefore be less able to maintain renal blood flow in the face of 
falling CO. However, it must be noted that our short-term study did not 
address or measure any changes in renal blood flow, urine output or 
RRF. Therefore, although we demonstrate significant changes in 
systemic haemodynamics, the effect that these changes have on RRF is 
entirely speculative. 
 
In conclusion, we have demonstrated that APD exerts significant 
haemodynamic effects, with rising TPR (possibly signifying a cooling 
effect) and falling CO over time. We have also shown that drain/fill 
periods are associated with significant change in haemodynamics and 
BP. We speculate that these changes may have the potential to affect 
renal perfusion and therefore the rate of decline of RRF.  
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11. Results: regional left ventricular function in response 
to the haemodynamic changes of peritoneal dialysis 
 
11.1 Introduction 
 
Following our demonstration of regional left ventricular wall motion 
abnormalities occurring in response to haemodialysis and of significant 
haemodynamic changes that are evident during CAPD, we performed a 
study to examine whether CAPD could induce subclinical myocardial 
ischaemia. In view of the rapid haemodynamic and BP effects occurring 
during fluid instillation and drainage (chapter 10), regional LV function 
was assessed by echocardiography before and after a PD exchange. 
 
 
11.2 Methods 
 
11.2.1 Patients 
The same patients that participated in the experiment in chapter 9 were 
recruited. Baseline patient characteristics are described in chapter 9 and 
in table 9-a. In contrast to the patients studied in chapter 4, none of these 
patients had atherosclerosis and only two had LVH. 
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11.2.2 Study protocol 
Patients attended for a single study day. Following a dwell period with 
1.36% glucose fluid, an exchange with 2.5L of 3.86% glucose-based 
dialysate was performed. All fluids were produced by Baxter Healthcare 
(Norfolk, UK) and were warmed to 370C prior to instillation. 2-D 
echocardiography was performed immediately before draining fluid from 
the abdomen and then following fluid instillation using commercially 
available equipment (1.5-3.6 MHz 3S probe, Vivid 3®, GE medical 
systems, Sonigen, Germany). Images were subsequently analysed for 
regional wall motion abnormalities using Echo-CMS (chapter 3). BP and 
haemodynamic data were recorded continuously using the Finometer 
(chapter 3). We collected blood in lithium-heparin tubes for cTnT analysis 
at baseline and at three hours after the end of the exchange. 
 
Primary endpoints were the number of new RWMAs developing in 
response to the haemodynamic changes of a PD exchange.   
 
All patients gave informed consent prior to commencement, and ethical 
approval for the project was granted by Derbyshire Research Ethics 
Committee. 
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11.3 Results 
 
11.3.1 Regional LV function  
There was a very low frequency of new RWMAs, occurring in only 3.9% 
of LV regions. Six patients did not demonstrate any new RWMAs. As a 
result, mean SF did not change following the exchange in two of the 
regions assessed; in the remaining eight regions mean SF increased 
significantly. Overall mean SF for all regions also increased significantly 
following the exchange from 2.8 ± 1.0% to 3.9 ± 0.94% (p<0.001). Data 
for pre and post SF for each region and overall are shown in table 11-a. 
EF did not change significantly following the exchange with means of 
69.6 ± 12% before the exchange and 76.6 ± 5% after (p=ns). 
 
 Pre SF (%) Post SF (%) p-value 
Basal Septal 2.0 ± 1.3 2.0 ± 1.0 ns 
Mid Septal 3.6 ± 1.4 4.4 ± 1.3 <0.05 
Apical (4 chamber) 1.7 ± 0.9 2.6 ± 1.1 <0.05 
Mid Lateral 2.7 ± 1.1 4.5 ± 1.4 <0.001 
Basal Lateral 3.6 ± 1.6 5.5 ± 2.1 <0.001 
Basal Inferior 2.8 ± 1.8 4.2 ± 1.8 <0.001 
Mid Inferior 3.9 ± 1.4 5.2 ± 1.5 <0.01 
Apical (2 chamber) 2.8 ± 1.6 3.6 ± 1.1 ns 
Mid Anterior 2.9 ± 1.6 3.6 ± 1.4 ns 
Basal Anterior 2.6 ± 1.7 4.1 ± 1.8 <0.001 
Overall 2.8 ± 1.0 3.9 ± 0.9 <0.001 
 
Table 11-a.  
Regional function in each of the LV regions assessed, and overall mean regional 
function before and after the PD exchange. 
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11.3.2 Blood pressure and haemodynamics 
BP varied significantly during the exchange, falling on drainage of fluid 
and rising upon instillation. Mean SBP was 160.1 ± 11mmHg prior to 
drainage and fell to 156 ± 11mmHg post drainage, and rose from 165 ± 
11 before instillation to 174 ± 13mmHg after (p<0.008). BP data are 
summarised in figure 11-a. 
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Figure 11-a.  
SBP at the start and end of fluid drainage and instillation. 
 
 
Mirroring the changes in BP, TPR also fell during fluid drainage from 29 ± 
8% to 19 ± 8%, whilst during fluid instillation TPR rose from 27 ± 10% to  
40 ± 9% (p<0.001).  
The observed changes in CO were less. Although CO rose during fluid 
drainage from -13 ± 8% to -11 ± 8%, and fell during fluid instillation from   
-13 ± 7% to -16 ± 7%, these changes did not reach statistical significance 
(p=ns). The changes in SV were similar to CO and also did not reach 
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statistical significance. HR varied very little throughout. Haemodynamic 
data are summarised in figure 11-b. 
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Figure 11-b.  
Haemodynamics at the start and end of fluid drainage and instillation. 
 
 
11.3.3 Troponin levels 
cTnT levels did not change at all following the exchange. Mean values 
were 0.02 ± 0.01µg/l both before and three hours after the study period 
(p=ns). 
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11.4 Discussion 
 
This study confirms that significant changes in BP and systemic 
haemodynamics occur during drainage and instillation of fluid in and out 
of the abdominal cavity. In a cohort of patients with no atherosclerosis 
and little structural heart disease, there was no evidence that these 
changes led to subclinical myocardial ischaemia. 
 
The fall in BP and TPR with an inadequate rise in CO during fluid 
drainage with the opposite seen during instillation are similar to the 
results observed during exchanges in chapter 10. The most likely 
explanation for this is that peripheral resistance is altered significantly by 
compression of the mesenteric vessels, which occurs during instillation of 
fluids and is relieved when fluid is drained. However, it remains unclear 
why HR and CO do not increment adequately to prevent the fall in BP 
during drainage, even in a cohort of patients with relatively little cardiac 
disease. Certainly, autonomic neuropathy is widespread in dialysis 
patients and it may be that a blunting of the baroreflex arc could explain 
this. This would also fit with absence of any change in heart rate in the 
same patients during the experiment described in chapter 9. However, 
autonomic function was not measured as part of this study. 
 
Despite these significant changes in haemodynamics, we did not observe 
any evidence of myocardial stunning. There were very few regions that 
demonstrated new RWMAs and overall SF in all LV regions remained 
 193
unchanged or increased. In addition, we did not observe any change in 
cTnT levels. In contrast to the patients described in chapter 4, this cohort 
was relatively free of cardiac disease and no patients had clinically 
apparent atherosclerosis. In keeping with this, baseline cTnT levels were 
also low. It is possible that CAPD patients with a greater degree of 
vascular disease and LVH would be more susceptible to subclinical 
myocardial ischaemia in response to these haemodynamic fluctuations, 
but this remains to be tested.  
 
It was interesting to observe that regional LV function in many regions 
increased following the exchange. This is similar to unaffected LV areas 
in the haemodialysis patients that also displayed increased wall motion by 
the end of dialysis. This suggests that myocardial performance (in terms 
of contractility) increases in an attempt to respond to the significant 
changes in haemodynamics. However, as evidenced by the inadequate 
rise in CO, this is insufficient to prevent changes in BP. This may in part 
be due to the inadequate chronotropic response.  
 
In conclusion, in a cohort of patients with relatively low risk for myocardial 
ischaemia, we found no evidence that the haemodynamic consequences 
of a PD exchange lead to myocardial stunning. 
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12.  Conclusions 
 
The risk of cardiovascular death in dialysis patients is grossly elevated. 
As the dialysis population continues to expand whilst donor kidneys 
remain scarce, this excess of mortality is becoming an increasingly 
important issue. There are many different factors that negatively impact 
on the cardiovascular system in the dialysis patient. However, our results 
suggest that the haemodialysis process itself may be implicated by 
inducing haemodynamic perturbation sufficient to induce subclinical 
myocardial ischaemia.  
 
In two separate groups of dialysis patients, we have demonstrated the 
occurrence of dialysis induced LV regional wall motion abnormalities. 
Although there are other reports of silent ischaemia occurring during 
dialysis [28, 43-52] our work is the first to suggest that it is possible to 
reduce this phenomenon by improving intradialytic haemodynamic 
stability. Our studies show that biofeedback dialysis and the simple and 
universally available technique of reducing dialysate temperature are both 
effective in this way. This is important as repeated episodes of ischaemia 
and myocardial stunning may be cumulative and contribute to the genesis 
of chronic heart failure in patients with ischaemic heart disease [59]. 
Therefore, as haemodialysis is repeated thrice weekly, it is possible that 
repeated dialysis induced myocardial stunning may contribute to chronic 
cardiac dysfunction. It remains to be seen whether improving the 
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haemodynamic tolerability of dialysis would be an effective intervention to 
reduce the development of heart failure in this patient group. 
 
Exploring additional haemodialysis techniques purported to reduce IDH, 
we found that acetate-free PHF is associated with a lower BP without 
increased instability and significantly less deterioration in systemic 
haemodynamics as compared to low-flux bicarbonate-based dialysis. We 
observed a non-significant trend towards less IDH during PHF; this 
difference may have been statistically significant if participant numbers 
were larger or more sessions studied. We suggest that one possible 
explanation for the improved haemodynamic response to PHF is the 
absence of acetate that may be important in maintaining myocardial 
contractility. Although these results imply that PHF has potential benefits, 
the lack of clear separation in terms of IDH suggests that PHF is not likely 
to be the most efficient technique to reduce dialysis induced regional LV 
dysfunction.  
Equally, within a setting of empirical reduction of dialysate sodium, 
Diacontrol® (DC) did not appear to have any short tem clinical advantage 
in terms of haemodynamic stability over standard dialysis. In addition, DC 
was not able to reduce plasma conductivity to as great a degree, with the 
range of lower conductivity settings limited by software programming on 
the dialysis monitor. 
 
Mirroring the published literature, we found conflicting results regarding 
the acute effects of dialysis upon cTnT levels. In one study (chapter 5) we 
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found no rise in cTnT post dialysis, even in the context of dialysis induced 
ischaemia. However, in chapter 6 we did see a rise in troponin with 
standard dialysis, whereas with PHF cTnT levels fell. In addition we also 
observed higher predialysis cTnT levels in IDH prone patients.  The acute 
rise in cTnT would be consistent with subclinical myocardial damage 
occurring during the dialysis procedure, but it appears that this is only 
intermittently detected with blood sampling immediately post dialysis. This 
may be because cTnT levels may take up to 12hours to rise following an 
ischaemic insult; therefore the studies that found no difference in pre and 
post dialysis troponin levels do not refute the development of dialysis 
induced myocardial cell damage. An alternative, practicable approach 
when looking for dialysis induced changes in cTnT would be to measure 
post dialysis cTnT levels at 44hours (i.e. measured at immediately before 
the subsequent dialysis session). An acute rise in cTnT has been 
demonstrated in this way following dialysis sessions complicated by IDH, 
but not following sessions in which the patients remained stable [78].  
 
We have also shown that peritoneal dialysis has significant 
haemodynamic effects. We observed higher blood pressure, SV and CO 
during 3.86% glucose dwells compared to 1.36% glucose, Icodextrin and 
1.1% amino acid solutions. We also demonstrated that there was a 
significant degree of hyperglycaemia and hyperinsulinaemia in response 
to CAPD with hypertonic glucose dialysate, and that his was associated 
with the acute rise in BP. In addition, a differing haemodynamic response 
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to conventional and newer biocompatible PD solutions was observed, the 
cause of which is at present unclear.  
Cardiovascular mortality rates are similar between haemodialysis and 
peritoneal dialysis populations [15], which in part is explained by some 
risk factors such as LVH and vascular calcification that exist in both 
groups. However, the two techniques of dialysis have many differences; 
as such it is not surprising that their short term effects on the 
cardiovascular system also differ. It is conceivable that the effects that we 
have described in this thesis attributable to each type of dialysis have the 
potential to negatively impact on long term cardiovascular risk, but in 
different ways. HD causes repetitive episodes of subclinical ischaemia 
that may lead to long term LV dysfunction and cardiac failure. In contrast 
to HD there was no evidence that the short term haemodynamic changes 
associated with CAPD led to myocardial stunning. However, CAPD with 
hypertonic glucose solutions leads to acute rises in BP, hyperglycaemia 
and hyperinsulinaemia, all of which predict poor cardiovascular outcomes 
in non dialysis patients. Importantly, we have shown that both dialysis 
modalities are potentially modifiable to lessen these short term effects. 
We have demonstrated that improving intradialytic BP and lessening IDH 
reduces the genesis of LV RWMAs during HD. The adverse 
haemodynamic and metabolic effects of CAPD are modifiable by using 
dialysis regimes consisting of low-glucose, biocompatible fluids. Whether 
modifying these short term effects of dialysis has the potential to improve 
long term cardiovascular outcomes of dialysis patients remains to be 
explored. 
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In addition, we demonstrated that APD exerts significant haemodynamic 
effects, with rising TPR (possibly signifying a cooling effect) and falling 
CO over time. We also showed that drain/fill periods are associated with 
significant change in haemodynamics and BP. We speculate that these 
changes, in particular the greater number of drain/fill phases as 
compared to CAPD may have the potential to affect renal perfusion and 
therefore the rate of decline of RRF. This is potentially important as RRF 
is not only crucial in maintaining adequacy in many peritoneal dialysis 
patients, but maintenance of RRF has been shown to affect survival. 
 
In conclusion, the results presented in this thesis show that both 
haemodialysis and peritoneal dialysis are associated with significant, but 
differing derangements in blood pressure and systemic haemodynamics. 
Associated with this, haemodialysis has a negative impact on regional left 
ventricular function whereas CAPD with hypertonic glucose causes an 
acute rise in blood pressure, hyperglycaemia and hyperinsulinaemia. In 
this population that has overwhelmingly high cardiac mortality rates, 
cardiovascular risk reduction is key to ensuring optimal outcomes. The 
findings of this thesis suggest several novel, modifiable mechanisms 
related to the short term effects of dialysis that are potentially implicated 
in the development of uraemic cardiomyopathy. 
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12.1 Future work 
 
This thesis explores the short term cardiac and haemodynamic effects of 
dialysis. However, some of the results are themselves hypothesis-
generating and there remain several unanswered questions. 
 
For definitive proof of dialysis induced myocardial stunning, further work 
is now needed to measure myocardial blood flow in conjunction with LV 
function. We are currently collaborating with the cardiology group at the 
Medical Research Council Clinical Sciences Centre, Imperial College 
London led by Professor Camici in order to measure myocardial blood 
flow during dialysis. This study combines the gold standard of positron 
emission tomography to measure myocardial blood flow with 
echocardiography to measure regional left ventricular function. Standard 
dialysis are compared Hemocontrol® in this way. 
 
We have also commenced a study to assess the long-term development 
of heart failure in response to repeated dialysis-induced myocardial 
ischaemia, and to determine whether a reduction in the frequency of 
dialysis RWMAs improves long term outcomes in terms of LV systolic 
function. In addition, this study will also allow characterisation of risk 
factors that predict the development of dialysis induced ischaemia. In 
particular, we aim to correlate new RWMAs with cTnT levels immediately 
before the subsequent dialysis session. Furthermore, we are also 
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planning studies to assess whether increasing tissue oxygen delivery has 
a beneficial effect on dialysis induced stunning. 
 
Cooling the dialysate improves IDH and our results show for the first time 
that it has a beneficial effect on intradialytic regional LV function. 
Furthermore, cooling the dialysate is possible on all dialysis monitors and 
is extremely simple to perform. However, concerns regarding unpleasant 
symptoms of cold have led to the relative under use of this intervention. 
Further work is therefore required to define the optimal dialysate 
temperature to maximise potential benefits whilst avoiding excessive 
thermal symptoms. 
 
It is possible to minimise glucose and GDP exposure in CAPD patients by 
combining Icodextrin and amino acid based fluids with biocompatible 
glucose based solutions. This approach theoretically should minimise the 
adverse changes in BP, glucose and insulin that we have demonstrated 
and should be studied in terms of longer term cardiovascular risk 
reduction. It also remains to be clarified as to whether the haemodynamic 
consequences of APD can accelerate the loss of residual renal function 
as compared to CAPD, and if so how the technique of APD could be 
altered (possibly by modulating dialysate temperature) to reduce this.  
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13. List of abbreviations 
 
ABPM ambulatory blood pressure monitoring 
AFB acetate free biofiltration 
ANOVA analysis of variance 
APD automated peritoneal dialysis 
BFD biofeedback dialysis; in this thesis this refers exclusively to 
Hemocontrol® 
BIA bioimpedance analysis 
BP blood pressure 
CAPD continuous ambulatory peritoneal dialysis 
CFR coronary flow reserve 
CI 95% confidence intervals 
CK creatinine kinase 
CKMB creatinine kinase MB 
CO cardiac output 
CRP C-reactive protein 
cTnI cardiac troponin I 
cTnT cardiac troponin T 
DBP diastolic blood pressure 
DC Diacontrol® 
DC13.5 Diacontrol, target plasma conductivity 13.5mS/cm 
DC13.6 Diacontrol, target plasma conductivity 13.6mS/cm 
DC13.7 Diacontrol, target plasma conductivity 13.7mS/cm 
DCH Diacontrol, matched with standard dialysis for end dialysis plasma 
conductivity 13.7mS/cm 
DCL Diacontrol, matched with standard dialysis for end dialysis plasma 
conductivity 13.5mS/cm 
DCM Diacontrol, matched with standard dialysis for end dialysis plasma 
conductivity 13.6mS/cm 
ECW extracellular water 
EF ejection fraction 
ELISA enzyme linked immunosorbent assay 
ERF established renal failure, CKD stage 5 
GDPs glucose degradation products 
Hb haemoglobin 
HD haemodialysis; standard bicarbonate haemodialysis 
HD35 dialysis using dialysate temperature of 350C 
HD37 dialysis using dialysate temperature of 370C 
HD13.2 standard haemodialysis, dialysate conductivity 13.2mS/cm 
HD13.6 standard haemodialysis, dialysate conductivity 13.6mS/cm 
HD13.4 standard haemodialysis, dialysate conductivity 13.4mS/cm 
HDH standard haemodialysis, matched with Diacontrol for end dialysis 
plasma conductivity 13.7mS/cm 
 202
HDL standard haemodialysis, matched with Diacontrol for end dialysis 
plasma conductivity 13.5mS/cm 
HDM standard haemodialysis, matched with Diacontrol for end dialysis 
plasma conductivity 13.6mS/cm 
HDF haemodiafiltration 
HF haemofiltration 
HOMA-IR homeostasis model of assessment index - insulin resistance 
HR heart rate 
HRP horseradish peroxidase  
ICW intracellular water 
IDH intradialytic hypotension 
IDWG interdialytic weight gain 
IL6 interleukin 6 
IMB ionic mass balance 
IQR interquartile range 
LA left atrium 
LV left ventricle 
LVH left ventricular hypertrophy 
LVMI left ventricular mass index 
MAP mean arterial blood pressure 
NYHA New York Heart Association 
OR odds ratio 
PD peritoneal dialysis 
PDFAA 1.1% Amino acid based peritoneal dialysis fluid, Nutrineal® 
PDFBIO biocompatible glucose-based peritoneal dialysis fluid, Physioneal® 
PDFCONV conventional glucose-based peritoneal dialysis fluid, Dianeal® 
PET  Positron emission tomography 
PHF paired haemodiafiltration 
RBV relative blood volume 
RRF residual renal function 
RWMA left ventricular regional wall motion abnormality 
SBP systolic blood pressure 
SD standard deviation 
SE/SEM standard error of the mean 
SF percentage shortening fraction (measure of regional LV wall 
motion) 
SFMEAN Mean regional LV motion for all regions 
SFWMA Mean regional LV motion for those regions with new RWMAs 
SF-36 short form 36 quality of life questionnaire 
SPECT single photon emission computed tomography 
SV stroke volume 
TBW total body water 
TMB tetramethylbenzydine 
TNFα tumour necrosis factor alpha 
TPR total peripheral resistance 
UF ultrafiltration 
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15. Appendices 
15.1 Temperature questionnaire 
 
1. Have you felt cold during dialysis in the last two weeks?  
 
Every session    (4) 
Sometimes      (3) 
Once      (2) 
Never     (1) 
        
 
2.  In the last 2 weeks, have you had to use blankets or extra clothes 
during dialysis to keep warm? 
  
Every session   (4)  
Sometimes      (3) 
Once      (2) 
Never     (1) 
      
 
3.  Have you felt uncomfortable due to symptoms of cold during 
dialysis in the last 2 weeks? 
  
Every session   (8) 
Sometimes      (6) 
Once      (4) 
Never     (2)   
 
 
4.  In the last 2 weeks, have you shivered during dialysis?  
  
Every session   (8) 
Sometimes      (6) 
Once      (4) 
Never     (2) 
 
 
5.  Overall, in the last 2 weeks whilst on dialysis, have you felt: 
  
Much better than usual    
Slightly better than usual    
No different from usual   
Slightly worse than usual   
Much worse than usual    (this question not scored) 
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15.2 Dialysis thirst score 
 
 
Thirst is a problem for me 
 
Never (1) occasionally (2) sometimes (3)   quite often (4) very often (5) 
 
 
 
I am thirsty during the day 
 
Never  occasionally  sometimes    quite often very often 
 
 
 
I am thirsty during the night 
 
Never  occasionally  sometimes    quite often very often 
 
 
 
My social life is influenced because of my thirst feelings 
 
Never  occasionally  sometimes    quite often very often 
 
 
 
I am thirsty before dialysis 
 
Never  occasionally  sometimes    quite often very often 
 
 
 
I am thirsty during dialysis 
 
Never  occasionally  sometimes    quite often very often 
 
 
 
I am thirsty after dialysis 
 
Never  occasionally  sometimes    quite often very often 
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